

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 25, 2005, 02:23:48 ; Search time 128.743 Seconds
(without alignments)
663.913 Million cell updates/sec

Title: US-09-745-792a-12

Perfect score: 1200
Sequence: 1 VPCVSGGLPKPANITFLSIN.....PSEKQCARTLKDSSEFPKAK 221

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:*

1: geneseqp19808:*\n2: geneseqp19808:*\n3: geneseqp20008:*\n4: geneseqp20018:*\n5: geneseqp20028:*\n6: geneseqp20038:*\n7: geneseqp20038:*\n8: geneseqp20048:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1200	100.0	221	4	AAB85269 Aab85269 Human IL-
2	1200	100.0	221	5	ABG67200 Abg67200 Human Int
3	1200	100.0	221	5	AAE23354 Aae23354 Human IL-
4	1200	100.0	221	8	ADJ83292 Adj83292 Human IL-
5	1200	100.0	222	6	ABR42390 Abr42390 Human sec
6	1200	100.0	542	4	AAU12265 Aau12265 Human PRO
7	1200	100.0	542	4	AAU29222 Aau29222 Human PRO
8	1200	100.0	542	6	ABU58598 Abu58598 Human PRO
9	1200	100.0	542	6	ABU88146 Abu88146 Novel hum
10	1200	100.0	542	6	ABU84461 Abu84461 Human sec
11	1200	100.0	542	6	ABR66335 ABR66335 Human sec
12	1200	100.0	542	6	ABR65725 ABR65725 Human sec
13	1200	100.0	542	6	ABU99665 Abu99665 Human sec
14	1200	100.0	542	6	ABU82904 Abu82904 Human PRO
15	1200	100.0	542	6	ABO17709 Abo17709 Novel hum
16	1200	100.0	542	6	ABU90025 Abu90025 Novel hum
17	1200	100.0	542	6	ABR68274 ABR68274 Human sec
18	1200	100.0	542	6	ABU96337 Abu96337 Novel hum
19	1200	100.0	542	6	ABU92758 Abu92758 Human sec
20	1200	100.0	542	6	ABO08835 Abo08835 Human sec
21	1200	100.0	542	6	ABO02887 Abo02887 Human sec
22	1200	100.0	542	6	ABR75041 ABR75041 Human sec
23	1200	100.0	542	6	ABR94803 ABR94803 Human sec
24	1200	100.0	542	6	ABU85776 Abu85776 Human PRO
25	1200	100.0	542	6	ABU98936 Abu98936 Novel hum

26	1200	100.0	542	6	ABU98151 Abu98151 Novel hum
27	1200	100.0	542	6	ABU80963 Abu80963 Human PRO
28	1200	100.0	542	6	ABU91857 Abu91857 Novel hum
29	1200	100.0	542	6	ABU89550 Abu89550 Human PRO
30	1200	100.0	542	6	ABU86391 Abu86391 Human sec
31	1200	100.0	542	6	ABU67604 Abu67604 Human sec
32	1200	100.0	542	6	ABU80632 Abu80632 Human PRO
33	1200	100.0	542	6	ABR99550 ABR99550 Human sec
34	1200	100.0	542	6	ABR98940 ABR98940 Human sec
35	1200	100.0	542	6	ABO16463 Abo16463 Human sec
36	1200	100.0	542	6	ABR92363 ABR92363 Human sec
37	1200	100.0	542	6	ABO19004 Abo19004 Human sec
38	1200	100.0	542	6	ABR78425 ABR78425 Human sec
39	1200	100.0	542	6	ABU85161 Abu85161 Novel hum
40	1200	100.0	542	6	ABU66663 Abu66663 Human PRO
41	1200	100.0	542	6	ABO00300 Abo00300 Novel hum
42	1200	100.0	542	6	ABO11632 Abo11632 Human sec
43	1200	100.0	542	6	ABO02277 Abo02277 Human sec
44	1200	100.0	542	6	ABU88851 Abu88851 Novel hum
45	1200	100.0	542	6	ABU83546 Abu83546 Human sec

ALIGNMENTS

RESULT 1
AAB85269
ID AAB85269 standard; protein; 221 AA.
XX
AC AAB85269;
XX
DT 07-SEP-2001 (first entry)
XX
DE Human IL-20 receptor subunit IL-20RA extracellular domain fragment.
XX
KW Interleukin 20; IL-20; IL-20RA; Zcytor7; IL-20RB; DIRS1; immunoglobulin;
XX antiinflammatory; antiproliferative; antiautomatic; antibacterial; human;
XX dermatological; antitumor; antagonist.
XX
OS Homo sapiens.
XX
PN WO200146232-A2.
XX
PD 28-JUN-2001.
XX
PF 22-DEC-2000; 2000WO-US035307.
XX
PR 23-DEC-1999; 99US-00471774.
XX
PR 22-JUN-2000; 2000US-0213416P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Foster DC, Xu W, Madden KL, Kelly JD, Sprecher CA, Brandt CS;
PI Rixon KW, Presnell SR, Fox BA;
XX
DR WPI; 2001-398320/42.
XX
PT Isolated interleukin 20 soluble receptor comprising two polypeptide
PT subunits IL-20RA and IL-20RB, useful for down-regulating IL-20 and thus
PT treating inflammatory diseases such as psoriasis.
XX
PS Claim 1; Page 65; 119pp; English.
XX
CC The invention relates to an interleukin 20 (IL-20) soluble receptor
CC comprising two polypeptide subunits IL-20RA (formerly known as Zcytor7)
CC and IL-20RB (formerly known as DIRS1). The two subunits are preferably
CC linked together. In one embodiment, one subunit is fused to the constant
CC region of the light chain of an immunoglobulin, and the other subunit is
CC fused to constant region of the heavy chain of an immunoglobulin. The
CC light chain and the heavy chain are connected via a disulphide bond. The
CC soluble receptor can be used to down-regulate IL-20 and thus treat
CC inflammatory diseases such as psoriasis, inflammatory lung injury such as
CC asthma or bronchitis, adult respiratory disease (ARD), septic shock.

CC multiple organ failure, bacterial pneumonia, eczema, atopic and contact dermatitis, and inflammatory bowel disease such as ulcerative colitis and Crohn's disease. The present sequence represents a human IL-20 receptor and subunit IL-20RA extracellular domain fragment

CC Sequence 221 AA;

Query Match 100.0%; Score 1200; DB 4; Length 221;
Best Local Similarity 100.0%; Pred. No. 3.3e-112;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKRANITFLSIMKNVLTQMPPEGLQGVKVTYTYGYFYIGQKMLNKSCECN 60
DB 1 VPCVSGGLPKRANITFLSIMKNVLTQMPPEGLQGVKVTYTYGYFYIGQKMLNKSCECN 60
QY 61 INRTYCDLSAETSDYEHQYAKVKAIWGTRCSKMAESGRFPFLETQIGPEVALTTDEX 120
DB 61 INRTYCDLSAETSDYEHQYAKVKAIWGTRCSKMAESGRFPFLETQIGPEVALTTDEX 120
QY 121 SISVLTAPBKRKNRPEDLPVSMQOITYSNLKNVSVLTNKSRTWSQCVTNHTLVLTWLE 180
DB 121 SISVLTAPBKRKNRPEDLPVSMQOITYSNLKNVSVLTNKSRTWSQCVTNHTLVLTWLE 180
QY 181 PNTLYCVHVESFVGPERRAOPSEKOCARTLKDQSEFFAK 221
DB 181 PNTLYCVHVESFVGPERRAOPSEKOCARTLKDQSEFFAK 221

RESULT 2
ABG67200
ID ABG67200 standard; protein; 221 AA.

XX ABG67200;
DT 24-SEP-2002 (first entry)
DE Human Interleukin-20 sub-unit IL20RA mature extracellular domain.
XX

KW Inflammation; interleukin-20; IL-20; interleukin-8; IL-8; chemokine;
KW neutrophil; monocyte; basophil; eosinophil; chemoattractant; psoriasis;
KW periodontal disease; rheumatoid arthritis; idiopathic pulmonary fibrosis;
KW angiogenesis-dependent chronic inflammatory condition; lung cancer;
KW melanoma; inflammatory disease; diabetes; arteriosclerosis; cataract;
KW reperfusion injury; cancer; meningitis; rheumatic disease; skin disease;
KW idiopathic pulmonary fibrosis; inflammatory bowel disease; psoriasis;
KW ulcerative colitis; eczema; atopic dermatitis; contact dermatitis;
KW inflammatory lung disease; AKD; adult respiratory disease; asthma;
KW bronchitis; pneumonia.

OS Homo sapiens.

PN US2002042366-A1.

PD 11-APR-2002.

PF 22-DEC-2000; 2000US-00746359.

PR 23-DEC-1999; 99US-0171969P.

PR 22-JUN-2000; 2000US-0213341P.

XX (THOM/) THOMPSON P.
PA (POST/) FOSTER D C.
PA (XUW/) XU W.
PA (MADD/) MADDEN K L.
PA (KELL/) KELLY J D.
PA (SPRE/) SPRECHER C A.
PA (BLUM/) BLUMBERG H.
PA (BAGA/) EAGAN M A.
PA (JASP/) JASPERS S R.
PA (CHAN/) CHANDRASEKHAR Y A.
PA (NOVA/) NOVAK J E.
XX Thompson P, Foster DC, Xu W, Madden KL, Kelly JD, Sprecher CA;

PI Blumberg H, Eagan MA, Jaspers SR, Chandrasekhar YA, Novak JE;
XX WPI, 2002-507215/54.

PT Treating inflammatory skin and lung diseases using antibodies against
PT Interleukins (IL)-20 (which indirectly modulates activation of IL-8),
PT useful for treating e.g. psoriasis, asthma and bronchitis.
XX

PS Disclosure, Page 21-22, 68pp; English.

XX The invention describes a method (I) for treating a mammal afflicted with
CC a disease in which an interleukin-20 (IL-20) polypeptide plays a role
CC comprising administering antagonist of the IL-20 polypeptide to the
CC individual. An important cytokine in the inflammatory process is
CC interleukin-8 (IL-8), a chemokine that acts as an agonist for neutrophils
CC via chemotaxis and the release of granule enzymes. IL-8 binds to
CC receptors on neutrophils, monocytes, basophils, and eosinophils. IL-8 is
CC a potent chemoattractant for neutrophils, and the early stages of
CC periodontal disease are characterized by the influx of neutrophils. IL-8
CC is a potent inducer of angiogenesis in several angiogenesis-dependent
CC chronic inflammatory conditions, including rheumatoid arthritis,
CC psoriasis, and idiopathic pulmonary fibrosis. Additionally, IL-8 is an
CC important source of angiogenic activity in human lung cancer. Also, IL-8
CC expression correlates with experimental metastatic activity of some
CC melanoma cell lines. Therefore an effective method to treat inflammatory
CC diseases would be to administer an agent that would inhibit IL-8. It has
CC been shown that IL-20 up-regulates IL-8. Therefore antagonists to IL-20
CC can be used to treat these diseases. The method is used for treating
CC diseases in which the IL-20 polypeptide plays a role e.g. inflammatory
CC injury, cancer, meningitis, rheumatic disease, idiopathic pulmonary
CC fibrosis, inflammatory bowel disease (ulcerative colitis), skin disease
CC (psoriasis, eczema, atopic dermatitis and contact dermatitis) or an
CC inflammatory lung disease (adult respiratory disease (ARD), asthma,
CC bronchitis and pneumonia). This sequence represents a human interleukin-
XX 20 (IL-20) polypeptide used in developing the method of the invention

Sequence 221 AA;

Query Match 100.0%; Score 1200; DB 5; Length 221;
Best Local Similarity 100.0%; Pred. No. 3.3e-112;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKRANITFLSIMKNVLTQMPPEGLQGVKVTYTYGYFYIGQKMLNKSCECN 60
DB 1 VPCVSGGLPKRANITFLSIMKNVLTQMPPEGLQGVKVTYTYGYFYIGQKMLNKSCECN 60
QY 61 INRTYCDLSAETSDYEHQYAKVKAIWGTRCSKMAESGRFPFLETQIGPEVALTTDEX 120
DB 61 INRTYCDLSAETSDYEHQYAKVKAIWGTRCSKMAESGRFPFLETQIGPEVALTTDEX 120
QY 121 SISVLTAPBKRKNRPEDLPVSMQOITYSNLKNVSVLTNKSRTWSQCVTNHTLVLTWLE 180
DB 121 SISVLTAPBKRKNRPEDLPVSMQOITYSNLKNVSVLTNKSRTWSQCVTNHTLVLTWLE 180
QY 181 PNTLYCVHVESFVGPERRAOPSEKOCARTLKDQSEFFAK 221
DB 181 PNTLYCVHVESFVGPERRAOPSEKOCARTLKDQSEFFAK 221

RESULT 3

ID AAE23354 standard; protein; 221 AA.

XX AAE23354;

DT 27-AUG-2002 (first entry)

DE Human IL-20RA mature extracellular protein.

XX Human; interleukin-19; IL-19; interleukin-20 receptor alpha; IL-20RA;
KW Human; interleukin-20 receptor beta; IL-20RB; inflammation; arteriosclerosis;
KW diabetes; reperfusion injury; cancer; infectious meningitis; cataract;

KW rheumatoid arthritis; rheumatic fever; systemic lupus erythematosus;
KW antibacterial; cytostatic; dermatological; ophthalmological; vasotropic.
XX Homo sapiens.
XX WO200222153-A2.
XX
XX 21-MAR-2002.
XX
XX 13-SEP-2001; 2001WO-US028557.
XX
XX 15-SEP-2000; 2000US-0233305P.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Chandrasekhar YA, Jaepers SR;
XX
XX MPI; 2002-425815/45.
XX
XX Method of down-regulating IL-19 useful for treating inflammation
PT comprises administration of a polypeptide comprised of the extracellular
PT domain of IL-20RA and IL-20RB.
XX
XX Claim 2; Page 47-48; 80pp; English.
XX
XX The present invention relates to a method of down-regulating interleukin
CC (IL)-19. The method involves administration of a polypeptide comprised of
CC the extracellular domain of interleukin-20 receptor alpha (IL-20RA) and
CC the extracellular domain of interleukin-20 receptor beta (IL-20RB). The
CC IL-20RA and IL-20RB are heterodimeric receptors that bind to both IL-19
CC and mda7. The method is useful for down-regulating IL-19, useful for the
CC treatment of inflammation e.g., in diabetes, atherosclerosis, cataracts,
CC reperfusion injury, cancer, infectious meningitis, rheumatoid arthritis,
CC rheumatic fever and systemic lupus erythematosus. The present sequence is
CC human IL-20RA mature extracellular protein
XX
XX Sequence 221 AA;
SQ

Query Match 100.0%; Score 1200; DB 5; Length 221;
Best Local Similarity 100.0%; Pred. No. 3.3e-112;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANTITFLSINMKNVLTQTPPEGLQGVKVTYTYQYFIYGKKMLNSECN 60
DB 1 VPCVSGGLPKPANTITFLSINMKNVLTQTPPEGLQGVKVTYTYQYFIYGKKMLNSECN 60
QY 61 INRTYCDLSAETSDYEHQYAKVKAIVGTCCKMAESGRFPFLETOIGPPEVALTTDEK 120
DB 61 INRTYCDLSAETSDYEHQYAKVKAIVGTCCKMAESGRFPFLETOIGPPEVALTTDEK 120
QY 121 SISVVLTAPEKWRNPEDLPVSMQOIVSNLKYNSVLTAKSNRTWSQCVTHLTLVLTWLE 180
DB 121 SISVVLTAPEKWRNPEDLPVSMQOIVSNLKYNSVLTAKSNRTWSQCVTHLTLVLTWLE 180
QY 181 PNTLYCVHVESFVPGPPRRAPSEKQACATLKDQSEFPKAK 221
DB 181 PNTLYCVHVESFVPGPPRRAPSEKQACATLKDQSEFPKAK 221

RESULT 4
ADJ83292
ID ADJ83292 standard; protein; 221 AA.
AC ADJ83292;
XX
XX 06-MAY-2004 (first entry)
XX
XX Human IL-20RA subunit extracellular domain protein - SEQ ID 12.
DE
XX
XX inflammation; single chain antibody; interleukin; IL-20; IL-20RA subunit;
KW IL-20RB subunit; antiinflammatory; dermatological; antipsoriatic;
KW antiarthritic; respiratory; antiasthmatic; anticancer; antibacterial;
KW immunosuppressive; gastrointestinal; skin; psoriasis; eczema;

KW atopic dermatitis; contact dermatitis; lung;
KW adult respiratory distress syndrome; asthma; bronchitis; pneumonia;
KW arthritis; septic shock; multiple organ failure; bowel;
KW ulcerative colitis; Crohn's disease; human; receptor;
KW extracellular domain.
XX
XX Homo sapiens.
XX
XX US2004005320-A1.
XX
XX 08-JAN-2004.
XX
XX 28-APR-2003; 2003US-00424658.
XX
XX 23-DEC-1999; 99US-0171969P.
XX 22-JUN-2000; 2000US-0213341P.
XX 22-DEC-2000; 2000US-00746359.
XX
XX (THOM/) THOMPSON P.
XX (FOST/) FOSTER D C.
XX (XUW/) XU W.
XX (MADD/) MADDEN K L.
XX (KELL/) KELLY J D.
XX (SPRE/) SPRECHER C A.
XX (BLUM/) BLUMBERG H.
XX (EAG/) EAGAN M A.
XX (JASP/) JASPERS S R.
XX (CHAN/) CHANDRASEKHAR Y A.
XX (NOVA/) NOVAK J E.
XX
XX Thompson P, Foster DC, Xu W, Madden KJ, Kelly JD, Sprecher CA,
PI Blumberg H, Eagan MA, Jaepers SR, Chandrasekhar YA, Novak JE;
XX
XX MPI; 2004-081696/08.
XX
XX Reducing or treating inflammation, e.g. inflammatory lung disease,
PT comprises administering an antibody, antibody fragment or single chain
PT antibody that specifically binds to an interleukin (IL)-20RA subunit of
PT an IL-20 receptor.
XX
XX Disclosure; SEQ ID NO 12; 69pp; English.
XX
XX The invention relates to a novel method of reducing or treating
CC inflammation in a mammal which comprises administering an antibody,
CC antibody fragment or single chain antibody which specifically binds to a
CC receptor of interleukin (IL)-20 comprising an IL-20RA subunit and an IL-
CC 20RB subunit. The method of the invention has antiinflammatory,
CC dermatological, antipsoriatic, antiarthritic, respiratory, antiasthmatic,
CC anticancer, antibacterial, immunosuppressive and gastrointestinal
CC applications and may be useful for reducing or treating an inflammation,
CC including an inflammatory skin disease such as psoriasis, eczema, atopic
CC dermatitis and contact dermatitis or an inflammatory lung disease such as
CC adult respiratory distress syndrome, asthma, bronchitis and pneumonia, as
CC well as arthritis, septic shock, multiple organ failure, inflammatory
CC bowel disease, ulcerative colitis or Crohn's disease. The current
CC sequence is that of the human IL-20RA subunit-related protein of the
CC invention.
XX
XX Sequence 221 AA;
SQ

Query Match 100.0%; Score 1200; DB 8; Length 221;
Best Local Similarity 100.0%; Pred. No. 3.3e-112;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANTITFLSINMKNVLTQTPPEGLQGVKVTYTYQYFIYGKKMLNSECN 60
DB 1 VPCVSGGLPKPANTITFLSINMKNVLTQTPPEGLQGVKVTYTYQYFIYGKKMLNSECN 60
QY 61 INRTYCDLSAETSDYEHQYAKVKAIVGTCCKMAESGRFPFLETOIGPPEVALTTDEK 120
DB 61 INRTYCDLSAETSDYEHQYAKVKAIVGTCCKMAESGRFPFLETOIGPPEVALTTDEK 120
QY 121 SISVVLTAPEKWRNPEDLPVSMQOIVSNLKYNSVLTAKSNRTWSQCVTHLTLVLTWLE 180

Db 121 SISVLTLPBEKKRNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
Oy 181 PNTLYCVHVESFVPPRRAPPSKKOCARTLKDOSSSEFKAK 221
Db 181 PNTLYCVHVESFVPPRRAPPSKKOCARTLKDOSSSEFKAK 221

RESULT 5
ABR42390
ID ABR42390 standard; protein; 222 AA.
AC ABR42390;

XX 11-AUG-2003 (first entry)

DE Human soluble interleukin-20 receptor subunit alpha.

KW Human; interleukin-20; receptor; cytokine; signal transduction;
KW antiinflammatory; immunosuppressive; anti-HIV; antiallergic;
KW antiatherosclerotic; neuroprotective; cardiovascular; cardiant;
KW thrombolytic; nephrotropic; haemostatic; cytostatic.

OS Homo sapiens.

XX WO2003035096-A1.

XX 01-MAY-2003.

XX 09-OCT-2002; 2002WO-US029844.

XX 22-OCT-2001; 2001US-0342233P.

XX (EHLI) LILLY & CO ELL.

XX Baldwin DB, Rowlinson SW;

XX WPI; 2003-421366/39.

DR N-PSDB; ACC58076.

PT Treating or preventing inflammation, immune system, cardiovascular and
PT hematopoietic disorders, and regulation of cellular proliferation
PT comprises administering proteins inhibiting cytokine signalling, e.g.
PT LP338s or LP39s.

PS Claim 1; Fig 1; 65pp; English.

XX The present sequence is the protein sequence of the human soluble
CC interleukin-20 (IL20) receptor alpha subunit. The invention provides a
CC method for the treatment and/or prevention of inflammation, immune
CC system, cardiovascular and haematopoietic disorders and regulation of
CC cellular proliferation by inhibiting the binding of a cytokine (e.g.
CC interleukin-15, interleukin-20 and/or interleukin-24) to its receptor
CC complex, thereby preventing signal transduction. The method uses purified
CC soluble receptor proteins, such as the soluble IL20 receptor alpha
CC subunit. A pharmaceutical composition comprising the polypeptide, or a
CC fusion protein including the polypeptide, is useful for modulating the
CC physiology or development of a cell in vivo, in vitro and/or in situ
SQ Sequence 222 AA;

Query Match 100.0%; Score 1200; DB 6; Length 222;
Best Local Similarity 100.0%; Pred. No. 3,3e-112; Mismatches 0; Gaps 0;
Matches 221; Conservative 0; Indels 0; Gaps 0;

Oy 1 VPCVSGGIPKPNATITFLINMKANVLQWTPPEGLQGVKVTYVQYFIYQKKMLNKSECRN 60
Db 1 VPCVSGGIPKPNATITFLINMKANVLQWTPPEGLQGVKVTYVQYFIYQKKMLNKSECRN 60
Oy 61 INRTYCDLSAETSDYEHQYAKVAKINQTKSKVAESGRFPFETQIGPEVALTTDEK 120
Db 61 INRTYCDLSAETSDYEHQYAKVAKINQTKSKVAESGRFPFETQIGPEVALTTDEK 120

Oy 121 SISVLTLPBEKKRNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
Db 121 SISVLTLPBEKKRNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
Oy 181 PNTLYCVHVESFVPPRRAPPSKKOCARTLKDOSSSEFKAK 221
Db 181 PNTLYCVHVESFVPPRRAPPSKKOCARTLKDOSSSEFKAK 221

RESULT 6
AAU12265
ID AAU12265 standard; protein; 542 AA.
AC AAU12265;

XX 24-OCT-2001 (first entry)

DE Human PRO4978 polypeptide sequence.

KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
KW A-peptide; factor VIIA; gene therapy.

OS Homo sapiens.

XX WO200140466-A2.

XX 07-JUN-2001.

XX 01-DEC-2000; 2000WO-US032678.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 09-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99US-0170262P.

XX 20-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 30-DEC-1999; 99WO-US030999.

XX 30-DEC-1999; 99WO-US031243.

XX 05-JAN-2000; 99WO-US031274.

XX 06-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 18-FEB-2000; 2000WO-US004342.

XX 22-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US004914.

XX 01-MAR-2000; 2000WO-US005004.

XX 02-MAR-2000; 2000WO-US005601.

XX 03-MAR-2000; 2000WO-US005841.

XX 10-MAR-2000; 2000US-0187202P.

XX 15-MAR-2000; 2000WO-US006319.

XX 20-MAR-2000; 2000WO-US006884.

XX 21-MAR-2000; 2000WO-US007377.

XX 30-MAR-2000; 2000WO-US007532.

XX 17-MAY-2000; 2000WO-US008435.

XX 22-MAY-2000; 2000WO-US013705.

XX 30-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US014941.

XX 05-JUN-2000; 2000US-0209832P.

XX 28-JUL-2000; 2000WO-US020710.

XX 11-AUG-2000; 2000WO-US022031.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-NOV-2000; 2000WO-US023328.

XX 08-NOV-2000; 2000WO-US030952.

XX 10-NOV-2000; 2000WO-US030873.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI, 2001-408281/43.
 DR N-PSDB; AAS21337.
 XX
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
 PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
 PT breast, prostate, cervical.
 PS
 XX Claim 12; Fig 188; 813pp; English.
 PS
 CC AAU2172-AAU12446 represent novel human secretory and transmembrane PRO
 CC polypeptides. The PRO polypeptides are useful to detect other PRO
 CC polypeptides, to link bioactive molecules to cells expressing PRO
 CC polypeptides, to modulate biological activities of cells expressing PRO
 CC polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumors by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample. Some
 CC of the 275 sequences are also useful to stimulate the release of tumour
 CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
 CC differentiation of chondrocytes, the proliferation or gene expression in
 CC pericyte cells, the release of proteoglycans from cartilage, the
 CC proliferation of inner ear utricular supporting cells or of T-
 CC lymphocytes, the release of a cytokine from peripheral blood monocytes
 CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
 CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
 CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 CC VIIa. The PRO polypeptides can be used in assays to identify molecules
 CC involved in binding interactions. The polynucleotides encoding PRO
 CC polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy
 XX
 SQ Sequence 542 AA;
 Query Match 100.0%; Score 1200; DB 4; Length 542;
 Best Local Similarity 100.0%; Pred. No. 1,2e-111;
 Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VPCVSGGLPKRANITFLSINKNVLQWTPREGIQGVKVTYVQYFIYQKKMLNKSECN 60
 DB 19 VPCVSGGLPKRANITFLSINKNVLQWTPREGIQGVKVTYVQYFIYQKKMLNKSECN 78
 QY 61 INRTYCDLSAETSDYEHQYAKVKAIWGTCCKMAESGRFPPLTQIGPPEVALTTDEK 120
 DB 79 INRTYCDLSAETSDYEHQYAKVKAIWGTCCKMAESGRFPPLTQIGPPEVALTTDEK 138
 QY 121 SISVVLTAPEKWRAPEDLPVSMQOISNLKYNVSLVNTKSNRTSQCVTNHTLVLTMLE 180
 DB 139 SISVVLTAPEKWRAPEDLPVSMQOISNLKYNVSLVNTKSNRTSQCVTNHTLVLTMLE 198
 QY 181 PNTLYCVAVESFVPGPPRRAQPSKQCAATTLKQSSSEPRAX 221
 DB 199 PNTLYCVAVESFVPGPPRRAQPSKQCAATTLKQSSSEPRAX 239
 RESULT 7
 AAU29222
 ID AAU29222 standard; protein; 542 AA.
 XX
 AC AAU29222;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Human PRO polypeptide sequence #199.
 XX
 KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.

XX OS Homo sapiens.
 XX
 PN WO20016848-A2.
 XX
 PD 20-SEP-2001. /
 XX
 PF 28-FEB-2001; 2001WO-US006520.
 XX
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 06-MAR-2000; 2000US-0186968P.
 PR 14-MAR-2000; 2000US-0189320P.
 PR 14-MAR-2000; 2000US-0189328P.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000US-0190828P.
 PR 21-MAR-2000; 2000US-0191007P.
 PR 21-MAR-2000; 2000US-0191048P.
 PR 21-MAR-2000; 2000US-0191314P.
 PR 28-MAR-2000; 2000US-0192655P.
 PR 29-MAR-2000; 2000US-0193032P.
 PR 29-MAR-2000; 2000US-0193053P.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 04-APR-2000; 2000US-0194449P.
 PR 04-APR-2000; 2000US-0194647P.
 PR 11-APR-2000; 2000US-0195975P.
 PR 11-APR-2000; 2000US-0196000P.
 PR 11-APR-2000; 2000US-0196187P.
 PR 11-APR-2000; 2000US-0196690P.
 PR 11-APR-2000; 2000US-0196820P.
 PR 18-APR-2000; 2000US-0198121P.
 PR 18-APR-2000; 2000US-0198585P.
 PR 25-APR-2000; 2000US-0199397P.
 PR 25-APR-2000; 2000US-0199550P.
 PR 25-APR-2000; 2000US-0199654P.
 PR 03-MAY-2000; 2000US-0201516P.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 05-JUN-2000; 2000US-0209832P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 22-AUG-2000; 2000US-00644848.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034956.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL,
 PI Pan U, Smith V, Watanabe CK, Wood WI, Zhang Z;
 DR WPI, 2001-602746/68.
 DR N-PSDB; AAS46123.
 XX
 PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the
 PT presence of tumors, such as prostate and breast tumors, in mammals and to
 PT screen for modulators of the compounds.
 XX
 PS Claim 11; Fig 398; 774pp; English.
 PS
 CC Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
 CC The PRO polypeptides and their associated nucleic acids can be used to
 CC detect the presence of a tumour in a mammal by comparing the level of
 CC expression of a PRO polypeptide in a test sample of cells from the animal
 CC and a control sample of normal cells, whereby a higher level of
 CC expression in the test sample indicates the presence of a tumour in the
 CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
 CC and rabbits but are preferably human. The polypeptides can be used to
 CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
 CC when contacted with it. A specific polypeptide can be used to stimulate

CC the proliferation or differentiation of chondrocyte cells. The PRO
CC proteins can be used to determine the presence of tumours and also
CC susceptibility to tumour development, particularly adrenal, lung, colon,
CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC can be used for genetic analysis of individuals with genetic disorders
XX
SQ Sequence 542 AA;

Query Match 100.0%; Score 1200; DB 4; Length 542;
Best Local Similarity 100.0%; Pred. No. 1,2e-111;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKRANITTFISINMKNVLQWTPPEGIGVGVYTYVYVYFIYGKKMINKSECRN 60
Db 19 VPCVSGGLPKRANITTFISINMKNVLQWTPPEGIGVGVYTYVYVYFIYGKKMINKSECRN 78
QY 61 INRTYCDLSAETSYEHQYAKYKAIWGTCKSKMAESGRVYPLETOIGPPEVALTTDEK 120
Db 79 INRTYCDLSAETSYEHQYAKYKAIWGTCKSKMAESGRVYPLETOIGPPEVALTTDEK 138
QY 121 SISVVLTAPEKMKRPEDLPVSMQOIYSNLKYNVSVLNTKSNRTWGOCTVNTHTLVLTWLE 180
Db 139 SISVVLTAPEKMKRPEDLPVSMQOIYSNLKYNVSVLNTKSNRTWGOCTVNTHTLVLTWLE 198
QY 181 PNTLYCVHVESFVGPFRRAQSEKOCARTLKQSSSEFPKX 221
Db 199 PNTLYCVHVESFVGPFRRAQSEKOCARTLKQSSSEFPKX 239

RESULT 8
ABUS8598
ID ABUS8598 standard; protein; 542 AA.
XX

AC ABUS8598;

XX 15-APR-2003 (first entry)

XX Human PRO polypeptide #199.

XX Human; PRO; cytosol; cancer; breast; lung; stomach; liver;
KW dog; cat; cow; horse; sheep; pig; goat; rabbit; ADPPT;
XX antibody-dependent enzyme mediated prodrug therapy.

XX Homo sapiens.

XX US2003027272-A1.

XX 06-FEB-2003.

XX 21-JUN-2002; 2002US-00176492.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 17-OCT-1997; 97US-0062250P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0063120P.

XX 28-OCT-1997; 97US-0063540P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063734P.

XX 31-OCT-1997; 97US-0063870P.

XX 31-OCT-1997; 97US-0064103P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066120P.

XX 24-NOV-1997; 97US-0066466P.

XX 11-DEC-1997; 97US-0069333P.

XX 12-DEC-1997; 97US-0069425P.

XX 17-DEC-1997; 97US-0069870P.

XX 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 29-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 09-JUN-1998; 98US-0088217P.
PR 10-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089514P.
PR 16-JUN-1998; 98US-0089512P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.

PR 24-JUN-1998; 98US-0090422P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095988P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 09-SEP-1998; 98US-0098843P.
PR 10-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.

PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103448P.
PR 07-OCT-1998; 98US-00168978.

Query Match 100.0%; Score 1200; DB 6; Length 542;
Best Local Similarity 100.0%; Pred. No. 1,2e-111;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANITFLSINMKNTVLQMTPEGLQGVKTTYVQVFIYQOKKWLKSECRN 60
DB 19 VPCVSGGLPKPANITFLSINMKNTVLQMTPEGLQGVKTTYVQVFIYQOKKWLKSECRN 78

QY 61 INRTYCDLSAETSDVEHOYVAKVKAIWGTCKSKAESGRFPLETOIGPPEVALTTTEK 120
DB 79 INRTYCDLSAETSDVEHOYVAKVKAIWGTCKSKAESGRFPLETOIGPPEVALTTTEK 138

QY 121 SISVLTAPKPKRNPEDLPVSMQIYSNLKYNNSVLNTKSNRTWSQCVTNHTLVLTWLE 180
DB 139 SISVLTAPKPKRNPEDLPVSMQIYSNLKYNNSVLNTKSNRTWSQCVTNHTLVLTWLE 198

QY 181 PNTLYCVHVESFVPGPPRRAPQSEKQCARLTKDQSSFEKAK 221
DB 199 PNTLYCVHVESFVPGPPRRAPQSEKQCARLTKDQSSFEKAK 239

ID ABU08146 standard; protein; 542 AA.
ABU08146
XX AC ABU08146;
XX DT 07-JUL-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4978.
XX DE Human; secreted and transmembrane protein; PRO; gene therapy;
KW tumour necrosis factor-alpha release; TNF-alpha release; tumour;
KW chondrocyte proliferation; chondrocyte differentiation; tumour;
KW adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX PN US2003032127-A1.
XX PD 13-FEB-2003.
XX PF 26-JUN-2002; 2002US-00183012.
XX PR 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PR 17-OCT-1997; 97US-0064250P.
XX PR 21-OCT-1997; 97US-0063486P.
XX PR 24-OCT-1997; 97US-0063120P.
XX PR 24-OCT-1997; 97US-0063121P.
XX PR 28-OCT-1997; 97US-0063540P.
XX PR 28-OCT-1997; 97US-0063541P.
XX PR 28-OCT-1997; 97US-0063544P.
XX PR 28-OCT-1997; 97US-0063564P.
XX PR 29-OCT-1997; 97US-0063734P.
XX PR 31-OCT-1997; 97US-0063870P.
XX PR 31-OCT-1997; 97US-0064103P.
XX PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0066017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0079939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085822P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 28-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088217P.
PR 05-JUN-1998; 98US-0088219P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088723P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 25-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095988P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 23-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.

PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

Query Match 100.0%; Score 1200; DB 6; Length 542;
Best Local Similarity 100.0%; Pred. No. 1,2e-111;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKRANITFLSINMKNVQWTPPEGLQGVKTYTYQYFIYQKKKLNKSEGN 60
DB 19 VPCVSGGLPKRANITFLSINMKNVQWTPPEGLQGVKTYTYQYFIYQKKKLNKSEGN 78
QY 61 INRTCDLSAETSDYEHQYAKVKAIWGTCKSKMAESGRFPLETOIGPPEVALTTDEK 120
DB 79 INRTCDLSAETSDYEHQYAKVKAIWGTCKSKMAESGRFPLETOIGPPEVALTTDEK 138
QY 121 SISVVLTAPEKRNPEDLVPSMOQIYSNLKYNVSVLTKSNRTWSQCVNHTLVLTWLE 180
DB 139 SISVVLTAPEKRNPEDLVPSMOQIYSNLKYNVSVLTKSNRTWSQCVNHTLVLTWLE 198
QY 181 PNTLYCVAVESVFPGRRAQSEKQCARTLLDOSSEFPKAK 221
DB 199 PNTLYCVAVESVFPGRRAQSEKQCARTLLDOSSEFPKAK 239

RESULT 10

ABU84461
ID ABU84461 standard; protein; 542 AA.

AC ABU84461;

XX 02-AUG-2003 (first entry)

DE Human secreted/transmembrane protein (PRO) #199.

XX Human; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing.

XX Homo sapiens.

XX US2003032112-A1.

XX 13-FEB-2003.

XX 21-JUN-2002; 2002US-00176756.

XX 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 21-OCT-1997; 97US-0062250P.

PR 24-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069425P.
PR 18-DEC-1997; 97US-0069870P.
PR 10-MAR-1998; 98US-007450P.
PR 11-MAR-1998; 98US-007633P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085882P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 05-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.

```

PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090451P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091549P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095988P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096767P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099603P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.

```

```

PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101766P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

```

Query Match 100.0%; Score 1200; DB 6; Length 542;
 Best Local Similarity 100.0%; Pred. No. 1,2e-111;
 Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 VPCVSGGLPKRPANTPTFSIMKNVLTQTPPEGLQGVKVTYVYFYFGQKMKNSBCRN 60
DB 19 VPCVSGGLPKRPANTPTFSIMKNVLTQTPPEGLQGVKVTYVYFYFGQKMKNSBCRN 78
QY 61 INRTYCDLSAETSDYEHQYAKYKAIWGTCSKMAESGRFPLEFIQIGPEVALTTDEX 120
DB 79 INRTYCDLSAETSDYEHQYAKYKAIWGTCSKMAESGRFPLEFIQIGPEVALTTDEX 138
QY 121 SISVLTAPBPKRMKNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQVNTHTLVLTWLE 180
DB 139 SISVLTAPBPKRMKNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQVNTHTLVLTWLE 198
QY 181 PNTLYCVHVSFPVGPBPRAPQSEKOCARTLKQSSSEFPK 221
DB 199 PNTLYCVHVSFPVGPBPRAPQSEKOCARTLKQSSSEFPK 239

```

```

RESULT 11
ABR66335
ID ABR66335 standard; protein; 542 AA.
XX
AC ABR66335;
XX
DT 05-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO4978, SEQ ID NO:398.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antithrombotic; vulnerary; gene therapy.
XX
OS Homo sapiens.
XX
PN US2003027278-A1.
XX
PD 06-FEB-2003.
XX
PF 21-JUN-2002; 2002US-00176987.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.

```

PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 11-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085799P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088031P.
PR 04-JUN-1998; 98US-0088032P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089658P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090679P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095989P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0098017P.
PR 01-SEP-1998; 98US-0098169P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.

PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102311P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match Best Local Similarity 100.0%; Score 1200; DB 6; Length 542;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANITFLSINMKNVLTQTPPEGLQGVKVVYVYQFYIGQKMLNKSECRN 60
DB 19 VPCVSGGLPKPANITFLSINMKNVLTQTPPEGLQGVKVVYVYQFYIGQKMLNKSECRN 78
QY 61 INRTYCDLSAETSDYHOYAYAKAIWTKCKSKMAESGFPYPLETOIGPREVALTTDEK 120
DB 79 INRTYCDLSAETSDYHOYAYAKAIWTKCKSKMAESGFPYPLETOIGPREVALTTDEK 138
QY 121 SISVVLTAPEKMKRNEDLPVSMQOITYSNLKTNVSVLNTKSRMTSQCVTHTLVLTWLE 180
DB 139 SISVVLTAPEKMKRNEDLPVSMQOITYSNLKTNVSVLNTKSRMTSQCVTHTLVLTWLE 198
QY 181 PNTLYCVHVESFVPGPPRAOPSEKQCAFTLKDQSEFPYAK 221
DB 199 PNTLYCVHVESFVPGPPRAOPSEKQCAFTLKDQSEFPYAK 239

RESULT 12
ABR65725

ID ABR65725 standard; protein; 542 AA.

AC ABR65725;

DT 05-AUG-2003 (first entry)

DE Human secreted polypeptide PRO4978, SEQ ID NO:398.

KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumor necrosis factor- α chain; TNF- α ; TNF- α ;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumor; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy.

OS Homo sapiens.

XX US2003036159-A1.

XX 20-FEB-2003.

XX 02-JUL-2002; 2002US-00188773.
PF 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 08-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083595P.
PR 29-APR-1998; 98US-0083599P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088831P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089518P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089608P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095988P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.

PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 100.0%; Score 1200; DB 6; Length 542;

Best Local Similarity 100.0%; Pred. No. 1.2e-111; Mismatches 221; Conservative 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANITFLSINMGNVLQWTPPEGIGQVKTYYQVFIYQKMKLNKSECN 60
DB 19 VPCVSGGLPKPANITFLSINMGNVLQWTPPEGIGQVKTYYQVFIYQKMKLNKSECN 78
QY 61 INRTYCDLSAETSDYEHQYAKVKAIWGTCKSKMAESGRFYFLETQICPPVVALTTDEK 120
DB 79 INRTYCDLSAETSDYEHQYAKVKAIWGTCKSKMAESGRFYFLETQICPPVVALTTDEK 138
QY 121 SISVLTAPKPKRPPEDLPVSMQOYISLTKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
DB 139 SISVLTAPKPKRPPEDLPVSMQOYISLTKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 198
QY 181 PNTLYCVHVESFVPGPPRAQPSKOCARTLKDQSSSEFAK 221
DB 199 PNTLYCVHVESFVPGPPRAQPSKOCARTLKDQSSSEFAK 239

RESULT 13

ABU99665
ID ABU99665 standard; protein; 542 AA.

XX ABU99665;

DT 09-AUG-2003 (first entry)

DE Human secreted/transmembrane protein (PRO) #199.

XX Human; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

XX tissue typing.

OS Homo sapiens.

XX US2003040070-A1.

PR 10-SEP-1998; 98US-0099741P.
 PR 10-SEP-1998; 98US-0099754P.
 PR 10-SEP-1998; 98US-0099763P.
 PR 10-SEP-1998; 98US-0099812P.
 PR 15-SEP-1998; 98US-0100388P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 16-SEP-1998; 98US-0101751P.
 PR 16-SEP-1998; 98US-0101751P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100684P.
 PR 17-SEP-1998; 98US-0100919P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-0101068P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101739P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101922P.
 PR 25-SEP-1998; 98US-0101786P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0016897B.

Query Match 100.0%; Score 1200; DB 6; Length 542;
 Best Local Similarity 100.0%; Pred. No. 1.2e-111;

Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANITFLSINMKNVLTQWTPPEGLOGVKVTYVQYFIQKMKLNKSECN 60
 DB 19 VPCVSGGLPKPANITFLSINMKNVLTQWTPPEGLOGVKVTYVQYFIQKMKLNKSECN 78
 QY 61 INRTYCDLSAETSDYEHQYKAIWGTCKSKMAESGRFPFLETOIGPPEVALTTDEK 120
 DB 79 INRTYCDLSAETSDYEHQYKAIWGTCKSKMAESGRFPFLETOIGPPEVALTTDEK 138
 QY 121 SISVVLTAPEKKRNPEDLPVMOQIYSMLKXNVSLTNKSNRTWSQCVTNHTLVLTWLE 180
 DB 139 SISVVLTAPEKKRNPEDLPVMOQIYSMLKXNVSLTNKSNRTWSQCVTNHTLVLTWLE 198
 QY 181 PNTLYCVHVESFVPGPRAPQSEKQCAATLKDOSEFFAK 221
 DB 199 PNTLYCVHVESFVPGPRAPQSEKQCAATLKDOSEFFAK 239

RESULT 14

ABU82904
 ID ABU82904 standard; protein; 542 AA.

AC ABU82904;

XX 27-JUN-2003 (first entry)

DE Human PRO polypeptide #199.

KW Human; PRO polypeptide; secreted and transmembrane protein; tumour;

KX chromosome mapping; gene mapping; cytostatic.

XX

OS Homo sapiens.
 XX 18-SEP-1997; 97US-0059263P.
 XX 18-SEP-1997; 97US-0059266P.
 PN US2003032113-A1.
 XX 17-OCT-1997; 97US-0063250P.
 PD 13-FEB-2003.
 XX 21-OCT-1997; 97US-0063486P.
 XX 24-OCT-1997; 97US-0063120P.
 XX 24-OCT-1997; 97US-0063121P.
 XX 28-OCT-1997; 97US-0063544P.
 XX 28-OCT-1997; 97US-0063544P.
 XX 28-OCT-1997; 97US-0063564P.
 XX 29-OCT-1997; 97US-0063734P.
 XX 31-OCT-1997; 97US-0063870P.
 XX 31-OCT-1997; 97US-0064103P.
 XX 13-NOV-1997; 97US-0065311P.
 XX 24-NOV-1997; 97US-0065120P.
 XX 24-NOV-1997; 97US-0065466P.
 XX 24-NOV-1997; 97US-0065772P.
 XX 11-DEC-1997; 97US-0069335P.
 XX 12-DEC-1997; 97US-0069425P.
 XX 17-DEC-1997; 97US-0069870P.
 XX 18-DEC-1997; 97US-0068017P.
 XX 10-MAR-1998; 98US-0077450P.
 XX 11-MAR-1998; 98US-0077632P.
 XX 11-MAR-1998; 98US-0077649P.
 XX 20-MAR-1998; 98US-0078886P.
 XX 20-MAR-1998; 98US-0078939P.
 XX 27-MAR-1998; 98US-0079664P.
 XX 27-MAR-1998; 98US-0079786P.
 XX 31-MAR-1998; 98US-0080107P.
 XX 31-MAR-1998; 98US-0080194P.
 XX 01-APR-1998; 98US-0080327P.
 XX 01-APR-1998; 98US-0080333P.
 XX 06-APR-1998; 98US-0081049P.
 XX 08-APR-1998; 98US-0081070P.
 XX 09-APR-1998; 98US-0081195P.
 XX 15-APR-1998; 98US-0081838P.
 XX 21-APR-1998; 98US-0082568P.
 XX 22-APR-1998; 98US-0082569P.
 XX 22-APR-1998; 98US-0082704P.
 XX 22-APR-1998; 98US-0082797P.
 XX 28-APR-1998; 98US-0083322P.
 XX 29-APR-1998; 98US-0083495P.
 XX 29-APR-1998; 98US-0083496P.
 XX 29-APR-1998; 98US-0083499P.
 XX 29-APR-1998; 98US-0083559P.
 XX 05-MAY-1998; 98US-0084366P.
 XX 06-MAY-1998; 98US-0084414P.
 XX 07-MAY-1998; 98US-0084639P.
 XX 07-MAY-1998; 98US-0084640P.
 XX 07-MAY-1998; 98US-0084643P.
 XX 15-MAY-1998; 98US-0085579P.
 XX 15-MAY-1998; 98US-0085580P.
 XX 15-MAY-1998; 98US-0085582P.
 XX 15-MAY-1998; 98US-0085700P.
 XX 18-MAY-1998; 98US-0086023P.
 XX 22-MAY-1998; 98US-0086392P.
 XX 22-MAY-1998; 98US-0086486P.
 XX 28-MAY-1998; 98US-0087098P.
 XX 28-MAY-1998; 98US-0087208P.
 XX 02-JUN-1998; 98US-0087609P.
 XX 02-JUN-1998; 98US-0087759P.
 XX 03-JUN-1998; 98US-0087827P.
 XX 04-JUN-1998; 98US-0088025P.
 XX 04-JUN-1998; 98US-0088028P.
 XX 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089538P.
PR 18-JUN-1998; 98US-0089538P.
PR 19-JUN-1998; 98US-0089538P.
PR 19-JUN-1998; 98US-0089538P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090252P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090441P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 25-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091559P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095988P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096869P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.

PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102311P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 100.0%; Score 1200; DB 6; Length 542;
Best Local Similarity 100.0%; Pred. No. 1,2e-111; Indels 0; Gaps 0;
Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VPCVSGGLPKPANITLSTINMKVLIQWTPPEGLQGVKVTYVQYFIYQKKMLNKSECRN 60
DB 19 VPCVSGGLPKPANITLSTINMKVLIQWTPPEGLQGVKVTYVQYFIYQKKMLNKSECRN 78
QY 61 INRTYCDLSAETSDYEHQYAVKAIWGTCKSKMAESGRFVFLFTQIGPPEVALTTDEK 120
DB 79 INRTYCDLSAETSDYEHQYAVKAIWGTCKSKMAESGRFVFLFTQIGPPEVALTTDEK 138
QY 121 SISVITLAPKWKRPEDIPVSMQIYSNLKXTNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
DB 139 SISVITLAPKWKRPEDIPVSMQIYSNLKXTNVSVLNTKSNRTWSQCVTNHTLVLTWLE 198
QY 181 PNTLYCVHVESFVPPRRAPQSEKQCARITLKQDSSEFKAK 221
DB 199 PNTLYCVHVESFVPPRRAPQSEKQCARITLKQDSSEFKAK 239

RESULT 15
ABO17709
ID ABO17709 standard; protein; 542 AA.
XX ABO17709;
AC
XX
DT 26-AUG-2003 (first entry)
XX

DE Novel human secreted and transmembrane protein PRO4978.
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiact; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bio reactor; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003032156-A1.
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUN-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005120.
PR 10-MAR-1999; 99WO-US005150.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030035.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX WPI, 2003-341980/32.
XX N-PEDB; ACD23946.
XX
XX New secreted and transmembrane PRO nucleic acids, for treating
XX inflammation, organ failure, atherosclerosis, cardiac injury,
XX infertility, birth defects, premature aging, acquired immunodeficiency
XX syndrome (AIDS), or cancer.
XX
XX Claim 12; Fig 188; 660pp; English.
XX
XX The invention describes an isolated nucleic acid (I) comprising, or which
XX has 80 % sequence identity to, or the full-length coding sequence of, one
XX of 275 nucleotide sequences, and which encodes a corresponding
XX polypeptide selected from 275 amino acid sequences, where all sequences
XX are given in the specification. The polypeptide encoded by (I) is used to
XX detect PRO polypeptides, link a bioactive molecule to a cell expressing a
XX PRO polypeptide, modulate a biological activity of a cell, stimulate the
XX release of tumour necrosis factor (TNF)-alpha from human blood, modulate
XX the uptake of glucose or free fatty acid by cells, stimulate or inhibit

CC the proliferation or differentiation of cells or gene expression,
 CC stimulate the release of proteoglycans, stimulate the release of cytokine
 CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
 CC to factor VIIa, or detect the presence of tumour in a mammal. The nucleic
 CC acid and polypeptide encoded by it, are useful for treating inflammatory
 CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
 CC birth defects, premature aging, acquired immunodeficiency syndrome
 CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
 CC hybridisation probes, in chromosome and gene mapping, and in generating
 CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
 CC This is the amino acid sequence of a novel human secreted and
 CC transmembrane PRO polypeptide
 XX

Sequence 542 AA;

Query Match 100.0%; Score 1200; DB 6; Length 542;
 Best Local Similarity 100.0%; Pred. No. 1.2e-111;
 Matches 221; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	VPCVSGGLPKPANTTFISIMKAVLQWTPPEGLQGVKVTYTVQYFIYGOKWLNKSECRN	60
Db	19	VPCVSGGLPKPANTTFISIMKAVLQWTPPEGLQGVKVTYTVQYFIYGOKWLNKSECRN	78
Qy	61	INRTYCDLSAETSDEHYQYAKYKATWGTCCKMAESGRYPPLFTQIGPPEVALTTDEK	120
Db	79	INRTYCDLSAETSDEHYQYAKYKATWGTCCKMAESGRYPPLFTQIGPPEVALTTDEK	138
Qy	121	SISVVLTAPEKWRNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE	180
Db	139	SISVVLTAPEKWRNPEDLPVSMQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE	198
Qy	181	PNTLYCVHVESFVPGPPRRAQPESEKQARTLKDQSSSEFRK	221
Db	199	PNTLYCVHVESFVPGPPRRAQPESEKQARTLKDQSSSEFRK	239

Search completed: February 25, 2005, 02:39:44
 Job time : 132.743 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 25, 2005, 02:33:14 ; Search time 25.5401 Seconds
(without alignments)
832.570 Million cell updates/sec

Title: US-09-745-792a-12

Perfect score: 1200
Sequence: 1 VPCVSGGLKPANITFLSIN.....PSEKQARTLKQSSSEPKAK 221

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : PIR_79:1*
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	232.5	19.4	325	2 A47003	cytokine receptor
2	230.5	19.2	349	2 JC6311	interferon receptor
3	196	16.3	590	2 A45283	interferon alpha/b
4	186.5	15.5	560	2 S27387	interferon alpha
5	168.5	14.0	557	2 A32694	interferon alpha/b
6	163.5	13.6	489	2 A31555	interferon gamma r
7	159	13.2	575	2 A49667	interleukin-10 rec
8	143	11.9	578	2 I56215	interleukin-10 rec
9	138.5	11.5	332	2 A49947	interferon gamma r
10	137	11.4	477	2 A34368	interferon gamma r
11	136.5	11.4	337	2 I38500	interferon gamma r
12	135.5	11.3	295	1 KFHU3	tissue factor prec
13	131.5	11.0	294	1 KFM53	tissue factor prec
14	130	10.8	292	1 KFRB3	tissue factor prec
15	129	10.8	282	1 KFRB3	tissue factor prec
16	118.5	9.9	26926	1 I38344	titin, cardiac mus
17	115	9.6	515	2 I39073	interferon alpha-b
18	112	9.3	331	2 A54295	interferon alpha/b
19	112	9.3	331	2 A59501	interferon recepto
20	109.5	9.1	896	2 I56562	interleukin-3 rece
21	105.5	8.8	896	1 A35782	cytokine receptor
22	101	8.4	917	2 I49699	glycoprotein 130 -
23	100.5	8.4	2302	2 T14328	protein-tyrosine-p
24	98.5	8.2	976	2 A36355	hypothetical prote
25	95.5	8.0	1014	2 T24412	hypothetical prote
26	95.5	8.0	1091	2 S01998	contactin precursor
27	95.5	8.0	2215	2 T00348	LR11 protein - mou
28	94.5	7.9	266	2 T28607	hypothetical prote
29	94.5	7.9	266	2 H72172	H9R protein - vari

30	93.5	7.8	266	2 I36855	gene B9R protein -
31	93.5	7.8	6658	2 T13931	proteoglycan - fruit
32	91.5	7.6	272	2 JQ1802	B6R 31K protein pr
33	91.5	7.6	2029	1 TDFELK	protein-tyrosine-p
34	90	7.5	1344	2 T14316	rig-1 protein - mo
35	90	7.5	1375	2 T13822	frazzled gene prot
36	90	7.5	1526	2 T19473	hypothetical prote
37	90	7.5	1526	2 T13823	frazzled gene prot
38	89.5	7.5	1897	1 TDHULK	leukocyte antigen-
39	89.5	7.5	1898	2 S46216	leukocyte antigen-
40	89	7.4	897	1 A39255	cytokine receptor
41	88.5	7.4	272	2 G42526	B6R protein - vacc
42	88.5	7.4	977	2 S49004	tyrosine kinase Mp
43	88	7.3	948	2 S51605	receptor-like tyro
44	86.5	7.2	440	2 I50213	protein-tyrosine-p
45	86.5	7.2	525	2 E86463	hypothetical prote

ALIGNMENTS

RESULT 1

A47003
Cytokine receptor family class II protein CRP2-4 precursor - human
C/Species: Homo sapiens (man)
C/Date: 09-Sep-1994 #sequence_revision 09-Sep-1994 #text_change 09-Jul-2004
C/Accession: A47003; G01418
R/Lutifalla, G.; Gardner, K.; Uze, G.
Genomics 16, 366-373, 1993
A/Title: A new member of the cytokine receptor gene family maps on chromosome 21 at 16p.
A/Reference number: A47003; PMID:93300510; PMID:8314576
A/Accession: A47003
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-325 <LU2>
A/Cross-references: UNIPROT:Q08334; GB:217227; NID:G393378; PIDN:CAA78933.1; PID:G393377.
R/Lutifalla, G.
submitted to the EMBL Data Library, April 1994
A/Reference number: G06935
A/Accession: G01418
A/Status: preliminary; translated from GB/EMBL/DBD
A/Molecule type: DNA
A/Residues: 1-123, 'D', 125-268, 'VGMR' <LU2>
A/Cross-references: EMBL:U08988; NID:G571295; PID:G571296
C/Genetics:
A/Gene: GDB:CRP2-4
A/Cross-references: GDB:138168; OMIM:123889
A/Map position: 21q, 21q22.1-21q22.2
A/Intons: 17/1; 58/2; 111/1; 166/3; 216/1
C/Keywords: transmembrane protein

Query Match 19.4%; Score 232.5; DB 2; Length 325;
Best Local Similarity 29.2%; Pred. No. 3.9e-12;
Matches 63; Conservative 36; Mismatches 94; Indels 23; Gaps 6;

Qy	6	GGLPKPNITFLSINKNVLTQTPPGLOGVKTYTVQVFIYQOKMLNKGKINRTY	65
Db	19	GMVPPENVMNSVKNILQWESPAFKG-NITFLAQVLSYR-----IPDCKMNTLTLE	73
Qy	66	CDLSAETSDYEHQYAKVAKIWTGKCSKMAESGRFPFLETQIGPPEVALTTDEKISV	125
Db	74	CDSSLSKYGDHT--LRVRAEFADSHSDWNI-TFCPVDDTIIGPQMQLVLAADSLMR	130
Qy	126	LTAP-----EKKRNPEDIPVSMQQLYSNLKYNVSLNKSRTWSQCTNHTLTIVTWL	179
Db	131	FLAPKLENEYETV-----TMKVYNSWTNVOYKNGKTDKFOITPQYDFEVLRL	181
Qy	180	EPNTLYCVHVESFVPPRRAPQSEKQACATLKDS	215
Db	182	EPWTTCVQVRGFLPDRNKAQSESEVCEGTHDET	217

RESULT 2

JC6311
 Interferon receptor class II cytokine receptor - mouse
 C:Species: Mus musculus (house mouse)
 C>Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 09-Jul-2004
 C:Accession: J06311
 R:Gibbs, V.C.; Fennica, D.
 Gene 186, 97-101, 1997
 A:Title: CRP2-4: isolation of cDNA clones encoding the human and mouse proteins.
 A:Reference number: J06311; MUID:97199375; PMID:9047351
 A:Accession: J06311
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-349 <GIB>
 A:Cross-references: UNIPROT:O8VHM7; GB:U53696

Query Match 19.2%; Score 230.5; DB 2; Length 349;
 Best Local Similarity 29.8%; Pred. No. 6.3e-12;
 Matches 67; Conservative 35; Mismatches 100; Indels 23; Gaps 8;
 QY 2 PCVSGGL-----PKRANITPLSINMKNVLTQWTPPEGLQGVKVTYVQYFYQ 49
 DB 3 PCVAGMLGGFLVLPALGMIPPEKVRMNSVNFKNILQWEVP-APPKNTLTFTAGYESYRS 61
 QY 50 KKWINKSECRNINFTYCDLSAFTSDYEHQYAKYKAIWGTCKSKMAESGRFPPELTQIG 109
 DB 62 ----FQDHCKRTASTQCDPS-HLSKY-GDYTVRVRABELADHSEWV-NVTFCEPVEDTIIIG 114
 QY 110 PPEVALTTDEKISIVLTAPPEKMKRNPEDLFVSMQOYSLNKYNSVLNTRKSNRTWQCVC 169
 DB 115 PPEMIGESLBSLHFRSAPQ-INNEPBTM-TLKANIYDSWAYKAVQYKNGKTEKEFQVVS 171
 QY 170 TNNHTLVLTWLEPNTLYCVHVESFVGPERRAOPSEKOCARTLKDQ 214
 DB 172 PYDESVLRNLEPMTTYCIVQGVFLDQNRGTGEMSEPICERTGNDE 216

RESULT 3

A45283
 Interferon alpha/beta receptor - mouse

C:Species: Mus musculus (house mouse)
 C>Date: 25-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
 C:Accession: A45283; I48423; I48424; I48425; I48426; I48427; I48428; I48429
 R:Uze, G.; Luftalla, G.; Bandu, M.T.; Proudhon, D.; Mogensen, K.E.
 Proc. Natl. Acad. Sci. U.S.A. 89, 4774-4778, 1992
 A:Title: Behavior of a cloned murine interferon alpha/beta receptor expressed in homospere
 A:Reference number: A45283; MUID:92262522; PMID:1533935
 A:Accession: A45283
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-590 <UZE>
 A:Cross-references: UNIPROT:P33896; GB:M89641; NID:g194111; PIDN:AAA37890.1; PID:g194112
 R:Luftalla, G.; Uze, G.
 Gene 148, 343-346, 1994
 A:Title: Structure of the murine interferon alpha/beta receptor-encoding gene: high-freq
 A:Reference number: I48423; MUID:95047447; PMID:7558966
 A:Accession: I48423
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 118-125 <RES>
 A:Cross-references: EMBL:U06237; NID:g497103; PIDN:AAA65003.1; PID:g755810
 A:Accession: I48424
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 127-224 <RE2>
 A:Cross-references: EMBL:U06238; NID:g497104; PIDN:AAAC01749.1; PID:g755811
 A:Accession: I48425
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 243-264 <RE3>
 A:Cross-references: EMBL:U06239; NID:g497106; PIDN:AAA65004.1; PID:g510261
 A:Accession: I48426
 A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA
 A:Residues: 265-375 <RE4>
 A:Cross-references: EMBL:U06240; NID:g497108; PIDN:AAA65005.1; PID:g510262
 A:Accession: I48427
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 397-424 <RE5>
 A:Cross-references: EMBL:U06241; NID:g497110; PIDN:AAA65006.1; PID:g755812
 A:Accession: I48428
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 426-445 <RE6>
 A:Cross-references: EMBL:U06242; NID:g497112; PIDN:AAA65007.1; PID:g755813
 A:Accession: I48429
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 473-590 <RE7>
 A:Cross-references: EMBL:U06244; NID:g497114; PIDN:AAA65008.1; PID:g510265
 A:Gene: IFNAR
 A:Interons: 177/3, 331/1
 C:Keywords: cytokine receptor; transmembrane protein

Query Match 16.3%; Score 196; DB 2; Length 590;
 Best Local Similarity 25.5%; Pred. No. 9.7e-09;
 Matches 55; Conservative 39; Mismatches 104; Indels 18; Gaps 5;
 QY 1 VPCVSGG--LPRANITPLSINMKNVLTQWTPPEGLQGVKVTYVQYFYQKKMLNKSSEC 58
 DB 20 LPSAAGGENTLKPENIDVYIIDNNTYTLKSSHGSEMG-SYFSALEVRKDEKMLKYVEEC 78
 QY 59 RNINFTYCDLSAFTSDYEHQYAKYKAIWGTCKSKMAESGRFPPELTQIGPEVALTTD 118
 DB 79 QHTTTKCBFLSDTNTVYIKQFVRABEGNSTGWEVDPIFYTAHMSPPREVRLEAE 138
 QY 119 EKSIISVLTAP---EKMKRNPEDLFVSMQOYSLNKYNSVLNTRKSNRTWQCCTNHTL 174
 DB 139 DKAILVHSPGQGDGMW-----ALEK-PSFSTIRIMKSSDDKKTINSTIYVE 187
 QY 175 VLTWLEPNTLYCVHVESFVGPERRAOPSEKOCART 210
 DB 188 KIPELLPTTYCLEYKAIHPSLKGHSVNSTVQCIST 223

RESULT 4

S27387
 Interferon alpha receptor type 1 precursor - bovine

C:Species: Bos primigenius taurus (cattle)
 C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
 C:Accession: S27387; S33770
 R:Monochel-Vielh, E.; Luftalla, G.; Mogensen, K.E.; Uze, G.
 FEBS Lett. 313, 255-259, 1992
 A:Title: Specific antiviral activities of the human alpha interferons are determined at
 A:Reference number: S27387; MUID:93076908; PMID:1446745
 A:Accession: S27387
 A:Status: preliminary; nucleic acid sequence not shown
 A:Molecule type: mRNA
 A:Residues: 1-560 <MOU>
 A:Cross-references: UNIPROT:Q04790; EMBL:X68443; NID:g431; PIDN:CAA48484.1; PID:g432
 A:Experimental source: MDBK cells
 R:Lim, J.K.; Langer, J.A.
 Biochim. Biophys. Acta 1173, 314-319, 1993
 A:Title: Cloning and characterization of a bovine alpha interferon receptor.
 A:Reference number: S33770; MUID:93305725; PMID:8318540
 A:Accession: S33770
 A:Status: preliminary; nucleic acid sequence not shown
 A:Molecule type: mRNA
 A:Residues: 1-421, 'V', 423-560 <LIM>
 A:Cross-references: EMBL:L06320; NID:g163187; PIDN:AAA02571.1; PID:g163188
 A:Experimental source: lung
 C:Keywords: antiviral; cytokine receptor; transmembrane protein
 P:1-34/Domain: signal sequence #status predicted <SIG>
 P:25-560/Product: Interferon alpha receptor type 1 #status predicted <MAT>

	Query Match	15.5%	Score 186.5	DB 2	Length 560;
	Best Local Similarity	28.7%	Pred. No. 5,7e-08;		
	Matches	56;	Conservative	38;	Mismatches 88; Indels 13; Gaps 8;
OY	1 VPCVSGGLP-KPANTFLSLNNKVNLTWTPBEGLOGVK-VITYVOFYIYGKKMLNNSGC	58			
Db	19 LPAASGEANLPENVEIHIIIDNPFLKN--SSSESVAGNVFSDADYQILGTDNMKLSGC	76			
OY	59 RNIRTYCDLA-ETSDYEHOYAKVIMGTSKMSRSPFLPETOIGPEVALTT	117			
Db	77 OHISTCKNFSSVELNEVFKELELRIPAEKGNTSTWTEVEBPFFLEAQIGPPVHLAA	136			
OY	118 DEKSISVVLTAPEKKRNRPEDLPVSMOOIYLNLKYNVS-LNTXSNRTWSOCVTNHTLVL	176			
Db	137 EDKAITLISPP---GTKDSIMMAMDR--SSFRYSVIWMKSSSLBERTETVPEDKIT Y	190			
OY	177 TWLBENTLYCVHVES 191				
Db	191 K-LSPEITVCLKVKA 204				

RESULT 5
A32694
interferon alpha/beta receptor precursor - human
C:Species: Homo sapiens (man)
C:Date: 22-Jun-1990 #sequence_revision 22-Jun-1990 #text_change 09-Jul-2004
C:Accession: A32694; S17112
R:Uze, G.; Lutfalla, G.; Gresser, I.
Cell 60, 225-234, 1990
A:Title: Genetic transfer of a functional human interferon alpha receptor into mouse cells
A:Reference number: A32694; MUID:90124632; PMID:2153461
A:Accession: A32694
A:Molecule type: mRNA
A:Residues: 1-557 <UZE>
A:Cross-references: UNIPROT:P17181; GB:J03171; NID:G184645; PIDN:AAA5730.1; PID:G306914
R:Lutfalla, G.
submitted to the EMBL Data Library, July 1991
A:Description: The structure of the human interferon alpha/beta receptor gene.
A:Reference number: S17112
A:Accession: S17112
A:Molecule type: DNA
A:Residues: 1-16, 'A', 18-329, 'V', 343-557 <LUT>
A:Cross-references: EMBL:X60459; NID:G32671
A:Genetic8:
A:Gene: GDB:1FNAR1, IFNAR, IFRC
A:Cross-references: GDB:120078; OMIM:107450
A:Map position: 21q22.1-21q22.1
A:Introns: 26/1; 67/2; 126/1; 177/3; 225/1; 263/2; 342/1; 381/3; 432/1; 480/3
C:Keywords: cytokine receptor; glycoprotein; transmembrane protein
F:1-31/Domain: transmembrane #status predicted <TRN1>
F:437-455/Domain: transmembrane #status predicted <TRN2>
F:50, 58, 81, 88, 110, 172, 254, 313, 314, 376, 416, 433, 507, 518, 537/Binding site: carbohydrate (NA

[illegible]

RESULT 6
A31555
interferon gamma receptor precursor - human
C:Species: Homo sapiens (man)
C:Date: 28-Feb-1990 #sequence_revision 28-Feb-1990 #text_change 09-Jul-2004
C:Accession: A31555
R:Aguet, M.; Dembic, Z.; Merlin, G.
Cell 55, 273-280, 1988
A:Title: Molecular cloning and expression of the human interferon-gamma receptor.
A:Reference number: A31555; MUID:89003065; PMID:2971451
A:Accession: A31555
A:Molecule type: mRNA
A:Residues: 1-489 <AGUG>
A:Cross-references: UNIPROT:P15260; GB:J03143; NID:9184650; PIDN:AAAS2731.1; PID:g30691
C:Genetics:
A:Gene: GDB:IFNGR1; IFNGR
A:Cross-references: GDB:120688; OMIM:107470
A:Map position: 6q23-6q24
C:Superfamily: interferon gamma receptor
C:Keywords: cytokine receptor; transmembrane protein

	Query March	13.6%;	Score 163.5;	DB 2;	Length 489;
	Best Local Similarity	24.8%;	Pred. No. 4.2e-06;		
	Matches	51;	Conservative	37;	Mismatches 79; Indels 39; Gaps 8;
Oy	8 LPKANITTFUSINKNQVLQW-----TPREGLOGKVTYVQVFIFYQOK--KMUNKSEC 58				
Db	29 VFPTNTNITBESYNNNPPIYMEYEQIMQVP-----VFIVBEVNKGVCVKSEWID--AC 77				
Oy	59 RNIRRTYCDSAETSPDEHOYAYAKAIWGTCSSKMAESGRFPYLETOIGPPVALATD 118				
Db	78 INIHHTCNISDHGDPBNSLMRYAKARVGQKESAYASBEFAVRDRDKIGEPKDIKE 137				
Oy	119 EKSIISVVLAPEKKRNPED-----LPVSQQOYY----SNLKTNSVYLTKSNET 164				
Db	138 EKOIMIDIHFPSVAVNGDEGEVDYDPEFTCYAIRVNVVYVRMGSEIQYKI-LTQKEDCD 196				
Oy	165 WSCCVTNHLLVLTLEPTILCYAHVE 190				
Db	197 EIQC-----QLAIPVSLINSQICYSAE 218				

```

RESULT 7
A49667
interleukin-10 receptor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: A49667
P:Ho, A.S.; Liu, Y.; Khan, T.A.; Hsu, D.H.; Bazan, J.F.; Moore, K.W.
A:Title: A receptor for interleukin 10 is related to interferon receptors.
A:Reference number: A49667; MUID:94068585; PMID:8248239
A:Accession: A49667
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-575 <RES>
A:Cross-references: UNIPROT:Q61727; GB:L12120; NID:g437615; PIDN:AAA16156.1; PID:g43761
C:Genetics:
A:Gene: IL10R
A:Superfamily: interleukin-10 receptor IL10R
C:Keywords: cytokine receptor

Query Match      13.2%; Score 159; DB 2; Length 575;
Best Local Similarity 26.0%; Pred. No. 1.2e-05;
Matches 58; Conservative 33; Mismatches 100; Indels 32; Gaps 8;

Oy      8 LKPRANITLISINKNVLYQWTPPEGLQGVKVTYVQYFIQOKKMLNKSERNINRTYCD 67
      |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db      26 LPSPSYVMFEARFPGHILHWKPIPN-QSESTYYEVALKQYGNSTWNIDIHCRKAQALSCD 84

Oy      68 LSAETSYEHQ--YVAKVKAIMGTCKSKMAESGRFPFLFTQIQPREVALTTDEKSI 124

```

```

Db      85 LTTFTLLDLYHRSXGYRARAADNSQYSNNWTTT-----ETFTVDEVLITVD-----SV 133
Qy      125 VLTA-----PEKMKRNPEDLPV--SMQOITYSLK-YNVSVLTKSNRTWSQCVTN 171
Db      134 TLKAMDGIIGYTIHPER-----PTTPAGDEVEQVFKDLRYKXISIRKFSKLKATKRVKQ 189
Qy      172 HTLVLTWLEPNTLYCVHVESFVPGPPRAOPSEKOCARTLMDQ 214
Db      190 ETFTLVIPIGVRKFCVAVLPRLBSRKINKAMSEBQCLLITTEQ 232

RESULT 8
156215
Interleukin-10 receptor - human
C/Species: Homo sapiens (man)
C/Date: 02-Jul-1996 #sequence, revision 02-Jul-1996 #text_change 09-Jul-2004
C/Accession: 156215
R/Liu, Y.; Wei, S.H.; Ho, A.S.; de Maal Malfeyt, R.; Moore, K.W.
J. Immunol. 152, 1821-1829, 1994
A/Title: Expression cloning and characterization of a human IL-10 receptor.
A/Reference number: 156215; MUID:94165477; PMID:8120391
A/Accession: 156215
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-578 <RBS>
A/Cross-references: UNIPROT:Q13651; EMBL:U00672; NID:9482802; PIDN:AAA17696.1; PID:94828
C/Genetics:
A/Gene: GDB:IL10R; HTL-10R
A/Cross-references: GDB:330958; OMIM:146933
A/Map position: 11q23.3-11q23.3
C/Superfamily: Interleukin-10 receptor IL10R
C/Keywords: cytokine receptor

Query Match      11.9%; Score 143; DB 2; Length 578;
Best Local Similarity 24.8%; Pred. No. 0.00028;
Matches 53; Conservative 37; Mismatches 94; Indels 30; Gaps 10;

Qy      8 LRPKANITPLSINMKVNLQWTPREGLOGVKTYTVQYFIYQCKMKLNKSECRINRTYCD 67
Db      26 LRPSPSWFAEPFAEPFHIIHMTPIPN-QSESTCEVALLRIGISWNSISNCQ-TLSY-D 82
Qy      68 LSAFTSDYHQ--YAAKVAIKWTKCSKMAESGRFPFLETQIGPEVALTTDEKSI--- 122
Db      83 LTAVTLDLYHSNGYRARVRADVDSRSHSNWTVT-----NTRPSVEVLTLYGSVNLFIH 135
Qy      123 -----SVVLTAEKKRNPEDLPVSMQOITYSLK-YNVSVLTKSNRTWSQCVTNHT-- 173
Db      136 NGRTILGKIQLPRKMAPAND-----TYESIFSHFRYETAIKRVPGNFTTHKKVGHENF 190
Qy      174 LVLTWLEPNTLYCVHVESFVPGPPRAOPSEKOC 207
Db      191 SLTSGEVEG-FCVOYKPSVASRSNKGMSKEEC 223

RESULT 9
A49947
Interferon gamma receptor beta subunit - mouse
N/Alternate names: IFN-gamma R beta chain; IFN-gamma R species-specific cofactor; type I
C/Species: Mus musculus (house mouse)
C/Date: 06-Oct-1994 #sequence, revision 18-Nov-1994 #text_change 09-Jul-2004
C/Accession: A49947
R/Hemmi, S.; Bohni, R.; Stark, G.; Di Marco, F.; Aguet, M.
Cell 76, 803-810, 1994
A/Title: A novel member of the interferon receptor family complements functionality of t
A/Reference number: A49947; MUID:94170381; PMID:8124717
A/Accession: A49947
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-332 <HEM>
A/Cross-references: UNIPROT:Q63953; GB:569336; NID:9545841; PIDN:AAB30165.1; PID:9545842
A/Experimental source: early B-cell line Y16
A/Note: sequence extracted from NCBI backbone (NCBIN:145654, NCBIPI:145656)

```

```

C/Keywords: cytokine receptor

Query Match      11.5%; Score 138.5; DB 2; Length 332;
Best Local Similarity 23.9%; Pred. No. 0.00034;
Matches 54; Conservative 37; Mismatches 108; Indels 27; Gaps 8;

Qy      8 LRPKANITPLSINMKVNLQWTP-REGLOGVKTYTVQYFIYQCKMKLNKSECRINRTY 65
Db      29 LAAFLNRLHLVNDQIILTWEPSSNDPRVYQVESFINGSHRLLEPCTDITETK 88
Qy      66 CDLS--AETSDEYHQ--YAAKVAIKWTKCSKMAESGRFPFLETQIGPEVALTTDEKS 121
Db      89 CDLTGGRLKLPHPHFFVFLRVRAKGNILTSKVGLEBFGHYENTVGPBKNIISVTPGK 148
Qy      122 ISVLTAEKKRNPEDLPVSMQOITYSLKYNVSLTKSNRTWSQCV-----TNHTVLT 177
Db      149 SLVHFSF-----PFD-----VFHGATFQYLVIHWYKESTQOEQVEGPFKNSIVLG 195
Qy      178 WLEPNTLYCVHVESFVPGPPRAOP-----SEKOCARTLKDOSSEPK 219
Db      196 NIKPRVYCLQTEAQLILKNKKIRPHGLSLNVSCHETTANMSARLQ 241

RESULT 10
A34368
Interferon gamma receptor precursor - mouse
C/Species: Mus musculus (house mouse)
C/Date: 08-Jun-1990 #sequence, revision 08-Jun-1990 #text_change 09-Jul-2004
C/Accession: A34368; A35468; A34423; A34508; A36224; 148941
R/Kumar, C.S.; Muthukumar, G.; Frost, L.J.; Noe, M.; Ahn, Y.H.; Mariano, T.M.; Pescka,
J. Biol. Chem. 264, 17939-17946, 1989
A/Title: Molecular characterization of the murine interferon gamma receptor cDNA.
A/Reference number: A34368; MUID:90036866; PMID:2530216
A/Accession: A34368
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-477 <KUN>
A/Cross-references: UNIPROT:P15261; GB:M25764; NID:9197962; PIDN:AAA39177.1; PID:9309393
R/Cofano, F.; Moore, S.K.; Tanaka, S.; Yuhki, N.; Landolfo, S.; Appella, E.
J. Biol. Chem. 265, 4064-4071, 1990
A/Title: Affinity purification, peptide analysis, and cDNA sequence of the mouse interf-
A/Reference number: A35468; MUID:90154099; PMID:2137461
A/Accession: A35468
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-477 <COR>
A/Cross-references: GB:J05265; NID:9197964; PIDN:AAA39178.1; PID:9309394
R/Gray, P.W.; Leong, S.; Fennie, E.H.; Farrar, M.A.; Pingel, J.T.; Fernandez-Luna, J.;
Proc. Natl. Acad. Sci. U.S.A. 86, 8497-8501, 1989
A/Title: Cloning and expression of the cDNA for the murine interferon gamma receptor.
A/Reference number: A34423; MUID:90046824; PMID:2530582
A/Accession: A34423
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-94, 'E', '96-477 <GRA>
A/Cross-references: GB:M26711; NID:9194126; PIDN:AAA37896.1; PID:9309330
R/Hemmi, S.; Peghini, P.; Metzler, M.; Merli, G.; Dembic, Z.; Aguet, M.
Proc. Natl. Acad. Sci. U.S.A. 86, 9901-9905, 1989
A/Title: Cloning of murine interferon gamma receptor cDNA: expression in human cells me
A/Reference number: A34508; MUID:90099370; PMID:253365
A/Accession: A34508
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-94, 'E', '96-477 <HEM>
A/Cross-references: GB:M28233; NID:9194131; PIDN:AAA37898.1; PID:9309331
R/Munro, S.; Maniatis, T.; U.S.A. 86, 9248-9252, 1989
Proc. Natl. Acad. Sci. U.S.A. 86, 9248-9252, 1989
A/Title: Expression cloning of the murine interferon gamma receptor cDNA.
A/Reference number: A36224; MUID:90083245; PMID:2531896
A/Accession: A36224
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 10-477 <MON>

```


C:Species: Bos taurus #species: taurus (cattle)
C:Date: 30-Sep-1993 #sequence_revision: revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: JQ1319
R:Takeyenko, Y.; Muta, T.; Miyata, T.; Iwanaga, S.
Biochem. Biophys. Res. Commun. 181, 1145-1150, 1991
A>Title: cDNA and amino acid sequences of bovine tissue factor.
A:Reference number: JQ1319; PMID:92109720; PMID:1764065
A:Accession: JQ1319
A:Molecule type: mRNA
A:Residues: 1-292 <TAK>
A:Cross-references: UNIPROT:P30931; GB:S74147; NID:9241438; PIDN:AA820755.1; PID:g241438
A:Experimental source: adrenal gland
A>Note: part of this sequence, including the amino end of the mature protein, was confirmed
C:Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor
C:Comment: Expression of tissue factor can be induced in a variety of tissues by certain
C:Superfamily: tissue factor
C:Keywords: blood coagulation; glycoprotein; lipoprotein; cholesterol bond; transmembrane
F:1-35/Domain: signal sequence #status predicted <SIG>
F:36-292/Product: tissue factor #status experimental <MUT>
F:36-248/Domain: extracellular #status predicted <EXT>
F:249-271/Domain: transmembrane #status predicted <TM>
F:272-292/Domain: intracellular #status predicted <INT>
F:143,153,181/Binding site: carboxylate (Asn) (covalent) #status predicted
F:81-89, 215-238/Disulfide bonds: #status predicted
F:118,124/Binding site: carboxylate (Thr) (covalent) #status predicted
F:274/Binding site: palmitate (Cys) (covalent) #status experimental

Query Match	Score	DB 1	Length
10.8%	129	292	

Best Local Similarity 23.7%; Pred. No. 0.0018;
Matches 53; Conservative 32; Mismatches 85; Indels 54; Gaps 10;

```

QY      13  NITFSLINKNVLTQWTPREGLOGVAKTYLYVQFPIYGOQKMLNSSECNRINRYCDLSAE  71
Db      43  NITWSTNFKLTLEBEP-----KPINHYTVQ-ISPPLGNKKK--CFYTTNTCDVTDEI  95

QY      72  TSDYEHQYYAKKVAWGTCKSKMAE-----SGRFYPLETQIGPREVALTTDEKSIISVYL  126
Db      96  VGNVARETFLARVLSPADTSSSTVEBPPFNSSPEFTYLETNIGQPII-----  142

QY      127  TAPEKMKRNPEDLPVYSMOQIYSNLKYNVSVLTKS-----NFT---W-----SQCVT  170
Db      143  ---OSFEOVGTLNNTVODARFLTVRANSAPLSLRDVGKDLNLTLYYMKASSTGKKATT  199

QY      171  NHTLVLTWLEPNTLYCVHVESFV-----PGPRRKAQPSRK  205
Db      200  NTNGFLIDVDKGENYCFHVOAVILSRVNOKSPESIKTSHEK  243

```

Search completed: February 25, 2005, 02:45:37
Job time : 27.5401 sec8

Job time : 27.5401 sec

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 25, 2005, 02:23:48 ; Search time 118.257 Seconds
(without alignments)
663.913 Million cell updates/sec

Title: US-09-745-792A-15

Perfect score: 1080

Sequence: 1 DEVAIIIPAPQNLSTLNK.....GRYSAPQTECVGEAIP 203

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: A_Geneseq_16Dec04:.*
2: geneeqp1980s:.*
3: geneeqp1990s:.*
4: geneeqp2000s:.*
5: geneeqp2001s:.*
6: geneeqp2002s:.*
7: geneeqp2003s:.*
8: geneeqp2004s:.*

SUMMARIES

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	ID	Description
1	1080	100.0	203	4	AAB85271 Human IL-
2	1080	100.0	203	5	ABG67202 Human int
3	1080	100.0	203	5	AAE23356 Human int
4	1080	100.0	203	5	AAE29065 Human IL-
5	1080	100.0	203	8	ADJ83295 Human int
6	1080	100.0	311	2	AAV41736 Human int
7	1080	100.0	311	3	AAV66676 Membrane-
8	1080	100.0	311	3	AAV44664 Human PRO
9	1080	100.0	311	3	AAV44664 Human PRO
10	1080	100.0	311	3	AAV44664 Human PRO
11	1080	100.0	311	3	AAV44664 Human PRO
12	1080	100.0	311	3	AAV44664 Human PRO
13	1080	100.0	311	4	AAU04059 Human int
14	1080	100.0	311	4	AAU04059 Human int
15	1080	100.0	311	4	AAU04059 Human int
16	1080	100.0	311	5	ABG67201 Human PRO
17	1080	100.0	311	5	ABG67201 Human PRO
18	1080	100.0	311	5	ABG67201 Human PRO
19	1080	100.0	311	5	ABG67201 Human PRO
20	1080	100.0	311	5	ABG67201 Human PRO
21	1080	100.0	311	5	ABG67201 Human PRO
22	1080	100.0	311	5	ABG67201 Human PRO
23	1080	100.0	311	6	ABU50922 Human PRO
24	1080	100.0	311	6	ABU50922 Human PRO
25	1080	100.0	311	6	ABU50922 Human PRO

26	1080	100.0	311	6	ABO17631 Novel hum
27	1080	100.0	311	6	ABU60523 Human sec
28	1080	100.0	311	6	ABO25238 Novel hum
29	1080	100.0	311	6	ABU13905 Human PRO
30	1080	100.0	311	6	ABU80885 Human PRO
31	1080	100.0	311	6	ABU72244 Novel hum
32	1080	100.0	311	6	ABU72490 Novel hum
33	1080	100.0	311	6	ABU65855 Human PRO
34	1080	100.0	311	6	ABU84924 Human sec
35	1080	100.0	311	6	ABU59666 Novel sec
36	1080	100.0	311	6	ABU61122 Human PRO
37	1080	100.0	311	6	ABU59239 Human sec
38	1080	100.0	311	6	ABO25936 Human PRO
39	1080	100.0	311	6	ABO24856 Human sec
40	1080	100.0	311	6	ABU80391 Human sec
41	1080	100.0	311	6	ABU58945 Human sec
42	1080	100.0	311	6	ABU92323 Novel hum
43	1080	100.0	311	6	ABU59388 Novel hum
44	1080	100.0	311	6	ABU6861 Human sec
45	1080	100.0	311	6	ABG75853 Human cla

ALIGNMENTS

RESULT 1
AAB85271
ID AAB85271 standard; protein; 203 AA.

AC AAB85271;

DT 07-SBP-2001 (first entry)

DE Human IL-20 receptor subunit IL-20RB extracellular domain fragment.

KM Interleukin 20; IL-20; IL-20RA; Zcytor7; IL-20RB; DIRS1; immunoglobulin;

KW antiinflammatory; antiproliferic; antiaesthetic; antibacterial; human;

KM dermatological; antitumor; antagonist.

XX Homo sapiens.

XX WO200146232-A2.

XX 28-JUN-2001.

XX 22-DEC-2000; 2000MO-US035307.

XX 23-DEC-1999; 99US-00471774.

XX 22-JUN-2000; 2000US-0213416P.

XX (ZYMO) ZYMOGENETICS INC.

XX Foster DC, Xu W, Madden KL, Kelly JD, Sprecher CA, Brandt CS;

XX Rixon MW, Preenell SR, Fox BA;

XX WPI; 2001-398320/42.

XX Isolated interleukin 20 soluble receptor comprising two polypeptide

XX subunits IL-20RA and IL-20RB, useful for down-regulating IL-20 and thus

XX treating inflammatory diseases such as psoriasis.

XX Claim 1; Page 69; 11pp; English.

XX The invention relates to an interleukin 20 (IL-20) soluble receptor

XX comprising two polypeptide subunits IL-20RA (formerly known as Zcytor7)

XX and IL-20RB (formerly known as DIRS1). The two subunits are preferably

XX linked together. In one embodiment, one subunit is fused to the constant

XX region of the light chain of an immunoglobulin, and the other subunit is

XX fused to constant region of the heavy chain of an immunoglobulin. The

XX light chain and the heavy chain are connected via a disulfide bond. The

XX soluble receptor can be used to down-regulate IL-20 and thus treat

XX inflammatory diseases such as psoriasis, inflammatory lung injury such as

XX asthma or bronchitis, adult respiratory disease (ARD), septic shock,

CC multiple organ failure, bacterial pneumonia, eczema, atopic and contact
CC dermatitis, and inflammatory bowel disease such as ulcerative colitis and
CC Crohn's disease. The present sequence represents a human IL-20 receptor
CC subunit IL-20RB extracellular domain fragment
XX

Sequence 203 AA;

Query Match 100.0%; Score 1080; DB 4; Length 203;
Best Local Similarity 100.0%; Pred. No. 5.1e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVALIPAPQNLSTVSTNMKLLMWSPIAPGETIYVSVEYQGEYESLYTSHIMIPSSWC 60
DB 1 DEVALIPAPQNLSTVSTNMKLLMWSPIAPGETIYVSVEYQGEYESLYTSHIMIPSSWC 60
QY 61 SLTEGPECDVDDITATVPYNLRVRAVLGSGTSAMSILKHPFNRRNSTILTRPGMEITKDG 120
DB 61 SLTEGPECDVDDITATVPYNLRVRAVLGSGTSAMSILKHPFNRRNSTILTRPGMEITKDG 120
QY 121 FHLVTELEDLGPQFEFLVAWRRBPGAEHVKWVRSGGIPVHLETMEPGAAYCVKQOTFV 180
DB 121 FHLVTELEDLGPQFEFLVAWRRBPGAEHVKWVRSGGIPVHLETMEPGAAYCVKQOTFV 180
QY 181 KAIGRYSAFSQTECEVQGEAIP 203
DB 181 KAIGRYSAFSQTECEVQGEAIP 203

RESULT 2
ABG67202
ID ABG67202 standard; protein; 203 AA.
XX
AC ABG67202;
XX
DT 24-SEP-2002 (first entry)
XX
DE Human interleukin-20 sub-unit IL20RB extracellular domain protein #1.
XX

XX Inflammation; interleukin-20; IL-20; interleukin-8; IL-8; chemokine;
KW neutrophil; monocyte; basophil; eosinophil; chemottractant; psoriasis;
KW periodontal disease; rheumatoid arthritis; idiopathic pulmonary fibrosis;
KW angiogenesis-dependent chronic inflammatory condition; lung cancer;
KW melanoma; inflammatory disease; diabetes; arteriosclerosis; catarract;
KW reperfusion injury; cancer; meningitis; rheumatic disease; skin disease;
KW idiopathic pulmonary fibrosis; inflammatory bowel disease; psoriasis;
KW ulcerative colitis; eczema; atopic dermatitis; contact dermatitis;
KW inflammatory lung disease; ARD; adult respiratory disease; asthma;
KW bronchitis; pneumonia.
XX

Homo sapiens.

US2002042366-A1.

11-APR-2002.

22-DEC-2000; 2000US-00746359.

23-DEC-1999; 99US-0171969P.

22-JUN-2000; 2000US-0213341P.

PA (THOM/) THOMPSON P.
PA (POST/) FOSTER D C.
PA (XUWU/) XU W.
PA (MADD/) MADDEN K L.
PA (KEL/) KELLY J D.
PA (SPRE/) SPRECHER C A.
PA (BLUM/) BLUMBERG H.
PA (EAGA/) EAGAN M A.
PA (JASP/) JASPERS S R.
PA (CHAN/) CHANDRASEKHAR Y A.
PA (NOVA/) NOVAK J E.
XX
XX Thompson P, Foster DC, Xu W, Madden KJ, Kelly JD, Sprecher CA;

PI Blumberg H, Eagan MA, Jaspers SR, Chandrasekhar YA, Novak JE;
XX WPI; 2002-507215/54.
DR
XX

PT Treating inflammatory skin and lung diseases using antibodies against
PT interleukins (IL)-20 (which indirectly modulates activation of IL-8),
XX useful for treating e.g. psoriasis, asthma and bronchitis.
XX

Example 2; Page 24; 68pp; English.

CC The invention describes a method (I) for treating a mammal afflicted with
CC a disease in which an interleukin-20 (IL-20) polypeptide plays a role
CC comprising administering an antagonist of the IL-20 polypeptide to the
CC individual. An important cytokine in the inflammatory process is
CC interleukin-8 (IL-8), a chemokine that acts as an agonist for neutrophils
CC via chemotaxis and the release of granule enzymes. IL-8 binds to
CC receptors on neutrophils, monocytes, basophils, and eosinophils. IL-8 is
CC a potent chemottractant for neutrophils, and the early stages of
CC periodontal disease are characterized by the influx of neutrophils. IL-8
CC is a potent inducer of angiogenesis in several angiogenesis-dependent
CC chronic inflammatory conditions, including rheumatoid arthritis,
CC psoriasis, and idiopathic pulmonary fibrosis. Additionally, IL-8 is an
CC important source of angiogenic activity in human lung cancer. Also, IL-8
CC expression correlates with experimental metastatic activity of some
CC melanoma cell lines. Therefore an effective method to treat inflammatory
CC diseases would be to administer an agent that would inhibit IL-8. It has
CC been shown that IL-20 up-regulates IL-8. Therefore antagonists to IL-20
CC can be used to treat these diseases. The method is used for treating
CC diseases in which the IL-20 polypeptide plays a role e.g. inflammatory
CC diseases including diabetes, arteriosclerosis, catarracts, reperfusion
CC injury, cancer, meningitis, rheumatic diseases, idiopathic pulmonary
CC fibrosis, inflammatory bowel disease (ulcerative colitis), skin disease
CC (psoriasis, eczema, atopic dermatitis and contact dermatitis), skin disease
CC inflammatory lung disease (adult respiratory disease (ARD), asthma,
CC bronchitis and pneumonia). This sequence represents a human interleukin-
CC 20 (IL-20) polypeptide used in developing the method of the invention
XX

Sequence 203 AA;

Query Match 100.0%; Score 1080; DB 5; Length 203;
Best Local Similarity 100.0%; Pred. No. 5.1e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVALIPAPQNLSTVSTNMKLLMWSPIAPGETIYVSVEYQGEYESLYTSHIMIPSSWC 60
DB 1 DEVALIPAPQNLSTVSTNMKLLMWSPIAPGETIYVSVEYQGEYESLYTSHIMIPSSWC 60
QY 61 SLTEGPECDVDDITATVPYNLRVRAVLGSGTSAMSILKHPFNRRNSTILTRPGMEITKDG 120
DB 61 SLTEGPECDVDDITATVPYNLRVRAVLGSGTSAMSILKHPFNRRNSTILTRPGMEITKDG 120
QY 121 FHLVTELEDLGPQFEFLVAWRRBPGAEHVKWVRSGGIPVHLETMEPGAAYCVKQOTFV 180
DB 121 FHLVTELEDLGPQFEFLVAWRRBPGAEHVKWVRSGGIPVHLETMEPGAAYCVKQOTFV 180
QY 181 KAIGRYSAFSQTECEVQGEAIP 203
DB 181 KAIGRYSAFSQTECEVQGEAIP 203

RESULT 3
AAE23356
ID AAE23356 standard; protein; 203 AA.
XX
AC AAE23356;
XX
DT 27-AUG-2002 (first entry)
XX
DE Human interleukin-20 receptor beta variant (V-IL-20RB) EC domain.
XX

XX Human; interleukin-19; IL-19; interleukin-20 receptor alpha; IL-20RA;
KW interleukin-20 receptor beta; IL-20RB; inflammation; atherosclerosis;
KW diabetes; reperfusion injury; cancer; infectious meningitis; catarract;
KW

KV	rheumatoid arthritis; rheumatic fever; systemic lupus erythematosus;
KW	antibacterial; cytostatic; dermatological; ophthalmological; vasotropic;
KW	variant.
XX	
XX	Homo sapiens.
OS	Synthetic.
OS	
XX	
FN	WO200222135-A2.
XX	
PD	21-MAR-2002.
XX	
PF	13-SEP-2001; 2001WO-US028557.
XX	
PR	15-SEP-2000; 2000US-023305P.
XX	
PA	(ZYMO) ZYMOGENETICS INC.
XX	
PI	Chandrasekher YA, Jaspers SR;
XX	
DR	WPI; 2002-425815/45.
DR	N-PSDB; AAD37555.
XX	
PT	Method of down-regulating IL-19 useful for treating inflammation
PT	comprises administration of a polypeptide comprised of the extracellular
XX	domain of IL-20RA and IL-20RB.
XX	
P5	Disclosure; Page 51-52; 80pp; English.
XX	
CC	The present invention relates to a method of down-regulating interleukin
CC	(IL)-19. The method involves administration of a polypeptide comprised of
CC	the extracellular domain of interleukin-20 receptor alpha (IL-20RA) and
CC	the extracellular domain of interleukin-20 receptor beta (IL-20RB). The
CC	IL-20RA and IL-20RB are heterodimeric receptors that bind to both IL-19
CC	and mdx7. The method is useful for down-regulating IL-19, useful for the
CC	treatment of inflammation e.g., in diabetes, atherosclerosis, cataracts,
CC	reperfusion injury, cancer, infectious meningitis, rheumatoid arthritis,
CC	rheumatic fever and systemic lupus erythematosus. The present sequence is
CC	human IL-20RB extracellular domain protein
XX	
50	Sequence 203 AA;

Query Match	Similarity	100.0%	Score	1080	DB 5	Length	203
Best Local	Similarity	100.0%	Pred. No.	5.1e-109			
Matches	203	Conservative	0	Mismatches	0	Indels	0
						Gaps	0
QY	1	DEVALILPAPQNLSTVSTMMKHLMMSPVIAFGCEITYYSVEVYOGGEYSILYTSHIMIPSSWC	60				
DB	1	DEVALILPAPQNLSTVSTMMKHLMMSPVIAFGCEITYYSVEVYOGGEYSILYTSHIMIPSSWC	60				
QY	61	SLTEGPECDVTDITATVPYNILRVATILGSGTSAMSILKHPFNRRSTILLTRPGMEITKDG	120				
DB	61	SLTEGPECDVTDITATVPYNILRVATILGSGTSAMSILKHPFNRRSTILLTRPGMEITKDG	120				
QY	121	FHLVLELEDLGPQEPFELVAYYRRREGAEHHYKMRSGGIPHLLETMERGAAYCYKAQTFF	180				
DB	121	FHLVLELEDLGPQEPFELVAYYRRREGAEHHYKMRSGGIPHLLETMERGAAYCYKAQTFF	180				
QY	181	KAIGRYSAFSQTECYVEVGGSAIP	203				
DB	181	KAIGRYSAFSQTECYVEVGGSAIP	203				
RESULT 4							
ID	AAE29065						
	AAE29065	standard; protein; 203 AA.					
XX	AAE29065;						
AC							
XX							
DT	27-JAN-2003	(first entry)					
XX							
DE	Human IL-22RB protein #2.						
XX							
KX	Human; heterodimeric cytokine receptor; interleukin-22R; IL-22R; asctma;						

XX	inflammatory disease; psoriasis; adult respiratory disease; bronchitis;
KW	septic shock; multiple organ failure; inflammatory lung injury; eczema;
KW	bacterial pneumonia; dermatitis; ulcerative colitis; Crohn's disease;
KW	antihistaminic; dermatological; antibacterial; immunosuppressive;
KW	antiviral; ZcytoR11.
XX	
OS	Homo sapiens.
XX	
XX	MO200272607-A2.
XX	
PD	19-SEP-2002.
XX	
XX	07-MAR-2002; 2002MO-US007214.
XX	
XX	09-MAR-2001; 2001US-0274560P.
PR	21-JUN-2001; 2001US-0299865P.
XX	
PA	(ZYMO) ZYMOGENETICS INC.
XX	
PI	Chandrasekher YA, Novak JB, Foster DC, Xu W, Vaspars SR;
XX	
DR	WPI; 2002-723314/78.
XX	
PT	Soluble heterodimeric cytokine receptor useful for down-regulating
XX	interleukin-20 and treating inflammatory diseases, such as psoriasis and
PT	asthma, comprises an interleukin-22R subunit and a interleukin-20RB
XX	subunit.
XX	
XX	Claim 1; Page 59-60; 82pp; English.
XX	
CC	The present invention relates to novel heterodimeric cytokine receptor
CC	which comprises an interleukin-22R (IL-22R; ZcytoR11) subunit. Receptor
CC	sequences are useful for down-regulating IL-20 and treating inflammatory
CC	diseases such as psoriasis, adult respiratory disease, multiple organ
CC	failure, septic shock, inflammatory lung injury such as bronchitis or
CC	asthma, bacterial pneumonia, eczema, atopic and contact dermatitis,
CC	ulcerative colitis and Crohn's disease. The present sequence is human
CC	interleukin-22RB (IL-22RB) protein
XX	
XX	Sequence 203 AA;

Query Match	100.0%	Score 1080	DB 5	Length 203
Best Local Similarity	100.0%	Pred. No. 5.1e-109		
Matches 203	Conservative 0	Mismatches 0	Indels 0	Gaps 0
Qy	1	DEVALIPAPONLSVLTSTNMKHLIWMSPVIA	PGETVTVYSVEYQGEYESLYTHIMI	PPSSWC 60
Sb	1	DEVALIPAPONLSVLTSTNMKHLIWMSPVIA	PGETVTVYSVEYQGEYESLYTHIMI	PPSSWC 60
Qy	61	SLTEGPECDDVTDITATVPYNLRVATLGSOTS	AMSILKHPFNENSTILTRPGMEITKDG	120
Sb	61	SLTEGPECDDVTDITATVPYNLRVATLGSOTS	AMSILKHPFNENSTILTRPGMEITKDG	120
Qy	121	PHVLIELBDIGPQPEFLVAYWRBPGABEHV	KVNRSGGIPVHLTMEPGAAYCVKAQTFV	180
Sb	121	PHVLIELBDIGPQPEFLVAYWRBPGABEHV	KVNRSGGIPVHLTMEPGAAYCVKAQTFV	180
Qy	181	KAIGRYSAFSQTECEVQGEAIP	203	
Sb	181	KAIGRYSAFSQTECEVQGEAIP	203	
RESULT 5				
ID	ADJ83295			
	ADJ83295	standard; protein; 203 AA.		
XX	ADJ83295;			
XX				
DT	06-MAY-2004	(first entry)		
DE	Human interleukin receptor IL-20RB	extracellular domain mature protein.		
XX				
XX				
FW	inflammation; single chain antibody; interleukin; IL-20; IL-20RA subunit;			

KW IL-20RB subunit; antiinflammatory; dermatological; antipsoriatic;
KW antiarthritic; respiratory; antiaschmatic; antitumor; antibacterial;
KW immunosuppressive; gastrointestinal; skin; psoriasis; eczema;
KW atopic dermatitis; contact dermatitis; lung; bronchitis; pneumonia;
KW adult respiratory distress syndrome; asthma; multiple organ failure; bowel;
KW arthritis; septic shock; multiple organ failure; Crohn's disease;
KW ulcerative colitis; Crohn's disease; human; receptor;
KW extracellular domain; mature.
XX
XX Homo sapiens.
XX
XX US2004005320-A1.
XX
XX 08-JAN-2004.
XX
XX 26-APR-2003; 2003US-00424658.
XX
XX 23-DEC-1999; 99US-0171969P.
XX 22-JUN-2000; 2000US-0213341P.
XX 22-DEC-2000; 2000US-00746359.
XX
XX (THOM/) THOMPSON P.
XX (FOST/) FOSTER D C.
XX (XUW/) XU W.
XX (MADD/) MADDEN K L.
XX (KELL/) KELLY J D.
XX (SPRE/) SPRECHER C A.
XX (BLIN/) BLUMBERG H.
XX (BAG/) BAGAN M A.
XX (JASP/) JASPERS S R.
XX (CHAN/) CHANDRASEKHAR Y A.
XX (NOVA/) NOVAK J E.
XX
XX Thompson P, Foster DC, Xu W, Madden KL, Kelly JD, Sprecher CA;
PI Blumberg H, Egan MA, Jaspers SR, Chandrasekhar YA, Novak JE;
XX
XX WPI; 2004-081696/08.
XX
XX N-PSDB; ADJ83293.
XX
XX
XX Reducing or treating inflammation, e.g. inflammatory lung disease,
PT comprises administering an antibody, antibody fragment or single chain
PT antibody that specifically binds to an interleukin (IL)-20RA subunit of
PT an IL-20 receptor.
XX
XX Example 2; SEQ ID NO 15; 69pp; English.
XX
XX The invention relates to a novel method of reducing or treating
CC inflammation in a mammal which comprises administering an antibody,
CC antibody fragment or single chain antibody which specifically binds to a
CC receptor of interleukin (IL)-20 comprising an IL-20RA subunit and an IL-
CC 20RB subunit. The method of the invention has antiinflammatory,
CC dermatological, antipsoriatic, antiarthritic, respiratory, antiaschmatic,
CC antitumor, antibacterial, immunosuppressive and gastrointestinal
CC applications and may be useful for reducing or creating an inflammation,
CC including an inflammatory skin disease such as psoriasis, eczema, atopic
CC dermatitis and contact dermatitis or an inflammatory lung disease such as
CC adult respiratory distress syndrome, asthma, bronchitis and pneumonia, as
CC well as arthritis, septic shock, multiple organ failure, inflammatory
CC bowel disease, ulcerative colitis or Crohn's disease. The current
CC sequence is that of the human IL-20RB subunit-related protein of the
CC invention.
XX
XX
XX Sequence 203 AA;
SQ

Query Match 100.0%; Score 1080; DB 8; Length 203;
Best Local Similarity 100.0%; Pred. No. 5,1e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVAIIIPAPONTLSVLTNNKHLMMSPVLAPEGTVYVYVYOGESLYTSHIMISSMC 60
DB 1 DEVAIIIPAPONTLSVLTNNKHLMMSPVLAPEGTVYVYVYOGESLYTSHIMISSMC 60
QY 61 SLTEGPECVDVTDITATVPYNLRATLGSQTSAMSLKHPFNRSITILTRPGMEITTKDG 120

DB 61 SLTEGPECVDVTDITATVPYNLRATLGSQTSAMSLKHPFNRSITILTRPGMEITTKDG 120
QY 121 FHLVLELDLGGQFEFLVAVYMRREGABEHVYVNSGGIPVLTETMEGAAVCVAQTFFV 180
DB 121 FHLVLELDLGGQFEFLVAVYMRREGABEHVYVNSGGIPVLTETMEGAAVCVAQTFFV 180
QY 181 KAIGRYSAFSQTECVGVEGAIP 203
DB 181 KAIGRYSAFSQTECVGVEGAIP 203

RESULT 6
AA41736
ID AA41736 standard; protein; 311 AA.
XX
XX AA41736;
XX
XX 07-DEC-1999 (first entry)
XX
XX Human PRO114 protein sequence.
XX
XX Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;
KW probe; blood coagulation disorder; cancer; cellular adhesion disorder;
KW secreted protein; transmembrane protein.
XX
XX Homo sapiens.
XX
XX WO9946281-A2.
XX
XX 16-SEP-1999.
XX
XX 08-MAR-1999; 99WO-US005028.
XX
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040220.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081838P.
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082767P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086450P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
XX (GETH) GENENTECH INC.
XX
PI Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;
XX WPI, 1999-551358/46.
DR N-PSDB; AA234190.
XX
PT New secreted and transmembrane polypeptides and their polynucleotides.
PT useful for treating blood coagulation disorders, cancers and cellular
XX adhesion disorders.
XX
XX Claim 12; Fig 142; 530P; English.
XX
XX The present invention describes secreted and transmembrane polypeptides
XX and their polynucleotides. The nucleotide sequences are useful as sources
XX of probes, primers, for chromosome mapping, and for generation of
XX antisense sequences. They can also be used to create transgenic animals.
XX The proteins can be used to treat a variety of diseases and disorders,
XX depending on their function. Diseases that may be treated include blood
XX coagulation disorders, cancers and cellular adhesion disorders. They may
XX also be used to raise antibodies. AA233891 to AA234338, and AA241685 to
XX AA241774 represent polynucleotide and polypeptide sequence given in the
XX exemplification of the present invention

XX SQ Sequence 311 AA;
Query Match 100.0%; Score 1080; DB 2; Length 311;
Best Local Similarity 100.0%; Pred. No. 9, 8e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DEVAIIIPAPQNLSTNMKHLMSPVIAFGSTVYVSVEYQGEYESTYSHIWPSSWC 60
DB 30 DEVAIIIPAPQNLSTNMKHLMSPVIAFGSTVYVSVEYQGEYESTYSHIWPSSWC 89
QY 61 SLTEGPCDVTDTITVFNLAVRATLGSQTSAWSTLKHPPRNSTILTRPGMETIKDG 120
DB 90 SLTEGPCDVTDTITVFNLAVRATLGSQTSAWSTLKHPPRNSTILTRPGMETIKDG 149
QY 121 FHLVIELEDLGPQFEFLVAYWRREPGAEHVKVVRSGGIPVHLETMEPGAAYCVAQTFFV 180
DB 150 FHLVIELEDLGPQFEFLVAYWRREPGAEHVKVVRSGGIPVHLETMEPGAAYCVAQTFFV 209
QY 181 KAIGRYSAFSQTECVVQGEAIP 203
DB 210 KAIGRYSAFSQTECVVQGEAIP 232
RESULT 7
ID AAY6676 standard; protein; 311 AA.
XX AAY6676;
AC AAY6676;
XX
DT 05-APR-2000 (first entry)
XX
XX
DE Membrane-bound protein PRO1114.
XX
XX
KM Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIB ligand;
KW pharmaceutical; receptor immunoadhesin; gene mapping.
XX
XX Homo sapiens.
OS
PN WO9963088-A2.
XX
PD 09-DEC-1999.
XX
XX
PF 02-JUN-1999; 99WO-US012252.
XX
XX 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 05-JUN-1998; 98US-0088255P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.

```

PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089050P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091358P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.

```

```

PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 12-JAN-1999; 99US-0115565P.

```

(GETH) GENENTECH INC.

Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK,
Wood WT, Yuan J;

WPI; 2000-072883/06.

DR N-PSDB; AA265011.

Membrane-bound proteins and related nucleotide sequences.

Claim 12, Fig 117, 822pp; English.

XX The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences will
CC also be useful for the preparation of PRO polypeptides, especially by
CC recombinant techniques
XX

SO Sequence 311 AA;

Query Match 100.0%; Score 1080; DB 3; Length 311;
Best Local Similarity 100.0%; Pred. No. 9, 8e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVALPAPONTLSVLTSMKHLMMSPVIAIGETVYVSVEYQGEYSYTHIPIPSWC 60
DB 30 DEVALPAPONTLSVLTSMKHLMMSPVIAIGETVYVSVEYQGEYSYTHIPIPSWC 89

ID	AAV44664 standard; protein, 311 AA.
AC	AAV44664;
XX	
DT	18-APR-2000 (first entry)
XX	
DE	Interferon Receptor-HKAEF92.
XX	
KM	Interferon receptor HKAEF92; INFR, ATCC No. 209746; viral infection;
KW	immune dysfunction; immune system disorder; proliferative disease;
KX	cancer; inflammatory disorder; persistent infection; autoimmune disease;
KM	arthritis; leukemia; lymphoma; immunosuppression; myeloid suppression;
XX	inflammatory bowel disease; Jaks-STATS signal transduction pathway.
OS	Homo sapiens.
XX	
FH	Key
FT	Peptide
FT	/label=Signal_peptide
FT	/note="Antigenic epitope-bearing peptide"
FT	69..77
FT	/note="Antigenic epitope-bearing peptide"
FT	92..107
FT	/note="Antigenic epitope-bearing peptide"
FT	129..162
FT	/note="Antigenic epitope-bearing peptide"
FT	130..223
FT	/label=Extracellular_domain
FT	172..199
FT	/note="Antigenic epitope-bearing peptide"
FT	234..250
FT	/label=Transmembrane_domain
FT	251..311
FT	/label=Intracellular_domain
FT	272..307
FT	/note="Antigenic epitope-bearing peptide"
PN	WO9962934-A1.
XX	
PD	09-DEC-1999.
XX	
PF	03-JUN-1999; 99WO-US012156.
XX	
PR	05-JUN-1998; 98US-0088185P.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
XX	
PI	Ruben SM, Ni J;
XX	
DR	WPI; 2000-147043/13.
DR	N-PSDB; AAZ49747.
PT	New isolated interferon receptor HKAEF92 polynucleotides, used to develop
PT	products for treating, e.g. Immune system related disorders.
XX	
PS	Claim 17; Fig 1; 98PP; English.
XX	
CC	The present sequence is interferon receptor (INFR) HKAEF92 encoded by
CC	cDNA clone HKAEF92 (ATCC No. 209746) derived from human keratinocyte cDNA
CC	library. INFR-HKAEF92 polypeptides are used in the treatment of disorders
CC	associated with viral infection, immune dysfunction and proliferative
CC	diseases such as cancer, inflammatory disorders, persistent infection,
CC	autoimmune diseases, arthritis, leukemias, lymphomas, immunosuppression,
CC	inflammatory bowel disease, or myeloid suppression. The products can also be
CC	used for detection, diagnosis and drug screening. INFR-HKAEF92 protein
CC	activates Jaks-STATS signal transduction pathway in a dose-dependent
CC	manner
XX	
XQ	Sequence 311 AA;

Qy	1	DEVAILPAPQNLSTLSTNMKRLMMSPIVIAGETVYTSVEXQGEESLYTSHIWPSSWC	60
Db	30	DEVAILPAPQNLSTLSTNMKRLMMSPIVIAGETVYTSVEXQGEESLYTSHIWPSSWC	89
Qy	61	SLTSGPECDVTDITATVPYNLRVRAVLGSGTSMSTLKHPPNNSITLIRPGMETKDG	120
Db	90	SLTSGPECDVTDITATVPYNLRVRAVLGSGTSMSTLKHPPNNSITLIRPGMETKDG	149
Qy	121	PHLVLEEDIGPQEFVLVAYRRRBPGEAEHVKNVRSGGIPVHLETMBPGAAVCYKAQTFV	180
Db	150	PHLVLEEDIGPQEFVLVAYRRRBPGEAEHVKNVRSGGIPVHLETMBPGAAVCYKAQTFV	209
Qy	181	KAIGRYSAFSOTCEVQGEAIP	203
Db	210	KAIGRYSAFSOTCEVQGEAIP	232
RESULT	10		
AAB44292	ID	AAB44292 standard; protein; 311 AA.	
XX	AC	AAB44292;	
XX	DT	08-FEB-2001 (first entry)	
XX	DE	Human PRO1114 (UNQ557) protein sequence SRQ ID NO:352.	
XX	KW	Human; secreted protein; transmembrane protein; PRO; EST; cytosstatic; expressed sequence tag; detection; cancer.	
XX	OS	Homo sapiens.	
XX	PN	WO200053756-A2.	
XX	PD	14-SEP-2000.	
XX	PF	18-FEB-2000; 2000MO-US004341.	
XX	PR	08-MAR-1999; 99WO-US005028.	
XX	PR	12-MAR-1999; 99US-0123957P.	
XX	PR	29-MAR-1999; 99US-0126773P.	
XX	PR	21-APR-1999; 99US-0130232P.	
XX	PR	28-APR-1999; 99US-0131445P.	
XX	PR	14-MAY-1999; 99US-0134287P.	
XX	PR	23-JUN-1999; 99US-0141037P.	
XX	PR	26-JUL-1999; 99US-0145698P.	
XX	PR	29-OCT-1999; 99US-0162506P.	
XX	PR	30-NOV-1999; 99WO-US028313.	
XX	PR	02-DEC-1999; 99WO-US028551.	
XX	PR	16-DEC-1999; 99WO-US028565.	
XX	PR	30-DEC-1999; 99WO-US031095.	
XX	PR	30-DEC-1999; 99WO-US031243.	
XX	PR	05-JAN-2000; 99WO-US031274.	
XX	PR	06-JAN-2000; 2000MO-US000219.	
XX	PR	06-JAN-2000; 2000MO-US000277.	
XX	XX	06-JAN-2000; 2000MO-US000376.	
XX	XX	(GETH) GENENTECH INC.	
XX	PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,	
XX	PI	Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,	
XX	PI	Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ,	
XX	PI	Klavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,	
XX	PI	Stewart TX, Tumas D, Williams PM, Wood WI;	
XX	XX	WPI; 2000-611443/58.	
XX	DR	N-PSDBJ; AAC78547.	
XX	PT	Novel PRO polypeptides and polynucleotides used in detection methods, to	
XX	PT	target bioactive molecules to specific cells, and to modulate cellular	
XX	PT	activities.	
XX	PS	Claim 12; Fig 142; 636PP; English.	

XX AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence tag) sequences which encode secreted or transmembrane PRO polypeptides. The PRO polynucleotides and polypeptides have cytostatic activity. The CC polynucleotides and polypeptides can be used for detecting the presence of PRO polypeptides in samples, for linking bioactive molecules to cells and for modulating biological activities of cells, using the polypeptides for specific targeting. The polypeptide targeting can be used to kill the target cells, e.g. for the treatment of cancers. The polypeptide pairs CC provide specific targeting of bioactive molecules to cells. AAC78600 to CC AAC78987 represent PCR primers and probes used in the isolation of the CC PRO polynucleotide sequences

XX Sequence 311 AA;

Query Match 100.0%; Score 1080; DB 3; Length 311;
Best Local Similarity 100.0%; Pred. No. 9.8e-109; Indels 0; Gaps 0;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVAIIPAPONLSVLTNNKHLMSPVIAAGETVYYSVYQGEYSLSYTSHTWIPSSWC 60
30 DEVAIIPAPONLSVLTNNKHLMSPVIAAGETVYYSVYQGEYSLSYTSHTWIPSSWC 89
QY 61 SLTEGPCDVTDDITATVPYNLRVATLGSQTSAMSLKHPFNNSITILTRPGMEITKDG 120
90 SLTEGPCDVTDDITATVPYNLRVATLGSQTSAMSLKHPFNNSITILTRPGMEITKDG 149
QY 121 FHLVLEBDLGPQEFVLVAYMRREPGEAEHVYKVRSGGIPVHLETMEPGAAYCVKAQTFV 180
150 FHLVLEBDLGPQEFVLVAYMRREPGEAEHVYKVRSGGIPVHLETMEPGAAYCVKAQTFV 209
QY 181 KAIGRYSAFSQTECEVGEAIP 203
210 KAIGRYSAFSQTECEVGEAIP 232
DB

RESULT 11
AA97046
ID AA97046 standard; protein; 311 AA.
XX

AC AA97046;
XX
DT 31-OCT-2000. (first entry)
XX
DE Human TANGO 242.

KM TANGO 242; transmembrane, class II; cytokine receptor; chromosome 3q21;
KW cytosolic; cerebroprotective; immunomodulatory; anti-inflammatory;
XX vitruoid; antibacterial; vasotropic.
XX

OS Homo sapiens.
XX

XX Key Location/Qualifiers
FH Peptide 1..29
FT /label= Signal_peptide
FT Protein 30..311
FT /label= Mature_protein
FT Domain 30..230
FT /label= Extracellular_domain
FT Domain 35..125
FT /label= Fibronectin_III_domain
FT Modified-site 40
FT /note= "N-linked glycosylation site"
FT Modified-site 134
FT /note= "N-linked glycosylation site"
FT Domain 231..255
FT /label= Transmembrane_domain
FT Domain 256..311
FT /label= Cytoplasmic_domain
XX
XX MO200039161-A1.
XX
XX 06-JUL-2000.

XX 30-DEC-1999; 99WO-US031328.
XX
XX 31-DEC-1998; 98US-00224669.
PR
XX (MILL-) MILLENNIUM PHARM INC.
PA
PI Busfield SJ;
XX
XX WPI: 2000-452372/39.
DR
DR N-PSDB; AAA51871, AAA51872.

PT New nucleic acid molecules encoding polypeptides designated TANGO 241 and TANGO 242 used for treating e.g. brain and pancreatic disorders.
XX

PS Claim 8; Fig 3; 127pp; English.

XX Novel transmembrane proteins, designated TANGO 241 and TANGO 242, are members of the class II cytokine receptor superfamily. The TANGO 241 and CC 242 genes have been localized to human chromosomes 1p36 and 3q21, CC respectively. The proteins, cDNA and their modulators can be used for the treatment of viral and bacterial infection, inflammatory and autoimmune disorders, vascular injury and inhibition of angiogenesis. In particular, CC TANGO 241 can be used to treat pancreatic disorders and TANGO 242 can be used to treat brain disorders
XX

SQ Sequence 311 AA;

Query Match 100.0%; Score 1080; DB 3; Length 311;
Best Local Similarity 100.0%; Pred. No. 9.8e-109; Indels 0; Gaps 0;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVAIIPAPONLSVLTNNKHLMSPVIAAGETVYYSVYQGEYSLSYTSHTWIPSSWC 60
30 DEVAIIPAPONLSVLTNNKHLMSPVIAAGETVYYSVYQGEYSLSYTSHTWIPSSWC 89
QY 61 SLTEGPCDVTDDITATVPYNLRVATLGSQTSAMSLKHPFNNSITILTRPGMEITKDG 120
90 SLTEGPCDVTDDITATVPYNLRVATLGSQTSAMSLKHPFNNSITILTRPGMEITKDG 149
QY 121 FHLVLEBDLGPQEFVLVAYMRREPGEAEHVYKVRSGGIPVHLETMEPGAAYCVKAQTFV 180
150 FHLVLEBDLGPQEFVLVAYMRREPGEAEHVYKVRSGGIPVHLETMEPGAAYCVKAQTFV 209
QY 181 KAIGRYSAFSQTECEVGEAIP 203
210 KAIGRYSAFSQTECEVGEAIP 232
DB

RESULT 12
AAU12187
ID AAU12187 standard; protein; 311 AA.
XX

AC AAU12187;
XX

DT 24-OCT-2001 (first entry)
XX

DE Human PRO1114 polypeptide sequence.
XX

KM Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW prostate; cervical; tumor necrosis factor-alpha; TNF-alpha; cartilage;
KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
XX A-peptide; factor VIIA; gene therapy.
XX

OS Homo sapiens.
XX

XX MO200140466-A2.
XX

PD 07-JUN-2001.
XX

XX 01-DEC-2000; 2000WO-US032678.
XX

XX 01-DEC-1999; 99WO-US028301.
PR

PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 09-DEC-1999; 99US-0170262P.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 05-JUN-2000; 2000US-0209832P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020711.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 BA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
 XX WPI: 2001-408281/43.
 DR N-PSDB; AAS21259.
 XX Isolated , secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
 PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
 PT breast, prostate, cervical.
 PS Claim 12; Fig 32; 813pp; English.
 XX AAU12172-AAU12446 represent novel human secretory and transmembrane PRO
 CC polypeptides. The PRO polypeptides are useful to detect other PRO
 CC polypeptides, to link bioactive molecules to cells expressing PRO
 CC polypeptides, to modulate biological activities of cells expressing PRO
 CC polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumors by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample. Some
 CC of the 275 sequences are also useful to stimulate the release of tumour
 CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation of
 CC differentiation of chondrocytes, the proliferation or gene expression in
 CC pericyte cells, the release of proteoglycans from cartilage, the
 CC proliferation of inner ear utricular supporting cells or of T-
 CC lymphocytes, the release of a cytokine from peripheral blood monocytes
 CC (BMMs), or the proliferation of endophageal cells. Some of the PRO
 CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
 CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 CC VIIA. The PRO polypeptides can be used in assays to identify molecules
 CC involved in binding interactions. The polynucleotides encoding PRO

CC polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy
 XX
 SQ Sequence 311 AA;
 Query Match 100.0%; Score 1080; DB 4; Length 311;
 Best Local Similarity 100.0%; Pred. No. 9.8e-109;
 Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DEVALIPAPQNLVSLTNKHLIMSPVAPGETYYSGYEGEYESTYTHIMIPSSWC 60
 DB 30 DEVALIPAPQNLVSLTNKHLIMSPVAPGETYYSGYEGEYESTYTHIMIPSSWC 89
 QY 61 SLTEGPCVCTDDITATVPYNLRVATGSGTSAWSILKHPNNRSTLLTRPGMEITKDG 120
 DB 90 SLTEGPCVCTDDITATVPYNLRVATGSGTSAWSILKHPNNRSTLLTRPGMEITKDG 149
 QY 121 FHLVTELEDPGQFEPFLVAYMRREPABEHVQMRSGSIPVHLETMERGAAYCVKAGTFV 180
 DB 150 FHLVTELEDPGQFEPFLVAYMRREPABEHVQMRSGSIPVHLETMERGAAYCVKAGTFV 209
 QY 181 KAIGRYSAFSQTECVYEGEALP 203
 DB 210 KAIGRYSAFSQTECVYEGEALP 232
 RESULT 13
 AAB85270
 ID AAB85270 standard; protein; 311 AA.
 AC AAB85270;
 XX
 DT 07-SEP-2001 (first entry)
 XX
 DE Human IL-20 receptor subunit IL-20RB.
 XX
 KW Interleukin 20; IL-20; IL-20RA; Zcytor7; IL-20RB; DIRS1; immunoglobulin;
 KW antiinflammatory; antipsoaratic; antiaesthetic; antibacterial; human;
 KW dermatological; antitumor; antagonist.
 XX
 OS Homo sapiens.
 XX
 PN WO200146232-A2.
 XX
 PD 28-JUN-2001.
 XX
 PF 22-DEC-2000; 2000WO-US035307.
 XX
 PR 23-DEC-1999; 99US-00471774.
 PR 22-JUN-2000; 2000US-0213416P.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Foester DC, Xu W, Madden KL, Kelly JD, Sprecher CA, Brandt CS;
 PI Rixon MW, Presnell SR, Fox BA;
 DR WPI: 2001-398320/42.
 DR N-PSDB; AAH22816.
 PT Isolated interleukin 20 soluble receptor comprising two polypeptide
 PT subunits IL-20RA and IL-20RB, useful for down-regulating IL-20 and thus
 PT treating inflammatory diseases such as psoriasis.
 XX
 PS Example 2; Page 68-69; 119pp; English.
 XX The invention relates to an interleukin 20 (IL-20) soluble receptor
 CC comprising two polypeptide subunits IL-20RA (formerly known as Zcytor7)
 CC and IL-20RB (formerly known as DIRS1). The two subunits are preferably
 CC linked together, in one embodiment, one subunit is fused to the constant
 CC region of the light chain of an immunoglobulin, and the other subunit is
 CC fused to constant region of an immunoglobulin. The
 CC light chain and the heavy chain are connected via a disulphide bond. The
 CC soluble receptor can be used to down-regulate IL-20 and thus treat

CC inflammatory diseases such as psoriasis, inflammatory lung injury such as
CC asthma or bronchitis, adult respiratory disease (ARD), septic shock,
CC multiple organ failure, bacterial pneumonia, eczema, atopic and contact
CC dermatitis, and inflammatory bowel disease such as ulcerative colitis and
CC Crohn's disease. The present sequence represents a human IL-20 receptor
CC subunit IL-20RB
XX
SQ Sequence 311 AA;

Query Match 100.0%; Score 1080; DB 4; Length 311;
Best Local Similarity 100.0%; Pred. No. 9, 8e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVAIIIPAPQNLVSLSTNMKHLMLMSPVIAFGETVYVSVEYQGEYSLSYTHIMIPSSWC 60
DB 30 DEVAIIIPAPQNLVSLSTNMKHLMLMSPVIAFGETVYVSVEYQGEYSLSYTHIMIPSSWC 89

QY 61 SLTEGPECVTDITATVPNNLRVRAVLGSGTSAMSLTKHPFRNNTILTRPCEMETTKDG 120
DB 90 SLTEGPECVTDITATVPNNLRVRAVLGSGTSAMSLTKHPFRNNTILTRPCEMETTKDG 149

QY 121 FHLVIELEDLGPQFEFLVAYMRREPGBAEHVKVNRSGGIPVHLETPMGPAAVCYKQTFV 180
DB 150 FHLVIELEDLGPQFEFLVAYMRREPGBAEHVKVNRSGGIPVHLETPMGPAAVCYKQTFV 209

QY 181 KAIGRYSAFSQTECEVQGEAIP 203
DB 210 KAIGRYSAFSQTECEVQGEAIP 232

RESULT 14
AAE00339
ID AAE00339 standard; protein; 311 AA.
XX
AC AAE00339;
XX
DT 19-JUN-2001 (first entry)
XX
DE Human cytokine receptor protein, CG92.
XX
XX
KM Human; cytokine receptor protein; CG92; antiinflammatory; antimicrobial;
KM immunosuppressive; blood coagulation disorder; antidiabetic; cytotoxic;
KM gastrointestinal; acute pancreatitis; glomerulonephritis; gene therapy;
KM severe combined immunodeficiency; SCID; autoimmune disorder; thrombosis;
KM multiple sclerosis; rheumatoid arthritis; Alzheimer's disease; xenograft;
KM graft versus host disease; GVHD; inflammatory bowel disease; haemostatic;
KM endotoxin shock; psoriasis; osteoporosis; hepatitis; vascular; allograft;
KM cell proliferative; haematopoietic; vasculitis; lupus; leukaemia; cancer;
KM sarcoidosis; sepsis.
XX
OS Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT Peptide 1..29
FT /label= Signal_peptide
FT Protein 30..311
FT /label= Mature_human CG92_protein
FT Region 35..224
FT /note= "Tissue factor structure region"
FT Region 38..57
FT /label= Tissue_factor_signature
FT Region 40..226
FT /note= "Tissue factor structure region"
FT Domain 84..119
FT /label= Tissue_factor_domain
FT Region 235..255
FT /note= "Shows high homology to bacterial chemotaxis
FT sensory transducer signature"
XX
XX
PN MO200123569-A1.
XX
PD 05-APR-2001.

PF 29-SEP-2000; 2000MO-US026850.
XX
XX 29-SBP-1999; 99US-00408027.
XX
XX (HYSE-) HYSEQ INC.
XX
PI Ballinger D, Ford J, Pace A, Sheridan J;
XX
XX WPI; 2001-266162/27.
DR N-PSDB; AAD03547.
XX
PT Polynucleotides encoding human cytokine receptor CG92, useful for
PT preventing, diagnosing and treating inflammation and disorders of blood
PT coagulation.
XX
XX Claim 10; Fig 1-3; 109pp; English.
XX
CC The present sequence is human cytokine receptor protein, designated as
CC CG92. CG92 is a member of the class II cytokine receptor (CRF2) family,
CC which includes R1 and R2 of chains of the IL-10 receptor complex, IFN-
CC alpha receptor complex, and tissue factor (TF). CG92 DNA and proteins are
CC used in the prevention, diagnosis and treatment of diseases associated
CC with inappropriate cytokine receptor expression such as inflammatory
CC disorders and disorders of blood coagulation. These disorders include
CC sepsis, thrombosis, acute pancreatitis, arthritis, vasculitis, lupus,
CC immune complex glomerulonephritis, diabetes, allograft and xenograft
CC transplantation, hepatitis, stroke and cancers. It is also used for
CC treating various immune deficiencies and disorders such as severe
CC combined immunodeficiency (scid) and autoimmune disorders such as
CC multiple sclerosis, rheumatoid arthritis; nervous system disorders (e.g.,
CC Alzheimer's disease); sarcoidosis; leukaemias (e.g., erythroleukaemia);
CC inflammations such as graft versus host disease (GVHD), inflammatory
CC bowel disease and endotoxin shock; hyperproliferative disorders (e.g.,
CC psoriasis); cancers (e.g., non-Hodgkin's lymphoma, prostate cancer) and
CC bone degenerative diseases such as osteoporosis. CG92 cDNA is also used
CC in gene therapy. CG92 possesses cytokine and cell
CC proliferation/differentiation activity, immune regulating activity,
CC haematopoiesis regulating activity, tissue growth activity, haemostatic
CC and thromolytic activity, receptor/ligand activity and anti-inflammatory
CC activity. CG92 is also used in assays to identify modulators of cytokine
CC receptor expression and their activities
XX
SQ Sequence 311 AA;

Query Match 100.0%; Score 1080; DB 4; Length 311;
Best Local Similarity 100.0%; Pred. No. 9, 8e-109;
Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DEVAIIIPAPQNLVSLSTNMKHLMLMSPVIAFGETVYVSVEYQGEYSLSYTHIMIPSSWC 60
DB 30 DEVAIIIPAPQNLVSLSTNMKHLMLMSPVIAFGETVYVSVEYQGEYSLSYTHIMIPSSWC 89

QY 61 SLTEGPECVTDITATVPNNLRVRAVLGSGTSAMSLTKHPFRNNTILTRPCEMETTKDG 120
DB 90 SLTEGPECVTDITATVPNNLRVRAVLGSGTSAMSLTKHPFRNNTILTRPCEMETTKDG 149

QY 121 FHLVIELEDLGPQFEFLVAYMRREPGBAEHVKVNRSGGIPVHLETPMGPAAVCYKQTFV 180
DB 150 FHLVIELEDLGPQFEFLVAYMRREPGBAEHVKVNRSGGIPVHLETPMGPAAVCYKQTFV 209

QY 181 KAIGRYSAFSQTECEVQGEAIP 203
DB 210 KAIGRYSAFSQTECEVQGEAIP 232

RESULT 15
AAU04059
ID AAU04059 standard; protein; 311 AA.
XX
XX AAU04059;
XX
XX
DT 23-OCT-2001 (first entry)
XX

Gene 186, 97-101, 1997
A>Title: CRF2-4: isolation of cDNA clones encoding the human and mouse proteins.
A/Reference number: JC6311; MUID:97199375; PMID:9047351
A/Accession: JC6311
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-349 <GIB>
A/Cross-references: UNIPROT:Q8VHM7; GB:U53696

Query Match 15.0%; Score 162; DB 2; Length 349;
Best Local Similarity 24.4%; Pred. No. 3.2e-07;
Matches 53; Conservative 37; Mismatches 93; Indels 34; Gaps 10;

QY 3 VALPAPONLSVLSTNNKHLMMSPVAPGETVYVSVEYQGEVSLYTSIMWIPSSWCSL 62
D 18 LGMIPPEKVRMSVNFKNILQWEPAPFKTNLFTMQYE-SYRS-FQDH-----CKR 68
QY 63 TEGSCVTDITATVYNNLRVATLGSQTSAM-SILKHPNNRSTILTRPGMEITKQGF 121
D 69 TASTQCDPS-HLSKYGDTVRVRAELADHSEWNVNFCFV--EDTIIIGPEMQI--ESL 123
QY 122 HLVELELDLGPQPE-----FLVAYMRREPQAEHVMKVRSGGIPLYLET 165
D 124 AESLELFPAPQIENEPETTLKTIYSMAIRVOYMKN--GTMKQVVSPPYDSEV-LRN 180
QY 166 MEGAAVCVAQGFVKAIGRYSAFSQTECVYQGEAI 202
D 181 LEFWTYCIVQGFLLDQNRGTGSEWSEPCERTGNDI 217

RESULT 3

A47003
Cytokine receptor family class II protein CRF2-4 precursor - human
C/Species: Homo sapiens (man)
C/Date: 09-Sep-1994 #sequence_revision 09-Sep-1994 #text_change 09-Jul-2004
C/Accession: A47003; G01418
R/Lutfalla, G.; Gardiner, K.; Uze, G.
Genomics 16, 366-373, 1993
A/Title: A new member of the cytokine receptor gene family maps on chromosome 21 at leas
A/Reference number: A47003; MUID:93300510; PMID:8314576
A/Accession: A47003
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-325 <LUT>
A/Cross-references: UNIPROT:Q08334; GB:Z17227; NID:G933378; PIDN:CAA78933.1; PID:G933379
R/Lutfalla, G.
submitted to the EMBL Data Library, April 1994
A/Reference number: G06935
A/Accession: G01418
A/Status: preliminary; translated from GB/EMBL/DDBJ
A/Molecule type: DNA
A/Residues: 1-123, 'D', 125-268, 'VGHME' <LU2>
A/Cross-references: EMBL:U08988; NID:G571295; PID:G571296
C/Genetics:
A/Gene: GDB:CRF4; CRF2-4
A/Cross-references: GDB:136168; OMIM:123889
A/Map position: 21q, 21q22.1-21q22.2
A/Intons: 17/1, 58/2, 111/1, 166/3; 216/1
C/Keywords: transmembrane protein

Query Match 14.8%; Score 159.5; DB 2; Length 325;
Best Local Similarity 25.7%; Pred. No. 5e-07;
Matches 57; Conservative 37; Mismatches 87; Indels 41; Gaps 12;
QY 3 VALPAPONLSVLSTNNKHLMMSPVAPGETVYVSVEYQGEVSLYTSIMWIPSSWCS 61
D 18 LGMIPPEKVRMSVNFKNILQWEPAPFKTNLFTMQYE-SYRS-FQDH-----CKR 68
QY 62 LTGSPEDVDDITATVYNNLRVATLGSQTSAM-SILKHPNNRSTILTRPGM-EITK 118
D 68 NTLLTDCDFS-SLSKYGDTVRVRAELADHSDWNVITFCV--DDTIIIGPDMQEVLA 124
QY 119 DGFHLVELELDLGPQPE-----FLVAYMRREPQAEHVMKVRSGGIPLYH 162

D 125 DSLH-----WRFLAPKLENEYETWTKNVNSWTYNVQVYKN--GTDEKQIRPOYDFEV- 177
QY 163 LETMEPGAAYCYKAQGFVKAIGRYSAFSQTECVY-QGEAIP 203
D 178 LRLLEFWTYCIVQVGRFLDPRNRKAGWSEBPVCEQTHDETVP 219

RESULT 4

A49947
Interferon gamma receptor beta subunit - mouse
N/Alternate names: IFN-gamma R beta chain; IFN-gamma R species-specific cofactor; type I
C/Species: Mus musculus (house mouse)
C/Date: 06-Oct-1994 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C/Accession: A49947
R/Hemmi, S.; Bohni, R.; Stark, G.; Di Marco, F.; Aguet, M.
Cell 76, 803-810, 1994
A/Title: A novel member of the interferon receptor family complements functionality of t
A/Reference number: A49947; MUID:94170381; PMID:8124717
A/Accession: A49947
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-332 <HEM>
A/Cross-references: UNIPROT:Q63953; GB:S69336; NID:G545841; PIDN:AAB30165.1; PID:G545842
A/Experimental source: early B-cell line Y16
A/Note: sequence extracted from NCBI backbone (NCBIN:145654, NCBI:P:145656)
C/Keywords: cytokine receptor

Query Match 14.6%; Score 158; DB 2; Length 332;
Best Local Similarity 28.8%; Pred. No. 7.1e-07;
Matches 65; Conservative 29; Mismatches 94; Indels 38; Gaps 14;

QY 1 DEVALPAPONLSVLSTNNKHLMMSPVAPGETVYVSVEYQGEVSLYTSIMWIPSSWC 60
D 24 DSFQSLAPLNRRLHLYNDEQLTWEP--SPSNDPRRVYQVEYS-----FIDGSH 74
QY 61 STGEPGEC-DVTD---DITA-----TVPN--LRVRAATLGSQTSAMSILKHPNNRST 107
D 75 RLLE-PNCTDITRETKCDLTGGRLKLPHPFTVFLRVRAKGNLTSKWGLE-PQHYEN 132
QY 108 ILTRP--GMEITKQGFHLVLELE--DL--GPQFFLVAYMRREPQAEHVMKVRSGGI 159
D 133 VTVGPPKNISVTPGSLVTHPSPPDFHGATTFQYLVHWEKSTQGEQVEGPPKNSI 192
QY 160 PVHLETPMEGAAYCYKAQGFV---KAIGRYSAFSQTECVYQGEA 201
D 193 V--LGNLKPVRVYCCQTEAQLIKKKIRPHGLLSNNSCHETYNAA 236

RESULT 5

S27387
Interferon alpha receptor type I precursor - bovine
C/Species: Bos primigenius taurus (cattle)
C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
C/Accession: S27387; S33770
R/Monchel-Vieilh, E.; Lutfalla, G.; Mogensen, K.E.; Uze, G.
FEBS Lett. 313, 255-259, 1992
A/Title: Specific antiviral activities of the human alpha interferons are determined at
A/Reference number: S27387; MUID:93076908; PMID:1446745
A/Accession: S27387
A/Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-560 <MOU>
A/Cross-references: UNIPROT:Q04790; EMBL:X68443; NID:G431; PIDN:CAA48484.1; PID:G432
A/Experimental source: MDBK cells
R/Lim, J.K.; Langer, J.A.
Blochim. Biophys. Acta 1173, 314-319, 1993
A/Title: Cloning and characterization of a bovine alpha interferon receptor.
A/Reference number: S33770; MUID:93305725; PMID:8318540
A/Accession: S33770
A/Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-421, 'V', 423-560 <LIM>

A;Cross-references: EMBL:U06320; NID:g163187; PIDN:AAA02571.1; PID:g163188
A;Experimental source: Lung
A;Keywords: antiviral; cytokine receptor; transmembrane protein
F;1-24/Domain: signal sequence #status predicted <SIG>
F;25-560/Product: interferon alpha receptor type 1 #status predicted <MAT>

Query Match 14.0%; Score 151; DB 2; Length 560;
Best Local Similarity 24.6%; Pred. No. 6.1e-06;
Matches 52; Conservative 38; Mismatches 87; Indels 34; Gaps 9;

6 LPAPONLSVLTSMKHLMSVPIAPGETVYVSVEYQGEYSYLSHTSHI-----W---IP 56
Db 229 VPEPBNQIQAADNRIYLKMK-----DYENKATFOAQMDRAFPKXI PGNHSDKMKQIP 281

57 SSWCSLTEGPECDVTDITATVPYNLRATLGSQTSAMSLKHPFRNRNTIILTRPGM-- 114
Db 282 N--CENTSTHCVPRREVSRGIIYVVRASNGNGSTPMSBEKGFNTMKTIIIPPIYSV 339

115 -BITKGFHLVIT---ELEDLGPO---PEFLVAYWRERPGAEHVMVRSGGIPVHLET 165
Db 340 KSTYDLSLHVSVGASESESMNSVQLYPLIYEVIFMENTSNAERKVLKKTNTFI---FPD 396

166 MEEGAACVCAKOTFVKAIGRY--SAFSQTEC 194
Db 397 LKPLTYVCVAKALLIENDRNKSSFSQDTC 427

RESULT 6
A45283
interferon alpha/beta receptor - mouse
C/Species: Mus musculus (house mouse)
C/Date: 25-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
A;Accession: A45283; I48423; I48424; I48425; I48426; I48427; I48428; I48429
R;Uze, G.; Lutfalla, G.; Bandu, M.T.; Proudhon, D.; Mogensen, K.E.
Proc. Natl. Acad. Sci. U.S.A. 89, 4774-4778, 1992

A;Title: Behavior of a cloned murine interferon alpha/beta receptor expressed in homosp
A;Reference number: A45283; MUID:92262522; PMID:1533935
A;Accession: A45283
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-590 <UZE>
A;Cross-references: UNIPROT:P33896; GB:M89661; NID:g194111; PIDN:AAA37890.1; PID:g194112
A;Note: sequence extracted from NCBI backbone (NCBIN:102354, NCBIPI:102357)
R;Lutfalla, G.; Uze, G.
Gene 148, 343-346, 1994

A;Title: Structure of the murine interferon alpha/beta receptor-encoding gene: high-fre
A;Reference number: I48423; MUID:95047447; PMID:7958966
A;Accession: I48423
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Residues: 118-125 <RES>
A;Cross-references: EMBL:U06237; NID:g497103; PIDN:AAA65003.1; PID:g755810
A;Accession: I48424
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Residues: 127-224 <RES>
A;Cross-references: EMBL:U06239; NID:g497106; PIDN:AAA65004.1; PID:g510261
A;Accession: I48425
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Residues: 263-375 <RES>
A;Cross-references: EMBL:U06240; NID:g497108; PIDN:AAA65005.1; PID:g510262
A;Accession: I48427
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 397-424 <RES>
A;Cross-references: EMBL:U06241; NID:g497110; PIDN:AAA65006.1; PID:g755812
A;Accession: I48428

A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 426-445 <RES>
A;Cross-references: EMBL:U06242; NID:g497112; PIDN:AAA65007.1; PID:g755813
A;Accession: I48429
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 473-590 <RES>
A;Cross-references: EMBL:U06244; NID:g497114; PIDN:AAA65008.1; PID:g510265
C;Genetic8:
A;Gene: IFNAR
A;Introns: 177/3; 331/1
C;Keywords: cytokine receptor; transmembrane protein

Query Match 13.1%; Score 142; DB 2; Length 590;
Best Local Similarity 24.9%; Pred. No. 4.4e-05;
Matches 49; Conservative 39; Mismatches 95; Indels 14; Gaps 8;

6 LPAPONLSVLTSMKHLMSVPIAPGETVYVSVEYQGEYSYLSHTSHI--WIPSSCSLT 63
Db 229 MPVPGNLQVDAQSKSYLKWID-YIASADVLFRQWLPYGSKSSGSHSDKMKPIPTCANV 287

64 EGPECDVTDITATVPYNLRATLGSQTSAMSLKHPFRNRNTIILTRPGMET--KDFG 121
Db 288 QTHCVFSSQDTVYTGTFPLHVQASEGNHVSFMSBEKPTDSQKHLPPPIVITVAMSDTL 347

122 HLVIIEEDL---GPOFEFLVAYWRERPGAEHVMVRSGGIPVHLETMEGAACVCAKOT 178
Db 348 LVYVNCODSTCDGLANE--IIFW--ENTSNTKLSMEKDF-EPLTKNLQPLTYVCVQARV 402

179 FVKA-IGRYSAFSQTEC 194
Db 403 LFPALLNKNTSNFSEKLC 419

RESULT 7
A32694
interferon alpha/beta receptor precursor - human
C/Species: Homo sapiens (man)
C/Date: 22-Jun-1990 #sequence_revision 22-Jun-1990 #text_change 09-Jul-2004
A;Accession: A32694; S17112
R;Uze, G.; Lutfalla, G.; Gresser, I.
Cell 60, 225-234, 1990

A;Title: Genetic transfer of a functional human interferon alpha receptor into mouse ce
A;Reference number: A32694; MUID:90124632; PMID:2153461
A;Accession: A32694
A;Molecule type: mRNA
A;Residues: 1-557 <UZE>
A;Cross-references: UNIPROT:P17181; GB:J031171; NID:g184645; PIDN:AAA52730.1; PID:g30691
R;Lutfalla, G.
submitted to the EMBL Data Library, July 1991
A;Description: The structure of the human interferon alpha/beta receptor gene.
A;Reference number: S17112
A;Accession: S17112
A;Molecule type: DNA
A;Residues: 1-16, 'A', '18-329', 'V', '343-557 <LUT>
C;Cross-references: EMBL:X60459; NID:g32671
C;Genetic8:
A;Gene: GDB:IFNAR1; IFNAR, IFRC
A;Cross-references: GDB:1120078; OMIM:107450
A;Map position: 21q22.1-21q22.1
A;Introns: 26/1; 67/2; 126/1; 177/3; 225/1; 263/2; 342/1; 381/3; 432/1; 480/3
C;Keywords: cytokine receptor; glycoprotein; transmembrane protein
F;1-21/Domain: transmembrane #status predicted <TRN1>
F;437-455/Domain: transmembrane #status predicted <TRN2>
F;50,58,81,88,110,172,254,313,314,376,416,433,507,518,537/Binding site: carbohydrate (A

Query Match 12.7%; Score 137.5; DB 2; Length 557;
Best Local Similarity 22.1%; Pred. No. 0.00011;
Matches 50; Conservative 37; Mismatches 74; Indels 65; Gaps 11;

6 LPAPONLSVLTSMKHLMSVPIAPGETVYVSVEYQGEYSYLSHTSHI--WIPSSCSLT 60

Db 229 LPPENIEVSQVONVVLKMM-----DYTAAMTFQVQMLHFLKRNPNHLY---KWK 278
QY 61 STLEGECVDITATVPYN-----LRYRATLGSQTSMS-----ILKH 100
Db 279 QI---PDGNNVTTQCVFQVFNQKGYTLRLVQASDGNNTSWSSEIKFDTIQAFLLP 335
QY 101 PNNRSTLTITRQMEITKDGPHLVI-----ELDLGQPEFFLVAYRRERGAEEH 150
Db 336 VFNIRS-----LSDSFHIYIGAPKQSGNTVDIDYPLIYE--IIFENINSNMRK 383
QY 151 VGVNWSGGIPVHLETMEGAAVCVKAQ--TFPKAIGRASASQTEC 194
Db 384 IIEKKT---DYVFNKLPYLCVAKARAHWDKLNKSSVPSDAVC 426

RESULT 8
156215
Interleukin-10 receptor - human
C:Species: Homo sapiens (man)
C>Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C:Accession: 156215
R:Lin, Y.; Wei, S.H.; Ho, A.S.; de Waal Malefyt, R.; Moore, K.W.
J. Immunol. 152, 1821-1829, 1994
A:Title: Expression cloning and characterization of a human IL-10 receptor.
A:Reference number: 156215; MUID:94165477; PMID:8120391
A:Accession: 156215
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-578 <RES>
A:Cross-references: UNIPROT:Q13651; EMBL:U00672; NID:g482802; PIDN:AAAI7896.1; PID:g4828
A:Genetics:
A:Gene: GDB:11L0R; HL-10R
A:Cross-references: GDB:330958; OMIM:146933
A:Map position: 11q23.3-11q23.3
C:Superfamily: interleukin-10 receptor IL10R
C:Keywords: cytokine receptor

Query Match 11.3%; Score 122.5; DB 2; Length 578;
Best Local Similarity 22.9%; Pred. No. 0.0027;
Matches 51; Conservative 33; Mismatches 86; Indels 53; Gaps 8;
QY 6 LPAPONSVLSTNMKHLIMSPLVAPGETVYVSVEYQGEYESLYTSHIWIPISSWCSLTEG 65
Db 26 LPSPSPWFAEPFAEPFHILHTPIPNQSESTCYEAL-----LRGIESMNSISNCQSLTS 80
QY 66 PECD-VTDDITATVPYNLRYRATLGSQTSMSILKHPNNRSTLT----- 110
Db 81 YDLATVTLDLYHSNGYRARRAVDGRSHSNMTVTRFSDVDTLVGVSNLHNGFTLL 140
QY 111 -----RPGMEITKDGPHLVILEDLQPF--EFLVAYRRERPG-----AEHVKNV 154
Db 141 GKTLQPPKNAIPANDTY-----ESIFSHREYEIAI-RKVPQNFPTTHKVKVGHENFSLL 193
QY 155 RSGGIPVHLETMERGAAYCVKAQTFVKAIGRASASQTECEV 197
Db 194 TSGEAV-----GEFCVQVAPSVASRSNKMKSKRECI SL 226

RESULT 9
KFRB3
tissue factor precursor - rabbit
N:Alternate names: coagulation factor III
C:Species: Oryctolagus cuniculus (domestic rabbit)
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: J00441; S23681
R:Andrews, B.S.; Rehmetulla, A.; Fowler, B.J.; Edgington, T.S.; Mackman, N.
Gene 98, 265-269, 1991
A:Title: Conservation of tissue factor primary sequence among three mammalian species.
A:Reference number: J00441; MUID:91200676; PMID:1840552
A:Accession: J00441
A:Molecule type: mRNA
A:Residues: 1-292 <AND>
A:Cross-references: UNIPROT:P24055; GB:M55390; NID:g165696; PIDN:AAA63469.1; PID:g165697

A:Experimental source: brain
R:Paswache, A.; Ezekowitz, M.; Lin, T.C.; Horton, R.; Bach, R.; Konigsberg, W.
Thromb. Haemost. 66, 315-320, 1991
A:Title: Molecule cloning, characterization and expression of cDNA for rabbit brain ti-
A:Reference number: S23681; MUID:92081032; PMID:1446002
A:Accession: S23681
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 35-292 <PAM>
A:Cross-references: EMBL:X53521; NID:g1495; PIDN:CAA37597.1; PID:g3960170
C:Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor
C:Superfamily: tissue factor
C:Keywords: blood coagulation; glycoprotein; lipoprotein; thiolester bond; transmembrane
F:1-32/Domain: signal sequence #status predicted <SIG>
F:33-292/Product: tissue factor #status predicted <NAT>
F:33-249/Domain: extracellular #status predicted <EXT>
F:250-271/Domain: transmembrane #status predicted <TM>
F:272-292/Domain: intracellular #status predicted <INT>
F:41, 114, 154, 167, 182/Binding site: carbohydrate (Asn) (covalent) #status predicted
F:78-87, 216-239/Disulfide bonds: #status predicted
F:274/Binding site: palmitate (Cys) (covalent) #status experimental

Query Match 10.8%; Score 117; DB 1; Length 292;
Best Local Similarity 25.0%; Pred. No. 0.0036;
Matches 57; Conservative 26; Mismatches 87; Indels 58; Gaps 11;
QY 11 NLSVLSTNMKHLIMSPLVAPGETVYVSVEYQGEYESLYTSHI-----WTPSSWCSLTE 64
Db 41 NLTWSYTFKLTLEWEP-----KSID-----YVTVQISTRLNN--KSKCFLLTA 83
QY 65 GPECVDITDITATV--PYNLRYRATLGSQTSMSILKHPNNR-----TLTRGGM 114
Db 84 ETRECDLTBEVVDVQCTMARVLSIPANNQTTGPEPPRNSDEFTPYLDITLQGPFT 143
QY 115 E-ITDQGFHLVIELED-----LGPQPEFLVAYRRERGAEEHVKNVRS 156
Db 144 QSEFQVGTKNLVTVQDARTLVRRNGTFLSLRAVFGKDLNLTLYTWR-----ASSGKKTAT 199
QY 157 GGIPVHLETMERGAAYCVKAQTFVKAIGR--YSAFSQTECV-ENQGEA 201
Db 200 TTNTEFLIDVDKGENYCPSVQAVIPSRKQKRSPESLTECTSRBOGRA 247

RESULT 10
KPFU3
tissue factor precursor [validated] - human
N:Alternate names: coagulation factor III
C:Species: Homo sapiens (man)
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: A43645; A47574; A28320; A29062; A29672; A29008
R:Mackman, N.; Morrissey, J.H.; Fowler, B.; Edgington, T.S.
Biochemistry 28, 1755-1762, 1989
A:Title: Complete sequence of the human tissue factor gene, a highly regulated cellular
A:Reference number: A43645; MUID:89247359; PMID:2719931
A:Accession: A43645
A:Molecule type: DNA
A:Residues: 1-295 <MAC>
A:Cross-references: UNIPROT:P13726; GB:J02846; NID:g339505; PIDN:AAA61152.1; PID:g33950
R:Fisher, K.L.; Gorman, C.W.; Vehn, G.A.; O'Brien, D.P.; Lawn, R.M.
Thromb. Res. 48, 89-99, 1987
A:Title: Cloning and expression of human tissue factor cDNA.
A:Reference number: A47574; MUID:88100453; PMID:3424286
A:Accession: A47574
A:Molecule type: mRNA
A:Residues: 1-295 <RTS>
A:Cross-references: GB:M27436; NID:g339507; PIDN:AAA6734.1; PID:g339508
R:Spicer, E.K.; Horton, R.; Bloem, L.; Bach, R.; Williams, K.R.; Guha, A.; Kraus, J.; L
Proc. Natl. Acad. Sci. U.S.A. 84, 5148-5152, 1987
A:Title: Isolation of cDNA clones coding for human tissue factor: primary structure of
A:Reference number: A94171; MUID:87260946; PMID:3037556
A:Accession: A28320
A:Molecule type: mRNA

A:Residues: 1-295 <SPI>
A:Cross-references: GB:02931; NID:G339501; PIDN:AAA61150.1; PID:G339502
R:Morrisey, J.H., Fakhrat, H., Edgington, T.S.
Cell 50, 129-135, 1987
Article: Molecular cloning of the cDNA for tissue factor, the cellular receptor for the
A:Reference number: A29062; MUID:87244317; PMID:3297348
A:Accession: A29062
A:Molecule type: mRNA
A:Residues: 1-295 <MOR>
A:Cross-references: GB:02931; NID:G339501; PIDN:AAA61150.1; PID:G339502
A:Note: part of this sequence, including the amino end of the mature protein, was confir-
R:Scarpaci, B.M., Wen, D., Brose Jr., G.U., Mlelech, J.P., Flendermeyer, R.R., Siegel,
Biochemistry 26, 5234-5238, 1987
A:Title: Human tissue factor: cDNA sequence and chromosome localization of the gene.
A:Reference number: A29672; MUID:88050796; PMID:2823875
A:Accession: A29672
A:Molecule type: mRNA
A:Residues: 1-259, 'A', 261-295 <SCA>
A:Cross-references: GB:M1653; NID:G339503; PIDN:AAA61151.1; PID:G339504
R:Bach, R., Konigsberg, W.H., Nemerson, Y.
Biochemistry 27, 4227-4231, 1988
A:Title: Human tissue factor contains thioester-linked palmitate and stearate on the Cys
A:Reference number: A37422; MUID:8900604; PMID:1166778
A:Contents: annotation; disulfide bonds and fatty acid binding site
C:Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor
C:Comment: Expression of tissue factor can be induced in a variety of tissues by certain
C:Genetics:
A:Gene: GDB:F3
A:Cross-references: GDB:119895; OMIM:134390
A:Map position: 1p22-1p21
A:Introns: 34/1; 71/2; 138/1; 197/3; 251/1
C:Superfamily: tissue factor
C:Keywords: blood coagulation; glycoprotein; lipoprotein; thiolester bond; transmembrane
F:1-32/Domain: signal sequence #status predicted <SIG>
F:33-295/Product: tissue factor #status experimental <MAT>
F:33-251/Domain: extracellular #status predicted <EXT>
F:252-274/Domain: transmembrane #status predicted <TM>
F:275-295/Domain: intracellular #status predicted <INT>
F:43/Binding site: carbohydrate (Asn) (covalent) #status experimental
F:81-89, 318-241/Disulfide bonds: #status experimental
F:156,169/Binding site: carbohydrate (Asn) (covalent) #status predicted
F:277/Binding site: palmitate (Cys) (covalent) #status experimental

```

A:Reference number: A49667; MUID:94068585; PMID:8248239
A:Accession: A49667
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-575 <RBS>
A:Cross-references: UNIPROT:Q61727; GB:L12120; NID:9437615; PID:AAA16156.1; PID:943761
A:Genes: IL10R
C:Superfamily: interleukin-10 receptor IL10R
C:Keywords: cytokine receptor

Query Match          10.4%; Score 112.5; DB 2; Length 575;
Best Local Similarity 28.4%; Pred. No. 0.022;
Matches 31; Conservative 15; Mismatches 54; Indels 9; Gaps 2;

QY 6 LPAPQNLSTNMKHLMSPIVAPGETVYVVEYQGEYSILYTSIHWIPSSWCSLTG 65
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 26 LPSSVYWFARPFQHIILWMPINQSESTYEVALK-----QGNSTWMDIHCRAQA 80
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

QY 66 PECVLT----DDIATVPYNLRVATLGSQTSAMSILKHPNRNSTLT 110
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 81 LSCDLTFTTLDLHRSYGYRVRVAVDNSQYSNMVTTETRTVDEVILT 129
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

RESULT 12
KRB03
tissue factor precursor - bovine
N:Alternate names: coagulation factor III
C:Species: Bos primigenius taurus (cattle)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: J01319
R:Takayenoki, Y.; Muta, T.; Miyata, T.; Iwanaga, S.
Biochem. Biophys. Res. Commun. 181, 1145-1150, 1991
A>Title: cDNA and amino acid sequences of bovine tissue factor.
A:Reference number: J01319; MUID:92109720; PMID:1764065
A:Accession: J01319
A:Molecule type: mRNA
A:Residues: 1-292 <TR>
A:Cross-references: UNIPROT:P30931; GB:S74147; NID:9241438; PID:AA820755.1; PID:924143
A:Experimental source: adrenal gland
A>Note: part of this sequence, including the amino end of the mature protein, was confi
C:Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor
C:Comment: Expression of tissue factor can be induced in a variety of tissues by certai
C:Superfamily: tissue factor
C:Keywords: blood coagulation; glycoprotein; lipoprotein; thioester bond; transmembran
R:1-35/Domain: signal sequence #status predicted <SIG>
F:1-35/Domain: signal sequence #status predicted <SIG>
F:36-292/Product: tissue factor #status experimental <MAT>
F:36-248/Domain: extracellular #status predicted <EXT>
F:248-271/Domain: transmembrane #status predicted <TM>
F:272-292/Domain: intracellular #status predicted <INT>
R:43,153,181/Binding site: carbohydrate (Asn) (covalent) #status predicted
F:81-89,215-238/Disulfide bonds: #status predicted
F:118,124/Binding site: carbohydrate (Thr) (covalent) #status predicted
F:274/Binding site: palmitate (Cys) (covalent) #status experimental

Query Match          9.5%; Score 103; DB 1; Length 292;
Best Local Similarity 20.3%; Pred. No. 0.07;
Matches 44; Conservative 31; Mismatches 88; Indels 54; Gaps 8;

QY 11 NLSTLSTNMKHLMSPIVAPGETVYVVEYQGEYSILYTSI-----WIPSSWCSLTG 64
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 43 NITWKSNTFKILMEWP-----KPINHYTVQIISPRIGNW--KNNCFYTT 85
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

QY 65 GPECDVDDIATVPYNLRVATLGSQTSAMSILKHPNRN-----STILTREGME-I 116
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 86 NTECDVDEIKVNRRETLARVLSYPADTSSYVPEPTNSPEPTPIVLETNLGCTIISF 145
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

QY 117 TKDGFHLVLELD-----LGPFELVAVYWRBEPGAEHVKVRSCTI 159
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 146 EQVGTKLNVQDARTLVRAVSFLSDVVGKDLNLTLYWVKASSTGKKKATTTNNG-- 203
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

QY 160 PVHLETFMGALYGVKQTFV--KAIGRYAIFSQTEC 194
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

```

Db 204 --FLAIDVDKGENYCFHVAQVILSRVYNQKSPESPIC 238

RESULT 13

KFMS3

tissue factor precursor - mouse

N/Alternate names: coagulation factor III

C/Species: Mus musculus (house mouse)

C/Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004

C/Accession: A33318; A39046

R/Hartzell, S.; Ryder, K.; Ianahan, A.; Lau, L.F.; Nathans, D.

Mol. Cell. Biol. 9, 2567-2573, 1989

A/Title: A growth factor-responsive gene of murine BALB/c 3T3 cells encodes a protein hc

A/Reference number: A33318; MUID:89343974; PMID:2761539

A/Accession: A33318

A/Molecule type: mRNA

A/Residues: 1-294 <HAR>

A/Cross-references: UNIPROT:P20352; GB:M26071; NID:G201924; PIDN:AAA40414.1; PID:G201925

R/Ranganathan, G.; Blatt, S.P.; Sudramaniam, M.; Fass, D.N.; Mathle, N.J.; Getz, M.J.

J. Biol. Chem. 266, 496-501, 1991

A/Title: Cloning of murine tissue factor and regulation of gene expression by transformi

A/Reference number: A39046; MUID:91093171; PMID:1985911

A/Accession: A39046

A/Molecule type: mRNA

A/Residues: 1-25, '1', 27-294 <RAN>

A/Cross-references: GB:M57896; GB:U05713; NID:G201926; PIDN:AAA63400.1; PID:G201927

A/Note: 26-Thr was also found

C/Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor

C/Keyword: Expression of tissue factor can be induced in a variety of tissues by certain

C/Keywords: blood coagulation; glycoprotein; lipoprotein; thiolester bond; transmembrane

F.1-29/Domain: signal sequence #status predicted <SIG>

F.30-294/Product: tissue factor #status predicted <EXT>

F.30-251/Domain: extracellular #status predicted <EXT>

F.25-274/Domain: transmembrane #status predicted <TMM>

F.37-57, 169, 200/Binding site: carbohydrate (asn) (covalent) #status predicted

F.75-83, 218-241/Disulfide bond: #status predicted

F.275/Binding site: palmitate (Cys) (covalent) #status experimental

Query Match 9.4%; Score 101.5; DB 1; Length 294; Best Local Similarity 23.7%; Pred. No. 0.097; Matches 54; Conservative 31; Mismatches 80; Indels 63; Gaps 13;

Db 11 NLSTLSTMMKHLMMSPVIAAGETVY-YSVEYQGEYSLSYSHIMPSMCSLTEGPEC 69

Db 37 NLWISIDFXTLSEWQ---PKPTNYTYTVOISDR-----SRW--KNKCFSTTDECD 84

Qy 70 VTDDIT--ATVPVNLRYRATL-----GSO-----TSAMSILHPPNRNSTLL 109

Db 85 LTDEIVDVMTWAYAKVLSVPRRNSVHGDDQLVTHGEPPFTNAPKFLPY---RDPTNL 140

Qy 110 TRPGM-RITKDGPHLVLELD-----LQPFELVAYWR-REPGAEEH 150

Db 141 GQPIVIOQFEDQGRKLVVVDLSLVKNGTFLTLRQVFKDQGYITTYKSGSTOKTN 200

Qy 151 VKWVRSGIPVHLETPGAAVC--VKAQTFVVAIGRYSAFSOTECVE 196

Db 201 ITTNESIDV---EEGVSYCFVQAMTFSRTKQNSGSSITVCTE 243

RESULT 14

A49724

protein-tyrosine-phosphatase (BC 3.1.3.48), receptor type H precursor - human

N/Alternate names: protein-tyrosine-phosphatase, stomach cancer-associated type 1; SAP-1

C/Species: Homo sapiens (man)

C/Date: 03-May-1994 #sequence_revision 23-Feb-1996 #text_change 09-Jul-2004

C/Accession: A49724

R/Matocaki, T.; Suzuki, T.; Uchida, T.; Inazawa, J.; Ariyama, T.; Matsuda, K.; Horita, K

J. Biol. Chem. 269, 2075-2081, 1994

A/Title: Molecular cloning of a human transmembrane-type protein tyrosine phosphatase an

A/Reference number: A49724; MUID:94124561; PMID:8294459

A/Accession: A49724

A/Molecule type: mRNA

A/Residues: 1-1118 <MATO>

A/Cross-references: UNIPROT:Q15426; GB:D15049; NID:G475003; PIDN:BA03645.1; PID:G475004

C/Genetics:

A/Gene: PTPRH; SAP-1

A/Cross-references: GDB:305504

A/Map position: 19q13.4-19q13.4

A/Note: highly expressed in colon and pancreatic cancer cells but not in the normal cel

C/Suprafamily: protein-tyrosine-phosphatase, receptor type H; fibronectin type III repe

C/Keywords: carcinogenesis; duplication; glycoprotein; phosphoprotein; phosphoric monoe

F.1-27/Domain: signal sequence #status predicted <SIG>

F.28-110/Domain: fibronectin type III repeat homology <3FNA>

F.28-761/Domain: protein-tyrosine-phosphatase, receptor type H #status predicted <MAT

F.116-199/Domain: fibronectin type III repeat homology <3FNB>

F.205-289/Domain: fibronectin type III repeat homology <3FNC>

F.296-379/Domain: fibronectin type III repeat homology <3FND>

F.385-468/Domain: fibronectin type III repeat homology <3FNE>

F.474-558/Domain: fibronectin type III repeat homology <3FNF>

F.564-658/Domain: fibronectin type III repeat homology <3FNG>

F.667-737/Domain: fibronectin type III repeat homology <3FNH>

F.772-778/Domain: transmembrane #status predicted <TMM>

F.779-1118/Domain: intracellular #status predicted <INT>

F.846-1070/Domain: protein-tyrosine-phosphatase homology <PTP1>

F.35, 78, 83, 107, 132, 149, 172, 196, 203, 286, 304, 312, 329, 352, 376, 383, 401, 436, 439, 470, 490, 558, 5

F.1022/Active site: Cys (phosphocysteine intermediate) #status predicted

F.1028/Binding site: substrate phosphate (Arg) #status predicted

Query Match 9.4%; Score 101.5; DB 1; Length 1118; Best Local Similarity 24.3%; Pred. No. 0.53; Matches 49; Conservative 18; Mismatches 76; Indels 59; Gaps 8;

Db 47 SLTSHIWRPSSWCSLTSBECVDYDDITATVP---YVLKRVATIGSOTS-AMSLIKHP 102

Db 93 SLTSGVWWEK-----DQVSSVGTVTATAPNPNVRLKRLKRAQNTSSIALTLWEVDPGD 146

Qy 103 NENSTTLTRPOMEITKDG-----FLVLELDLGPQFELVAYW-----R 142

Db 147 PONSRY---GVEYTGDDGAGRTAHTNTITVDSLEGCLYARSMWVGKNGINSRRT 202

Qy 143 REPGAEEHVKVRSQGT-----PVHLETPGAAVCYKAQTF----- 179

Db 203 NATYAHNPVRKPSGSDHQLHPGLGPRWHRPTELDILRTSLAEWVAEQRLTQGTPE 262

Qy 180 --VKAIGRYSAFSOTECVEVOG 199

Db 263 SPVDLGLGSLTSGVWWEKDG 284

RESULT 15

151669

tumor suppressor - African clawed frog

C/Species: Xenopus laevis (African clawed frog)

C/Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 09-Jul-2004

C/Accession: 151669

R/Pierceall, W.E.; Reale, M.A.; Candia, A.F.; Wright, C.V.; Cho, K.R.; Fearon, E.R.

Dev. Biol. 166, 654-665, 1994

A/Title: Expression of a homologue of the deleted in colorectal cancer (DCC) gene in the

A/Reference number: 151668; MUID:95113183; PMID:7813784

A/Accession: 151669

A/Status: preliminary; translated from GB/EMBL/DBJ

A/Molecule type: mRNA

A/Residues: 1-1427 <PIE>

A/Cross-references: UNIPROT:Q91562; EMBL:U10986; NID:G606873; PIDN:AAA70168.1; PID:G6068

C/Genetics:

A/Gene: XDCca

Query Match 8.3%; Score 89.5; DB 2; Length 1427; Best Local Similarity 21.0%; Pred. No. 9.2; Matches 48; Conservative 26; Mismatches 74; Indels 81; Gaps 9;

Qy 9 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

Db 626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

626 PONSIVSLTMKHL-LMMSVIAAGETVYVSVEY-----QGEYSLSYSHIMW--- 55

```

QY 56 -----PSSWCSLTGPECVTDITATVPYNLRVATIGSQTSA 94
Db 685 GLEKGSQYSPQVAMTVNGTGPSSSDWYTAETPENDLDSCQVPDPSSLHVPLTT$IMS 744
QY 95 W$ILKHPFNNSITLTPGMEITKDGPHLVIELEDLGPQPEFLVAYWRREPGAEHVMV 154
Db 745 WT--PPLNPN--IVR-----GYIIGVGVSYPAE--TVRV 774
QY 155 RSGGIPVHLEMTBEPGAAYCVAAQTFFVKAIGRYSAFSQTECEVQGEAIP 203
Db 775 DSKQRYYSIENLEBSSHVVISLKAFFNA-----GEGVP 807

```

Search completed: February 25, 2005, 02:45:39
 Job time : 25.4539 sec8

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 25, 2005, 02:24:39 ; Search time 107.724 Seconds
(without alignments)
964.985 Million cell updates/sec

Title: US-09-745-792A-15

Perfect score: 1080

Sequence: 1 DEVAIIIPAPQNTSLVSTNMK.....GRYSAPSQECVEVQGEAIP 203

Scoring table: BLAST62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: UniProt_03:*

1: uniprot_prot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1080	100.0	311	1 T20S HUMAN	Q6UX10 homo sapien
2	712	65.9	147	1 Q81Y5	Q81Y5 homo sapien
3	173	16.0	337	1 INGS HUMAN	P38484 homo sapien
4	173	16.0	442	1 Q9PVJ9	Q9PVJ9 gallus gall
5	173	16.0	569	1 Q9YH0	Q9YH0 gallus gall
6	164.5	15.2	231	2 Q96A41	Q96A41 homo sapien
7	160	14.8	349	1 I10S MOUSE	Q61190 mus. musculu
8	160	14.8	351	1 Q8VHM7	Q8VHM7 mus. musculu
9	159.5	14.8	325	1 I10S HUMAN	Q8H334 homo sapien
10	159.5	14.8	325	2 Q9BUT4	Q9BUT4 homo sapien
11	159.5	14.8	337	2 Q6ZVU9	Q6ZVU9 homo sapien
12	158	14.6	332	2 Q63953	Q63953 mus musculu
13	158	14.6	332	2 Q78EC1	Q78EC1 mus sp. int
14	151.5	14.0	262	2 Q6UWM1	Q6UWM1 homo sapien
15	151.5	14.0	263	2 Q969J5	Q969J5 homo sapien
16	151	14.0	560	1 INR1 BOVIN	Q04780 bos taurus
17	150	13.9	435	2 Q7ZT26	Q7ZT26 tetraodon n
18	149	13.8	213	2 Q8C352	Q8C352 mus musculu
19	147.5	13.7	553	1 I20R HUMAN	Q9UHL4 homo sapien
20	146	13.5	546	1 I20R MOUSE	Q9PH06 mus musculu
21	146	13.5	569	2 Q99ND6	Q99ND6 rattus norv
22	144	13.3	301	2 Q7ZT35	Q7ZT35 tetraodon n
23	142	13.1	560	1 INR1 SHEEP	Q28589 ovis aries
24	142	13.1	580	1 INR1 MOUSE	Q33836 mus musculu
25	139	12.9	505	2 Q6DCU5	Q6DCU5 xenopus lae
26	138	12.8	530	2 Q80UR8	Q80UR8 mus musculu
27	137.5	12.7	203	2 Q7ZT05	Q7ZT05 tetraodon n
28	137.5	12.7	557	1 INR1 HUMAN	P17181 homo sapien
29	137.5	12.7	557	2 Q8WTZ2	Q8WTZ2 homo sapien
30	136	12.6	362	2 Q764M7	Q764M7 sus scrofa
31	136	12.6	508	2 Q9YHV9	Q9YHV9 gallus gall

32	136	12.6	590	2 Q80UJ3	Q80UJ3 mus musculu
33	135	12.5	508	2 Q6QIU4	Q6QIU4 gallus gall
34	135	12.5	508	2 Q9PVX0	Q9PVX0 gallus gall
35	130.5	12.1	244	2 Q8IV66	Q8IV66 homo sapien
36	128	11.9	341	2 Q9YGC8	Q9YGC8 gallus gall
37	128	11.9	560	2 Q764M8	Q764M8 sus scrofa
38	126.5	11.7	491	2 Q8IZI8	Q8IZI8 homo sapien
39	126.5	11.7	520	2 Q8IU57	Q8IU57 homo sapien
40	126.5	11.7	521	2 Q6ZML8	Q6ZML8 homo sapien
41	125.5	11.6	338	2 Q80UG2	Q80UG2 tetraodon n
42	123	11.4	209	2 Q96SH7	Q96SH7 homo sapien
43	122.5	11.3	333	2 Q7ZT30	Q7ZT30 tetraodon n
44	122.5	11.3	578	1 I10R HUMAN	Q13631 homo sapien
45	119.5	11.1	336	2 Q80UE8	Q80UE8 tetraodon n

ALIGNMENTS

RESULT 1
ID 120S HUMAN STANDARD; PRT; 311 AA.
AC Q6UX10: Q6P438; Q8YAJ7;
DT 25-OCT-2004 (Rel. 45, Created)
DT 25-OCT-2004 (Rel. 45, Last sequence update)
DT 25-JAN-2005 (Rel. 46, Last annotation update)
DE Interleukin-20 receptor beta chain precursor (IL-20R-beta) (IL-20R2)
DE (UNOS57/PRO1114).
GN Name=IL20RB; Synonyms=DIRS1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1).
RX MEDLINE=22867296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.V., Abaya B., Baker K., Baldwin D., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J., Grimaldi C., Gu Q., Haas P.E., Heldens S.,
RA Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA Seshagiri S., Simons L., Singh J., Smith V., Stinson J., Vagta A.,
RA Vanden R., Watanabe C., Wleand D., Woode K., Xie M.-H., Yansura D.,
RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P., Gray A.;
RT "The secreted protein discovery initiative (SPDI), a large-scale
RT effort to identify novel human secreted and transmembrane proteins: a
RT bioinformatics assessment.";
RL Genome Res. 13:2265-2270(2003).
[2]
RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC TTSUB=Cervix; and Skin;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haile F.,
RA Datchenko L., Maritska K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
RA Brownstein M.J., Ueda T.B., Tohyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulhally S.J.,
RA Bosak S.A., McMan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A.C., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Boufield G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Gough J., Schmutz J., Myers R.M.,
RA Butterfield V.S.N., Krzywicki M.I., Skaleka U., Smilley D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RN [3]
 RP SEQUENCE OF 30-44 (ISOFORM 1).
 RX PubMed=15340161; DOI=10.1110/ps.04682504;
 RA Zhang Z., Henzel W.J.;
 RT "Signal peptide prediction based on analysis of experimentally
 RT verified cleavage sites."
 RL Protein Sci. 13:2819-2824(2004).
 RN [4]
 RP SUBUNIT, LIGAND BINDING, AND TISSUE SPECIFICITY.
 RX MEDLINE=21097717; PubMed=1116236; DOI=10.1016/S0092-8674(01)00187-8;
 RA Blumberg H., Conklin D., Xu W.F., Grossmann A., Brendler T.,
 RA Carroll S., Bagan W., Foster D., Haldeman B.A., Hammond A., Haugen H.,
 RA Jellinek L., Kelly J.D., Madden K., Maurer M.F., Parrish-Novak J.,
 RA Prunkard D., Sexson S., Sprecher C., West J.,
 RA Whitmore T.E., Yao L., Knechle M.K., Dale B.A., Chandrasekhar Y.A.;
 RT "Interleukin 20: discovery, receptor identification, and role in
 RT epidermal function."
 RL Cell 104:9-19(2001).
 RN [5]
 RP SUBUNIT, AND LIGAND BINDING.
 RX PubMed=11564763;
 RA Dumoulier L., Leemans C., Lejeune D., Kotenko S.V., Renaud J.-C.;
 RT "STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor
 RT complexes of two types."
 RL J. Immunol. 167:3545-3549(2001).
 RN [6]
 RP SUBUNIT, AND LIGAND BINDING.
 RX PubMed=12351624; DOI=10.1074/jbc.M205114200;
 RA Parrish-Novak J., Xu W., Brendler T., Yao L., Jones C., West J.,
 RA Brandt C., Jellinek L., Madden K., McKernan P.A., Foster D.C.,
 RA Jaspers S., Chandrasekhar Y.A.;
 RT "Interleukin 19, 20, and 24 signal through two distinct receptor
 RT complexes: Differences in receptor-ligand interactions mediate unique
 RT biological functions."
 RL J. Biol. Chem. 277:47517-47523(2002).
 RN [7]
 RP SUBUNIT, AND LIGAND BINDING.
 RX PubMed=1580208; DOI=10.1021/bi0354583;
 RA Pletnev S., Magracheva E., Kozlov S., Tobin G., Kotenko S.V.,
 RA Wlodawer A., Zdanov A.;
 RT "Characterization of the recombinant extracellular domains of human
 RT interleukin-20 receptors and their complexes with interleukin-19 and
 RT interleukin-20."
 RL Biochemistry 42:12617-12624(2003).
 CC -1- FUNCTION: The IL20RA/IL20RB dimer is a receptor for IL19, IL20 and
 CC IL24. The IL22RA1/IL20RB dimer is a receptor for IL20 and IL24.
 CC -1- SUBUNIT: Heterodimer with IL20RA and heterodimer with IL22RA1.
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein (by similarity).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Name=Alternative splicing; Named isoforms=2;
 CC Name=1;
 CC IsoId=Q6UXL0-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=Q6UXL0-2; Sequence=VSP_011499, VSP_011500;
 CC -1- TISSUE SPECIFICITY: Widely expressed with highest levels in skin
 CC and testis. Highly expressed in psoriatic skin.
 CC -1- SIMILARITY: Belongs to the type II cytokine family of receptors.
 CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation-
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC -----
 DR EMBL: AY358905; AA086672.1; -;
 DR EMBL: BC027449; AA827449.1; -;
 DR EMBL: BC063696; AA63696.1; -;
 DR Genew; HGNC:6004; IL20RB.
 DR MIM: 605621; -;
 DR InterPro; IPR000282; Cytok_receptor_2.

DR InterPro; IPR003961; FN_III.
 DR InterPro; IPR008957; FN_III-like.
 DR Pfam; PF0041; FN3_1.
 DR PROSITE; PS00853; FN3_1.
 KW Alternative splicing; Direct protein sequencing; Glycoprotein;
 KW Receptor; Repeat; Signal; Transmembrane.
 FT SIGNAL 1 29
 FT CHAIN 1 29 Interleukin-20 receptor beta chain.
 FT DOMAIN 30 233 Extracellular (Potential).
 FT TRANSMEM 234 254 Potential.
 FT DOMAIN 255 311 Cytoplasmic (Potential).
 FT DOMAIN 36 137 Fibronectin type-III 1.
 FT DOMAIN 144 228 Fibronectin type-III 2.
 FT DISUFPID 202 223 By similarity.
 FT CARBOHYD 40 40 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 134 134 N-linked (GlcNAc...) (Potential).
 FT VARSPPLIC 1 47 Missing (in isoform 2 and isoform 3).
 FT VARSPPLIC 48 142 Missing (in isoform 2).
 FT VARSPPLIC 142 1500 /FTId=VSP_011500.
 SQ SEQUENCE 311 AA; 35076 MW; FP366DSI8116D9E3 CRC64;
 Query Match 100.0%; Score 1080; DB 1; Length 311;
 Best Local Similarity 100.0%; Pred. No. 8.3e-94;
 Matches 203; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DEVATLPAPQNVSTWTKKHLMSVPYAPGETVYVVEVGESESLYTSIWTSSMC 60
 DB 30 DEVATLPAPQNVSTWTKKHLMSVPYAPGETVYVVEVGESESLYTSIWTSSMC 89
 QY 61 SLTEGPECDVTDITATVPYNLRVATLGSOTSAMSIKHPFNRSITLIRPGMEITDGG 120
 DB 90 SLTEGPECDVTDITATVPYNLRVATLGSOTSAMSIKHPFNRSITLIRPGMEITDGG 149
 QY 121 FHLVTELEDLPQPEFPLVAYMRREPAGAEHYVMVRSGLIPVHLETMEPGAAYCVAKQTFV 180
 DB 150 FHLVTELEDLPQPEFPLVAYMRREPAGAEHYVMVRSGLIPVHLETMEPGAAYCVAKQTFV 209
 QY 181 KAIGRYSAFSQTECVGGEAIP 203
 DB 210 KAIGRYSAFSQTECVGGEAIP 232
 RESULT 2
 ID 081YVS PRELIMINARY; PRT; 147 AA.
 AC 081YVS;
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE MGC34923 protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 OX NCBI_TaxId=9606;
 OX [1]
 RP SEQUENCE FROM N.A.
 RP TISSUE=Skin;
 RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Berge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein W.J., Usdin T.B., Toshiyuki S., Carninci P., Frange C.,
 RA Kohn S.S., Loquellano N.A., Peters G.J., Adamson R.D., Mullahy S.J.,
 RA Bosak S.A., McGowan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
 RA Villalón D.K., Wuzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywnicki M.I., Skalka U., Smallus D.B., Schnerch A., Schein J.B.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RP SEQUENCE FROM N.A.
 RC TISSUE=Skin;
 RA Strausberg R.;
 RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL: BC033292; AA033282.1; -
 DR GO: GO:0016020; C:membrane; IEA.
 DR GO: GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .); IEA.
 DR InterPro: IPR000282; Cytok_receptor_2.
 DR InterPro: IPR008957; FN_III-like.
 SO SEQUENCE 147 AA; 16945 MW; 71BAF49274618999 CRC64;
 Query Match 65.9%; Score 712; DB 2; Length 147;
 Best Local Similarity 100.0%; Pred. No. 2,3e-59;
 Matches 131; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 19 MKHLNMSPIVAGEYTYVSEVQGEYSLYTSHWIPSGMCSLTGEGCDVDDITATV 78
 1 MKHLNMSPIVAGEYTYVSEVQGEYSLYTSHWIPSGMCSLTGEGCDVDDITATV 60
 Qy 79 PYNLRVATLGSOTSAWSILKHPNRSITLTPRGMEITKDGPHLVLELDIGPQEPFLV 138
 61 PYNLRVATLGSOTSAWSILKHPNRSITLTPRGMEITKDGPHLVLELDIGPQEPFLV 120
 Db 139 AYWRREPGAE 149
 121 AYWRREPGAE 131
 Db
 RESULT 3
 INGS_HUMAN STANDARD; PRT; 337 AA.
 AC P38484; Q9BTL5;
 DT 01-OCT-1994 (Rel. 30, Last sequence update)
 DT 01-OCT-1994 (Rel. 30, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Interferon-gamma receptor beta chain precursor (Interferon-gamma
 DE receptor accessory factor-1) (AF-1) (Interferon-gamma transducer-1).
 GN Name=IFNGR2; Synonyms=IFNGT1;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 OX NCBI_TaxID=9606;
 RN (1)
 RP SEQUENCE FROM N.A.
 RC TISSUE=lung fibroblast;
 RX MEDLINE=94110380; PubMed=8124716; DOI=10.1016/0092-8674(94)90354-9;
 RA Soh J., Donnelly R.J., Kotenko S., Mariano T.M., Cook J.R., Wang N.,
 RA Emanuel S.L., Schwartz B., Mikl T., Pestka S.;
 RT "Identification and sequence of an accessory factor required for
 RT activation of the human interferon gamma receptor";
 RL Cell 76:793-802(1994).
 RP SEQUENCE FROM N.A.
 RC TISSUE=Skin;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Pelinold E.A., Grouse L.H., Dere J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heile F.,
 RA Diatchenko L., Marusik K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Uebli T.B., Tothiyuki S., Carninci P., Muliyil S.J.,
 RA Bosak S.A., Loggellano N.A., Peters G.J., Abramson R.D., Muliyil S.J.,
 RA Richez S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Huiyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahney J., Helton E., Ketterman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywnicki M.I., Skalka U., Smallus D.B.,
 RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RP SEQUENCE OF 1-24 FROM N.A.
 RX MEDLINE=97067142; PubMed=8910544; DOI=10.1074/jbc.271.46.28947;
 RA Rhee S., Ebensperger C., Dembic Z., Pestka S.;
 RT "The structure of the gene for the second chain of the human
 RT interferon gamma receptor";
 RL J. Biol. Chem. 271:28947-28952(1996).
 CC -1- FUNCTION: Part of the receptor for interferon gamma. Required for
 CC signal transduction. This accessory factor is an integral part of
 CC the IFN-gamma signal transduction pathway and is likely to
 CC interact with GAF, JAK1, and/or JAK2.
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -1- SIMILARITY: Belongs to the type II cytokine family of receptors.
 CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.1db-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC -----
 DR EMBL: U05875; AAA16955.1; -
 DR EMBL: U05877; AAA16956.1; -
 DR EMBL: BC003624; AA003624.1; -
 DR EMBL: U06755; AAC52066.1; -
 DR PIR: I38500; I38500.
 DR Genew: HGNC:5440; IFNGR2.
 DR H-InvDB: HIX0016076; -
 DR MIM: 147569; -
 DR MIM: 209950; -
 DR GO: GO:0005887; C:integral to plasma membrane; TAS.
 DR GO: GO:0004906; F:interferon-gamma receptor activity; TAS.
 DR GO: GO:0007166; F:cell surface receptor linked signal transdu. . .; TAS.
 DR GO: GO:0009618; P:response to pathogenic bacteria; TAS.
 DR GO: GO:0009615; P:response to virus; TAS.
 DR InterPro: IPR000282; Cytok_receptor_2.
 DR InterPro: IPR003961; FN_III.
 DR InterPro: IPR008957; FN_III-like.
 DR Pfam: PF00041; fn3; 1.
 DR PROSITE: PS50853; FN3; 2.
 KW Glycoprotein; Receptor; Repeat; Signal; Transmembrane.
 FT CHAIN 1 27
 FT STAGNAL 27
 FT STAGNAL 28 337
 FT DOMAIN 28 247
 FT TRANSMEM 248 268
 FT DOMAIN 269 337
 FT DOMAIN 31 129
 FT DOMAIN 139 229
 FT CARBOHYD 56 56
 FT CARBOHYD 85 85
 FT CARBOHYD 110 110
 FT CARBOHYD 137 137
 FT CARBOHYD 219 219
 FT CARBOHYD 231 231
 FT VARIANT 64
 FT
 SO SEQUENCE 337 AA; 37834 MW; 18C61B10AD90E509 CRC64;
 Query Match 16.0%; Score 173; DB 1; Length 337;
 Best Local Similarity 28.2%; Pred. No. 6.7e-08;
 Matches 64; Conservative 31; Mismatches 96; Indels 36; Gaps 11;

```
OY 1 DEVALPAPQNLSTLSTNMKHLMMSPVIAPEGT--VYYSVEQGESESLYTSHTIMVSS 58
DB 25 DPLSGLPAPQHPKRLRYAEOVLSMEPVALSNSRPPVRYQFQTKSMTALIMSIGV 84
OY 59 WCSLTEGECVTDITATVP-----YNLRATLGSQTSAMSIL--KHPFRNS 106
DB 85 NCTOITATREC-----DFTAASPSAGFPMDFNVTLRRLRATLGALHSAWYTMPFQH--YRNV 138
OY 107 TILRRPGMEITKDDGPHVY-----BLELDGPOFE-FLVAVYRRRPGAEHVK-MVRSOG 158
DB 139 TVGPPENIEVTPGSGSLIIRSSPPDIADSTAFICYVHW--EKGGIQCVKGPFRNS 196
OY 159 IPVHLETMPEGAAYCVKAQTFV---NAIGRYSAFSQTECVVOGEA 201
DB 197 I--SLDNLKPSRVCYCLQVQAOLMWNKSNIFRVGHLNSICVETMADA 241
```

RESULT 4

```
O9PVU9 PRELIMINARY; PRT; 442 AA.
AC O9PVU9;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Interferon alpha/beta receptor 1 (Fragment).
GN Name=IFNAR1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
NC NCB1_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99177346; PubMed=10077530;
RA Reboul J., Gardiner K., Monneron D., Uze G., Lutfalla G.;
RT "Comparative genomic analysis of the interferon/interleukin-10
RT receptor gene cluster.";
RL Genome Res. 9:242-250(1999).
DB EMBL; AF082667; AAD13679.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; CytoK_receptor_2.
DR InterPro; IPR003961; FN_III.
DR SMART; SM00060; FN3; 2.
DR PROSITE; PS50853; FN3; 1.
KW Receptor.
FT NON_TER 442
SQ SEQUENCE 442 AA; 49877 MW; 839EBE92170609E0 CRC64;

Query Match 16.0%; Score 173; DB 2; Length 442;
Best Local Similarity 27.0%; Pred. No. 9,3e-08;
Matches 60; Conservative 27; Mismatches 91; Indels 44; Gaps 8;
```

```
OY 6 LPAPQNLSTLSTNMKHLMMSPVIAPEGTYYSVEY-QGEYESLYT--SHIWPSSWCSL 62
DB 237 LILCTPTNVRFPALNMKFYLLMDNHY--NEHVYTYVQYLTKLVLDYDSSKQKXSGCEN 294
OY 63 TEGPECVTDITAT-VPYNLRVRAATLGSQTSAMS-----I 97
DB 295 ITSMKCNLSVYKFTSASYFRVQAMNEXSKSLSKDVEVDPVTNIEGPPDVKYDISV 354
OY 98 LKHFPNRNSTLITRPGMETTKDGFHVLIELDGLQPOFEFLVAYWRREPGAEHVMNSG 157
DB 355 LILH-----IKITPRG---GPGNKIMSDLYD---FSYQILYKXNSDNEEVEVKMKETK 400
OY 158 GIPVHLETMPEGAAYCVKAQTFVKAIGRYSAFSQTECVVOG 199
DB 401 QTIATVSDLAPSTLYCVKQVAFSEAYKNSSDPSRECICTAG 442
```

RESULT 5

```
O9YHMO PRELIMINARY; PRT; 569 AA.
AC O9YHMO;
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Interferon alpha/beta receptor 1.
GN Name=IFNAR1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
NC NCB1_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=liver;
RX MEDLINE=99177346; PubMed=10077530;
RA Reboul J., Gardiner K., Monneron D., Uze G., Lutfalla G.;
RT "Comparative genomic analysis of the interferon/interleukin-10
RT receptor gene cluster.";
RL Genome Res. 9:242-250(1999).
DB EMBL; AF082664; AAD13669.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; CytoK_receptor_2.
DR InterPro; IPR003961; FN_III.
DR SMART; SM00060; FN3; 2.
DR PROSITE; PS50853; FN3; 1.
KW Receptor.
SQ SEQUENCE 569 AA; 64055 MW; 6A757DDFB891E605 CRC64;

Query Match 15.0%; Score 173; DB 2; Length 569;
Best Local Similarity 27.0%; Pred. No. 1,3e-07;
Matches 60; Conservative 27; Mismatches 91; Indels 44; Gaps 8;
```

```
OY 6 LPAPQNLSTLSTNMKHLMMSPVIAPEGTYYSVEY-QGEYESLYT--SHIWPSSWCSL 62
DB 237 LILCTPTNVRFPALNMKFYLLMDNHY--NEHVYTYVQYLTKLVLDYDSSKQKXSGCEN 294
OY 63 TEGPECVTDITAT-VPYNLRVRAATLGSQTSAMS-----I 97
DB 295 ITSMKCNLSVYKFTSASYFRVQAMNEXSKSLSKDVEVDPVTNIEGPPDVKYDISV 354
OY 98 LKHFPNRNSTLITRPGMETTKDGFHVLIELDGLQPOFEFLVAYWRREPGAEHVMNSG 157
DB 355 LILH-----IKITPRG---GPGNKIMSDLYD---FSYQILYKXNSDNEEVEVKMKETK 400
OY 158 GIPVHLETMPEGAAYCVKAQTFVKAIGRYSAFSQTECVVOG 199
DB 401 QTIATVSDLAPSTLYCVKQVAFSEAYKNSSDPSRECICTAG 442

RESULT 6
O96A41 PRELIMINARY; PRT; 231 AA.
AC O96A41;
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)
DT 05-JUL-2004 (Tremblrel. 27, Last annotation update)
DE Soluble cytokine class II receptor, short isoform precursor
DE (interleukin 22-binding protein CRF2-10) (Class II cytokine receptor)
DE (IL22RA2).
GN Name=CRF2-S1; Synonyms=IL-22BP, IL22BP, IL22RA2; ORFNames=UNQ5793;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCB1_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Mammary gland;
RX MEDLINE=21518574; PubMed=11607789; DOI=10.1038/sj.gene.6363786;
```

RA Gruenberg B.H., Schoenemeyer A., Weiss B., Tosechi L., Kunz S.,
 RA Moik K., Asadullah K., Sabat R.;
 RA "A novel, soluble homologue of the human IL-10 receptor with
 RT preferential expression in placenta."; [Genes Immun. 2:329-334\(2001\).](#)
 RL [2]
 RN
 RP SEQUENCE FROM N.A.
 RC TISSUE=Breast;
 RA Dumoutier L., Lejeune D., Renaud J.C.;
 RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21286453; PubMed=11390454;
 RA Kotenko S.V., Iotova L.S., Mironchukchenko O.V., Esterova E.,
 RA Dickensheets H., Donnelly R.P., Pestka S.;
 RT "Identification, cloning, and characterization of a novel soluble
 RT receptor that binds IL-22 and neutralizes its activity."; [J Immunol. 166:7096-7103\(2001\).](#)
 RL [4]
 RN
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21396522; PubMed=11481447; DOI=10.1073/pnas.171303198;
 RA Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S.,
 RA Chen Z., Dillon S.R., Gao Z., Gilbert T., Madden K., Schlusmeyer S.,
 RA Yao L., Whitmore T.E., Chandrasekhar Y., Grant P.J., Maurer M.,
 RA Jelinek L., Storey H., Brander T., Hammond A., Topouzis S.,
 RA Clegg C.H., Foster D.C.;
 RT "A soluble class II cytokine receptor, IL-22RA2, is a naturally
 RT occurring IL-22 antagonist."; [Proc. Natl. Acad. Sci. U.S.A. 98:9511-9516\(2001\).](#)
 RL [5]
 RN
 RP SEQUENCE FROM N.A.
 RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
 RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
 RA Chen J., Chow B., Chu C., Crowley C., Currell B., Denel B., Dowd P.,
 RA Eaton D., Foster J., Grimaldi C., Gu Q., Hase P.E., Heldens S.,
 RA Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
 RA Lewis L., Lao D., Mark M., Robble B., Sanchez C., Schoenfeld J.,
 RA Seeshagiri S., Simmons L., Smith V., Stinson J., Vagts A.,
 RA Vandlen R., Watanabe C., Wiand D., Woods K., Xie M.H., Yansura D.,
 RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
 RA Godowski P.;
 RT "The secreted protein discovery initiative (SPDI), a large-scale
 RT effort to identify novel human secreted and transmembrane proteins: a
 RT bioinformatics assessment."; [Genome Res. 13:2265-2270\(2003\).](#)
 RL EMBL: AJ131161; CAC85634.1; -;
 DR EMBL: AJ1397262; CAC83097.1; -;
 DR EMBL: AY040566; AK85714.1; -;
 DR EMBL: AY044429; AK91775.1; -;
 DR EMBL: AY358111; AAC8478.1; -;
 DR HSSP: P24055; 1A21.
 DR GO: GO:0016020; C:membrane; IEA.
 DR GO: GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .); IEA.
 DR GO: GO:0004872; F:receptor activity; IEA.
 DR Interpro: IPR000282; Cytok_receptor_2.
 DR Interpro: IPR008957; FN_III-like.
 DR Receptor; Signal.
 FT SIGNAL 1 21 Potential.
 FT CHAIN 22 231 soluble cytokine class II receptor, short
 FT isoform.
 SQ SEQUENCE 231 AA; 26979 MW; 24A6912BFF75100F CRC64;
 Query Match 15.2%; Score 164.5; DB 2; Length 231;
 Best Local Similarity 27.3%; Pred. No. 2.7e-07;
 Matches 57; Conservative 30; Mismatches 93; Indels 29; Gaps 7;
 QY 9 PONTSLVSTNMKILMWSPIVA--PGETVYYSVEYQGEYESLYTSHIWPISWCSLTEGPE 67
 DB 31 PQRVQFSRHFHNLQQRGALTGNSGVFYQVK-----IYGRQKKNKEDCGTQEL 85
 QY 68 CDVTDDITATV--PYNLRVRAITLGSQTSAMSILKHPNRNSTILTRGEMITK-DGFHLV 124
 DB 86 CDLTSE-TSDIQEYVGRVRAASAGSYSEWSPTRFTPMWETKIDPPVNIITVNGSLV 144

QY 125 I-----ELEDLGPQPEFLVAYNRREPGEAEHVKMVRSGGI PVHLETMP 168
 DB 145 ILHAPNLPYRYQKEKNVSIID---YYELVRFVFINNSLEKQKVEGARVAIEALTTP 201
 QY 169 GAAYCYKACQTFVVAIRGRYSAFSGTECEV 197
 DB 202 HSSYCVAAETVQPLDRRSQSRSERCVEI 230
 RESULT 7
 ID 1105_MOUSE STANDARD; PRT; 349 AA.
 AC 061190;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 25-OCT-2004 (Rel. 45, Last annotation update)
 DE Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)
 DE (Cytokine receptor family 2 member 4) (Cytokine receptor class-II
 DE CRF2-4).
 GN Name=1110rb; Synonyms=CRFb4;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=9719375; PubMed=9047351; DOI=10.1016/S0378-1119(96)00690-7;
 RA Gibbs V.C., Pennica D.;
 RT "CRF2-4: Isolation of cDNA clones encoding the human and mouse
 RT proteins."; [Gene 186:97-101\(1997\).](#)
 RL Gene 186:97-101(1997).
 RN [2]
 RP CHARACTERIZATION.
 RX MEDLINE=98130620; PubMed=9463407;
 RA Spencer S.D., Di Marco F., Hookey J., Pitts-Meek S., Bauer M.,
 RA Ryan A.M., Sordat B., Gibbs V.C., Aguet M.;
 RT "The orphan receptor CRF2-4 is an essential subunit of the interleukin
 RT 10 receptor."; [J. Exp. Med. 187:571-578\(1998\).](#)
 RL J. Exp. Med. 187:571-578(1998).
 CC -1- FUNCTION: Receptor for IL10 and IL22. Serves as an accessory chain
 CC essential for the active IL10 receptor complex and to initiate
 CC IL10-induced signal transduction events.
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -1- SIMILARITY: Belongs to the type II cytokine family of receptors.
 CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.1sb-sib.ch/announce/>
 CC or send an email to license@1sb-sib.ch).
 CC -----
 CC EMBL: U53696; AAC53062.1; -;
 CC MGD: MGI:109380; 1110rb.
 DR GO: GO:0004920; F:interleukin-10 receptor activity; IMP.
 DR GO: GO:0005515; F:protein binding; IPI.
 DR Interpro: IPR000282; Cytok_receptor_2.
 DR Interpro: IPR008957; FN_III-like.
 DR PROSITE: PS50853; FN3; 2.
 DR Glycoprotein; Receptor; Repeat; Signal; Transmembrane.
 FT SIGNAL 1 19 Potential.
 FT CHAIN 20 349 Interleukin-10 receptor beta chain.
 FT DOMAIN 20 220 Extracellular (Potential).
 FT TRANSMEM 221 241 Potential.
 FT DOMAIN 242 349 Cytoplasmic (Potential).
 FT DOMAIN 22 107 Fibronectin type-III 1.
 FT DOMAIN 111 208 Fibronectin type-III 2.
 FT DISUPID 66 74 By similarity.
 FT DISUPID 188 209 By similarity.
 FT CARBOHYD 49 49 N-linked (GlcNAc. . .) (Potential).

FT	CARBOHYD	102	102	N-1-linked (GlcNAc. . .) (Potential)
FT	CARBOHYD	161	161	N-1-linked (GlcNAc. . .) (Potential)
FT	CARBOHYD	199	199	N-1-linked (GlcNAc. . .) (Potential)
SQ	SEQUENCE	349 AA;	39774 KM;	58BA4FEB86330A39 CRK64;

Query Match	14.8%	Score 160,	DB 1,	Length 349,
Best Local Similarity	24.7%	Pred. No. 1.2e-06,		
Matches 53, Conservative	40,	Mismatches 92,	Indels 30,	Gaps 11,

OY 3 VALLPAPONTLSVLTNNKHLILMSPIVAIGETIVYSVEQEGYESLYTSHIMIESWCL 62
 : :: : : : : : : : : : : :
Db 18 LGMIIPPEEKVRNMSVNFEKNILQLWEVPAPFKTNLITFAQE-SYSS-FODH-----CKR 68

Qy 63 TEOPECDVTDITATVPINLRVRATLGQSOTSAW-SILKHPFNRRNSTILTRPGMEITK--D 119
::: :
Db 69 TASTQCPS-HLSKYGDYTVRVAELADEHSEMNWNVTFCPV--EDTIIIEPPEMOIESLAE 125

QY 120 GSHL-----VIE-----LEDLGPQFELVAAYRRPGEAEHYKVMRSGGIPVHLEITME 167
 126 SLHHRFAPQIEEBPETWTLKNIYDSMAVRVQWKN -GTNEKQVVSPEYDSEV -LRNIE 182
 Db

QY	168	PGAAVCYKAQTFVKALGRYSASFQTECEVQGEI	202
Db	183	PWTTCIOVQGFLLDNRTGEWSEPICERTGNEI	217

RESULT 8
08VHM7

AC	ENT	SSI	ADM.
Q8VHM7			
01-MAR-2002	(TREMBlere)	20.	Created
01-MAR-2002	(TREMBlere)	20.	last sequence update

```
DE Interleukin 10 receptor 2 base annotation update;
GN Name=IL10r2; Synonyms=IL10r2;
NS Mus musculus (Mouse) .
```

OC Mammalia; Cetacea; Narceata; Canidae; Velebatia; Eulastostoma;
OX Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_taxonomy=10090;
[1]

RC STRAIN=C57BL/6;
RA Hardy M.P., Hertzog P.J., Owczarek C.M.¹
Submitted (OCT-2001) to the EMBL/Genbank/DBJ databases.

DR PIR; A6430/87; AAL-0546.1; --
DR PIR; UC6311; UC6311.
MGD; MGI:109380; I110rb.
RR GO; GO:0004920; F:interleukin-10 receptor activity; IMP.

DR GO:0005513; f:protein binding; 1.1.
SMART; SM00060; FN3; 2.
DR PROSITE; PS50853; FN3; 1.
KW Receptor; Signal; 1.

Query Match	F1	Signal	SQ
14.8%	1	22	351
Score 160	AA	Potential 1	AA
DB 2	MM	Potential 2	MM
length 351	531023D95809AF5D0	CRCC4	531023D95809AF5D0

```

XY      3 VALPAPQNLSTLNNKGLILMSPVYARAGETYYYSVOGEVESLYNHSHTWIPDASWSSTI.62
        Best Local Similarity    24.7%;   Pred. No. 1.2e-06;
        Matches     53; Conservative 40; Mismatches 92; Indels 30; Gaps 11;

```

Db

```
20 LGMIPEEKVRNMSVNFKNIILOMEVPAFPKTNILFTQAYE-SYRS-FODH-----CKR 70
63 TEGPECCVTDIDTATVAPYNIILRRATILSOTSAM-SILAKHPENNSTIILTRPGMEITR--D 119
```

Db

71 TASTQCDPS-HLSKYGDTVRVRAELDDEHSEWVNVTFCPP--EDTIIQPPMEMQISLAE 127

120 GFHL-----VF-----LEHLGPROEFTVAVMPREGAEEFVTKMTRCCGDTTSPMR 167

DB

128 SLHLRSPAQIENEPETWTLTKLIYDSWAYRVQWKN--GTNEKQVVSYPDSEV-LRYLLE 184

168 PGAAYCYKAOTFVKATIGRYSAPSSOTEECEVQEPAT 202

LY

—
—
**
—
—
**

—

**
—
**
—

**
—

DR PIR: A47003; A47003.
 DR HSP; P13726; 1TFH.
 DR Genew; HGNC:5965; IL10RB.
 DR H-invDB; HIX0016074; -.
 DR MIM; 123889; -.
 DR GO; GO:0016021; C: integral to membrane; TAS.
 DR GO; GO:0005886; C: plasma membrane; TAS.
 DR GO; GO:0004920; F: interleukin-10 receptor activity; TAS.
 DR GO; GO:0004872; F: receptor activity; TAS.
 DR GO; GO:0006955; P: immune response; TAS.
 DR GO; GO:0006954; P: inflammatory response; TAS.
 DR GO; GO:0007165; P: signal transduction; TAS.
 DR InterPro; IPR000282; CytoK_receptor_2.
 DR InterPro; IPR008957; FN_III-like.
 DR InterPro; IPR001187; Tissue factor.
 DR Pfam; PF01108; Tissue fac; 1.
 DR Direct protein sequencing; Glycoprotein; Receptor; Signal;
 KM Transmembrane.
 FT SIGNAL 1 19
 FT CHAIN 20 325 Interleukin-10 receptor beta chain.
 FT DOMAIN 20 220 Extracellular (Potential).
 FT TRANSMEM 221 242 Potential.
 FT DOMAIN 243 325 Cytoplasmic (Potential).
 FT DOMAIN 113 205 Fibronectin type-III.
 FT DISULFID 113 205 By similarity.
 FT DISULFID 188 209 By similarity.
 FT CARBOHYD 49 209 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 68 68 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 102 102 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 161 161 N-linked (GlcNAc...) (Potential).
 FT CONFLICT 124 124 A -> D (in Ref. 2).
 FT CONFLICT 269 273 FLGHP -> VGRME (in Ref. 2).
 FT CONFLICT 274 325 Missing (in Ref. 2).
 SQ SEQUENCE 325 AA; 37011 MW; 66706C79F8514B23 CRC64;
 Query Match 14.8%; Score 159.5; DB 1; Length 325;
 Best Local Similarity 25.7%; Pred. No. 1.2e-06;
 Matches 57; Conservative 37; Mismatches 87; Indels 41; Gaps 12;
 QY 3 VALPAPQNI SVLTSTNKKHLLMW-SPVLAPEGTYYVSVEYQGEYSYTIHIMPSMWS 61
 DB 18 LGWVPPENVRNMSVNFKNILQWESPAPAKG-----NLTPAQYLSTR-----IFQDKM 67
 QY 62 LTGSPCEDVDITATVPYRLRVATLGSQTSAN-SILKHPFNNSITILTRPGM--BITK 118
 DB 68 NTTLTECDPS-SISKYGDHILRVARADSHSDVNVITPCV--DPTIGPQGVEVLA 124
 QY 119 DGFHLVLELDLPQPE-----FLVAYRRBPGEAEHVNKVSGLIPVH 162
 DB 125 DSLH-----KRFAPKINNEYETMTKVVNSWTYVQYMKV--GTDEKFPQITPYDREV- 177
 QY 163 LETMEPGAAYCVAQTQVKAIGRYSAFSQTECV-VOGEAIP 203
 DB 178 LRNLBPWTTYCVQVRGFLPDRNKAGWSEPVCEQTTHDETVP 219
 RESULT 10
 Q9BU04 PRELIMINARY; PRT; 325 AA.
 AC Q9BU04
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
 DB Interleukin 10 receptor, beta.
 GN Name=IL10RB;
 OS Homo sapiens (human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Kidney;
 RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heile F.,
 RA Diatchenko L., Marusik K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stepieton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshilyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullah S.J.,
 RA Bosak S.A., McGwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Wooley K.C., Harte S., Garcia A.M., Gay L.J., Huliy S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Rahey J., Helton E., Kettelman M., Madan A.C., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzyzanski M.I., Skaleka U., Smallus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 (2)
 SEQUENCE FROM N.A.
 RC TISSUE=Kidney;
 RA Strausberg R.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
 (3)
 SEQUENCE FROM N.A.
 RA Rieder M.J., Carrington D.P., de Ponte S.H., Hastings N.C.,
 RA Ahearn M.O., Kuldanek S.A., Rajkumar N., Toth E.J., Yi Q.,
 RA Nickerson D.A.;
 RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
 (4)
 SEQUENCE FROM N.A.
 RA Kolinte N., Chen X., Rolfe A., Halleck A., Hines L., Eisenstein S.,
 RA Koundinya M., Raphael J., Moreira D., Kelley T., Laber J., Lin Y.,
 RA Pheasant M., Farmer A.;
 RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC001903; AA01903.1; -
 DR EMBL; AY323826; AA072016.1; -
 DR EMBL; BT009777; AA08779.1; -
 DR HSP; P13726; 1TFH.
 DR GO; GO:0016021; C: integral to membrane; IEA.
 DR GO; GO:0004896; F: hemolysate/interferon-class (D200-domain...); IEA.
 DR GO; GO:0004872; F: receptor activity; IEA.
 DR GO; GO:0007596; P: blood coagulation; IEA.
 DR InterPro; IPR000282; CytoK_receptor_2.
 DR InterPro; IPR003961; FN_III.
 DR InterPro; IPR008957; FN_III-like.
 DR InterPro; IPR001187; Tissue factor.
 DR Pfam; PF01108; Tissue fac; 1.
 DR SMART; SM00060; FN3; 2.
 KM Receptor.
 SQ SEQUENCE 325 AA; 36995 MW; E470726619AF54C2 CRC64;
 Query Match 14.8%; Score 159.5; DB 2; Length 325;
 Best Local Similarity 25.7%; Pred. No. 1.2e-06;
 Matches 57; Conservative 37; Mismatches 87; Indels 41; Gaps 12;
 QY 3 VALPAPQNI SVLTSTNKKHLLMW-SPVLAPEGTYYVSVEYQGEYSYTIHIMPSMWS 61
 DB 18 LGWVPPENVRNMSVNFKNILQWESPAPAKG-----NLTPAQYLSTR-----IFQDKM 67
 QY 62 LTGSPCEDVDITATVPYRLRVATLGSQTSAN-SILKHPFNNSITILTRPGM--BITK 118
 DB 68 NTTLTECDPS-SISKYGDHILRVARADSHSDVNVITPCV--DPTIGPQGVEVLA 124
 QY 119 DGFHLVLELDLPQPE-----FLVAYRRBPGEAEHVNKVSGLIPVH 162
 DB 125 DSLH-----KRFAPKINNEYETMTKVVNSWTYVQYMKV--GTDEKFPQITPYDREV- 177
 QY 163 LETMEPGAAYCVAQTQVKAIGRYSAFSQTECV-VOGEAIP 203
 DB 178 LRNLBPWTTYCVQVRGFLPDRNKAGWSEPVCEQTTHDETVP 219

```

RESULT 11
062VU9 PRELIMINARY; PRT; 327 AA.
AC 062VU9;
DT 05-JUL-2004 (TEMBLrel. 27, Created)
DT 05-JUL-2004 (TEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TEMBLrel. 27, Last annotation update)
DE Hypothetical protein FLU42063.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Synovial membrane tissue; Shoji T., Ichihara T., Shiohara N.,
RA Suzuki O., Sasaki N., Aotsuka S., Nomura R., Yoshikawa Y.,
RA Matsumoto K., Hirano M., Sano S., Nomura R., Yoshikawa Y.,
RA Matsumura Y., Moriya S., Chiba E., Momiyama H., Onogawa S.,
RA Kaeriyama S., Satch N., Matsunawa H., Takahashi E., Kataoka R.,
RA Koga N., Kuroda A., Satch I., Kamata K., Takami S., Terasima Y.,
RA Watanabe M., Sugiyama T., Irie R., Otsuki T., Sato H., Wakamatsu A.,
RA Ishii S., Yamamoto J., Isono Y., Kawai-Hio Y., Saito K., Nishikawa T.,
RA Kimura K., Yamashita H., Matsuo K., Nakamura Y., Sekine M.,
RA Kikuchi H., Kanda K., Magatsuma M., Murakawa K., Kanehori K.,
RA Takahashi-Pujit A., Oshima A., Sugiyama A., Kawakami B., Suzuki Y.,
RA Sugano S., Nagahari K., Masuno Y., Nagai K., Itoigai T.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK124057; BAC85761.1; -
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor.
SQ SEQUENCE 327 AA; 37430 MW; DACB38F7312B0EP6 CRC64;

Query Match 14.8%; Score 159.5; DB 2; Length 327;
Best Local Similarity 25.7%; Pred. No. 1.7e-06;
Matches 57; Conservative 37; Mismatches 87; Indels 41; Gaps 12;

QY 3 VALIPAPONTLSVLTNMKHLIMW-SPVIAGETVYVSEYQGEYSLYTSIMIPSSWC 61
DB 20 LGWVPPENVRNMSVNFKNILQWSPAFAG-----NLTTAQLYLR-----IFQDKM 69
QY 62 LTGPECVDVTDITATVPYNLVRATLGSGTSAM-SILKHPFNKNSITILTRPGM-ETIK 118
DB 70 NTLTTECDFS-SLSKYGDHTLRVAREPADSDMNVNTTFCPV--DPTIIGPPGQVEVLA 126
QY 119 DGFHIVLEEDLGPQPE-----FLVVMYRREPGAEHVMVNSGGIPVH 162
DB 127 DSIH---MKFLAPKLENEYETWTKNVNSWTVTVQVYMWK--GTDEKFOITPOYDFEV- 179
QY 163 LETMEPGAAYCVAQTFVKAIGRYSAFSQTECVE-VQGEAIP 203
DB 180 LRNLPEFWTTYCYVQGRFLPPRNKAGSESPVCEGTHTDVTP 221

RESULT 12
063953 PRELIMINARY; PRT; 332 AA.
AC 063953;
DT 01-NOV-1996 (TEMBLrel. 01, Created)
DT 01-NOV-1996 (TEMBLrel. 01, Last sequence update)
DT 25-OCT-2004 (TEMBLrel. 28, Last annotation update)
DE Ifngr2 protein (interferon gamma receptor 2).
GN Name=ifngr2; Synonyms=ifngr2;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_Taxid=10090;
RN [1]

```

```

RP SEQUENCE FROM N.A.
RC STRAIN=129SV/U;
RX MEDLINE=97128072; PubMed=8972742;
RA Ebersperger C., Rhee S., Muthukumar G., Lembo D., Donnelly R.,
RA Pestka S., Dembic Z.;
RT "Genomic organization and promoter analysis of the gene ifngr2
RT encoding the second chain of the mouse interferon-gamma receptor.";
RL Scand. J. Immunol. 44:599-606(1996).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Brain;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullighy S.J.,
RA Bosak S.A., McGowan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettlemen M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Boufield G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywicki M.I., Skalska U., Smalls D.E., Scherch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Brain;
RA Strausberg R.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; U69599; AAC52938.1; JOINED.
DR EMBL; U69594; AAC52938.1; JOINED.
DR EMBL; U69596; AAC52938.1; JOINED.
DR EMBL; U69595; AAC52938.1; JOINED.
DR EMBL; U69597; AAC52938.1; JOINED.
DR EMBL; U69598; AAC52938.1; JOINED.
DR EMBL; BC055745; AAH55745.1; -.
DR PIR; A49947; A49947.
DR MGI; 107654; Ifngr2.
DR GO; GO:000615; C:extracellular space; TAS.
DR GO; GO:0016021; C:integral to membrane; TAS.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR008957; FN_III-like.
DR Pfam; PF00041; fn3; 1.
DR SMART; SM00060; FN3; 1.
DR PROSITE; PSS0853; FN3; 1.
KW Receptor.
SQ SEQUENCE 332 AA; 37471 MW; E2DD53B934BA087 CRC64;

Query Match 14.6%; Score 158; DB 2; Length 332;
Best Local Similarity 28.8%; Pred. No. 1.7e-06;
Matches 65; Conservative 29; Mismatches 94; Indels 38; Gaps 14;

QY 1 DEVAIPAPONTLSVLTNMKHLIMWSPVIAGETVYVSEYQGEYSLYTSIMIPSSWC 60
DB 24 DSFSQLAAPLNPRLHYLNDEQLITWEP--SPSSNDPRPVYQVEYS-----FIDGSMH 74
QY 61 SLTGEPEC-DVTD--DITF-----TVPYN--LVRATLGSGTSAMSLKHPFNKNSIT 107
DB 75 RLLE-FNCTDITETKCDLFGGRLKLPHPFTVFLVRVRAKGNLTSKWGLB-PFOHYEN 132
QY 108 ILTRP--GMEITDTGCHIVLEL---DL--GPGFEELVYMRREPGAEHVH-MVNSGGI 159
DB 133 VTVGPNNKISVTEGKSLVTHFSPPPDVEHGATFOYLHYHWEKSEFTQOQBOVBGPFKNSI 192

```

QY 160 PVHLETPGAAVCVAQTIV---KAIGRYSAFSQTECVGEA 201
 DB 193 V--LGNLKPYYVCLQTEADILNKKKIRPHGLSLNSVCHETTANA 236

RESULT 13

Q78BC1 PRELIMINARY; PRT; 332 AA.
 AC Q78BC1
 DT 05-JUL-2004 (TREMBlrel. 27, Created)
 DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
 DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
 DE Interferon gamma receptor beta subunit.
 OS Mus sp.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10095;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=94170381; PubMed=8124717; DOI=10.1016/0092-8674(94)90355-7;
 RA Hammel S., Bohm R., Stark G., Di Marco F., Agnet M.;
 RT "A novel member of the interferon receptor family complements
 RT functionality of the murine interferon gamma receptor in human
 RT cells.";
 RL Cell 76:803-810(1994).
 RL EMBL, S69336; AAB30165.1; -
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR000282; Cytok_receptor_2.
 DR InterPro; IPR003961; FN_III.
 DR InterPro; IPR008957; FN_III-like.
 DR Pfam; PF00041; fn3; 1.
 DR PROSITE; PS50853; FN3; 1.
 KW Receptor

KW Receptor
 SQ SEQUENCE 332 AA; 37471 MW; E2DD53BF934BA087 CRC64;

Query Match 14.0%; Score 158; DB 2; Length 332;
 Best Local Similarity 28.8%; Pred. No. 1.7e-06;

Matches 65; Conservative 29; Mismatches 94; Indels 38; Gaps 14;

QY 1 DEVAILPAPONLSVLTNMKHLMSPVIAFGERTVYSVYQGYSELYSHITIPSSWC 60
 DB 24 DSFSQLAAPNPLMLVNDQILTWEP--SPSSNDPPVYQVYVS-----FIDGSM 74
 QY 61 SLTEGPEC-DVTD---DITA-----TVPN--LRYRATLGSOTSAWSILKHPFNST 107
 DB 75 RLAE-PVCTDITETKCDLTGGRLKLPHPPTVFLKRAKGNLTSMVGLL-PFOHYEN 132
 QY 108 ILTRP--GMEITKDGFLVLEL---DL--GPOEPLVAVWRREGAEHYK-MVRSGGI 159
 DB 133 VTVGPNNISVTGKSLVHFSPRPVPHGATFOYLHNHWEKSETQEQVEGPFKNSI 192
 QY 160 PVHLETPGAAVCVAQTIV---KAIGRYSAFSQTECVGEA 201
 DB 193 V--LGNLKPYYVCLQTEADILNKKKIRPHGLSLNSVCHETTANA 236

RESULT 14

Q6UMM1 PRELIMINARY; PRT; 262 AA.
 AC Q6UMM1
 DT 05-JUL-2004 (TREMBlrel. 27, Created)
 DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)
 DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
 DE IL22RA2.
 OS ORFNames=UNG5793;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.

RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
 RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Bruen J.,
 RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
 RA Baton D., Foster J., Grimaldi C., Gu O., Hass P.E., Heldens S.,
 RA Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
 RA Lewis L., Liao D., Mark M., Robbie B., Sanchez C., Schoenfeld J.,
 RA Seehagiri S., Simmons L., Singh J., Smith V., Stinson U., Vagte A.,
 RA Vanden R., Watanabe C., Wleand D., Woods K., Xie M.H., Yamsura D.,
 RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
 RA Godowski P.;
 RT "The secreted protein discovery initiative (SPDI), a large-scale
 RT effort to identify novel human secreted and transmembrane proteins: a
 RT bioinformatics assessment.";
 RT Genome Res. 13:2265-2270(2003).
 RL EMBL; AY358737; AAQ89097.1; -
 DR HSP; P24055; IAA21.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
 DR InterPro; IPR000282; Cytok_receptor_2.
 DR InterPro; IPR008957; FN_III-like.
 SQ SEQUENCE 262 AA; 30418 MW; B46EF4DE78ADFDA CRC64;

Query Match 14.0%; Score 151.5; DB 2; Length 262;
 Best Local Similarity 25.0%; Pred. No. 5.3e-06;
 Matches 59; Conservative 32; Mismatches 94; Indels 51; Gaps 8;

QY 9 PONIULSVLTNMKHLMSPVIA-FGERTVYSVYQGYSELYSHITIPSSW----- 59
 DB 30 PQVVOGFSRFRPHNLIQWQPRALTNSSVYFVQYKIMFSSMSKSHQKPGCGMHSICNF 89
 QY 60 -----CSLTGPECVTDITATV--PYNLRVATLGSOTSAWSIL 98
 DB 90 PCGRTIACYGQROWKNKEDCMGTQELSCDLTSE-TSDIQRPYGRVYAAAGSYSEWSMT 148
 QY 99 KHPFNSTLTLPNGEITK-DGFHLY-----ELEDLQPOEFLVAVM 141
 DB 149 PRFTPMWETKIDPPVNMITVNGSLVLIHAPMLPRYQEKVNSIED--YELLYRVF 205
 QY 142 RREPGAEHYKVRSGGI-PVHLETPGAAVCVAQTIVKAIGRYSAFSQTECV 197
 DB 206 IINNSLEKQYVBAHRAVEIALTPHSSYCVAAEITYQMLDRSGRSERCEVI 261

RESULT 15

Q969J5 PRELIMINARY; PRT; 263 AA.
 AC Q969J5
 DT 01-DEC-2001 (TREMBlrel. 19, Created)
 DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
 DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)
 DE Soluble cytokine class II receptor, long isoform precursor
 DE (Interleukin 22-binding protein CRP2-10L).
 GN Name=CRP2-S1; Synonyms=IL22BP;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Placenta;
 RX MEDLINE=21518574; PubMed=11607789; DOI=10.1038/sj.gene.6363786;
 RA Gruenberg B.H., Schoenemeyer A., Weiss B., Toechi L., Kunz S.,
 RA Wolk K., Asadullah K., Sabat R.;
 RT "A novel, soluble homologue of the human IL-10 receptor with
 RT preferential expression in placenta.";
 RL Genes Immun. 2:329-334(2001).
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21286453; PubMed=11390454;
 RA Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E.,
 RA Dickensheets H., Donnelly R.P., Pestka S.;
 RT "Identification, cloning, and characterization of a novel soluble
 RT receptor that binds IL-22 and neutralizes its activity.";

```

RL J. Immunol. 166:7096-7103(2001).
DR EMBL; AJ313162; CAC85635.1; -.
DR EMBL; AY040567; AAK85715.1; -.
DR HSP; P24055; 1A21.
DR Genew; HGNC:14901; IL22RA2.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor; Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 22 263 soluble cytokine class II receptor, long
FT isoform.
SQ SEQUENCE 263 AA; 30550 MW; C96EC65D78AC79B CRC64;

Query Match 14.0%; Score 151.5; DB 2; Length 263;
Best Local Similarity 25.0%; Pred. No. 5.3e-06;
Matches 59; Conservative 32; Mismatches 94; Indels 51; Gaps 8;

QY 9 PONTSLSTNMKHLMMSPVIA-PGETVYVYVEYOGAYE-SLYTSHIWIPSSW----- 59
DB 31 PQRVQPSRNFHNLQMPERALTGNSSVYFVQKIMFSCMSKSHQKPSGCMQHISCNF 90
QY 60 -----CSLTGPECDVTDDITATV--PYNLRVRAITLGSQTSAMSLI 98
DB 91 PGCRTLAKYQGRQWKNKEDCWGTQELSCDLTSE-TSDIQEPYGRVRAASAGSYSEWSMT 149
QY 99 KHPFNKNSLTILTPGMEITK-DGFHLVI-----ELEDLGPQFEFLVAYW 141
DB 150 PRFTPMWETKIDPPVNNITQVNGSLVTLHAPNLPRYQREKQVSLSD--YVELLYRVF 206
QY 142 RREPGEAEHYKAVRSGGIPVHLETMERGAAYCVKAQTFVKAIGRYSAFSQTECEV 197
DB 207 IINNSLEKEQKVEGAHRAVEIALTPHSSYCVAAETIOPMLDRRQSRSEERCVEI 262

```

Search completed: February 25, 2005, 02:43:36
 Job time : 109.724 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 25, 2005, 02:24:39 ; Search time 117.276 Seconds

(Without alignments)
964.985 Million cell updates/sec

Title: US-09-745-792a-12

Perfect score: 1200

Sequence: 1 VPCVSGGLPKPANITPLSLN.....PSEKQCARILKDGSSSEPKAK 221

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database: UniProt_03.*

1: uniprot_sprot.*

2: uniprot_trtbl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1200	100.0	553	1 I20R HUMAN	Q9UH4 homo sapien
2	965	80.4	546	1 I20R MOUSE	Q6PH0 mus musculu
3	888.5	74.0	209	2 Q96SH7	Q96SH7 homo sapien
4	336	28.0	231	2 Q96A41	Q96A41 homo sapien
5	333.5	27.8	568	2 Q800P7	Q800P7 tetradon n
6	333.5	27.8	568	2 Q800G1	Q800G1 tetradon n
7	315	26.2	229	2 Q7TNI4	Q7TNI4 rattus norv
8	310	25.8	262	2 Q6UWM1	Q6UWM1 homo sapien
9	310	25.8	262	2 Q969J5	Q969J5 homo sapien
10	277	23.1	230	2 Q7TNI5	Q7TNI5 mus musculu
11	275	22.9	230	2 Q80XFS	Q80XFS mus musculu
12	264.5	22.0	341	2 Q9YGC8	Q9YGC8 gallus gall
13	233.5	19.5	327	2 Q6ZVU9	Q6ZVU9 homo sapien
14	232.5	19.4	325	1 I10S HUMAN	Q083J4 homo sapien
15	232.5	19.4	325	2 Q9BUT4	Q9BUT4 homo sapien
16	229.5	19.1	349	1 I10S MOUSE	Q61190 mus musculu
17	229.5	19.1	352	2 Q764M7	Q764M7 sus scrofa
18	226.5	18.9	338	2 Q800G2	Q800G2 tetradon n
19	223.5	18.6	336	2 Q800E8	Q800E8 tetradon n
20	223	18.6	351	2 Q9VHM7	Q9VHM7 mus musculu
21	221	18.4	130	2 Q96G0R	Q96G0R homo sapien
22	204	17.0	203	2 Q7ZT05	Q7ZT05 tetradon n
23	204	17.0	442	2 Q9PVU9	Q9PVU9 gallus gall
24	202	16.8	569	2 Q9YHMO	Q9YHMO gallus gall
25	196	16.3	550	1 INR1 MOUSE	P33896 mus musculu
26	196	16.3	590	2 Q80UJ3	Q80UJ3 mus musculu
27	196	16.3	590	2 Q80UR8	Q80UR8 mus musculu
28	194	16.2	333	2 Q7ZT30	Q7ZT30 tetradon n
29	192.5	16.0	574	2 Q8N6P7	Q8N6P7 homo sapien
30	192.5	16.0	574	2 Q9H8Z2	Q9H8Z2 homo sapien
31	190	15.8	305	2 Q6DCU5	Q6DCU5 xenopus lae

32	187	15.6	550	2 Q764M8	Q764M8 sus scrofa
33	186.5	15.5	550	1 INR1 BOVIN	Q04730 bos taurus
34	183	15.2	581	2 Q80XZ4	Q80XZ4 mus musculu
35	177.5	14.8	284	2 Q7ZT22	Q7ZT22 tetradon n
36	168.5	14.0	557	1 INR1 HUMAN	P17181 homo sapien
37	167.5	14.0	301	2 Q7ZT35	Q7ZT35 tetradon n
38	166.5	13.9	332	2 Q9GK86	Q9GK86 ovis aries
39	166.5	13.9	387	2 Q6PKD7	Q6PKD7 homo sapien
40	166.5	13.9	557	2 Q8WT22	Q8WT22 homo sapien
41	166.5	13.9	560	1 INR1 SHEEP	Q28589 ovis aries
42	163.5	13.6	489	1 INGR HUMAN	P15260 homo sapien
43	162	13.5	289	1 TP CAURO	Q91108 cavia porce
44	161.5	13.5	489	2 Q9B769	Q9B769 homo sapien
45	159.5	13.3	294	2 Q90W13	Q90W13 oncorhynch

ALIGNMENTS

RESULT 1

ID	120R HUMAN	STANDARD	PRT	553 AA
AC	Q9UH4; Q6UW9; Q96SH7			
DT	25-OCT-2004 (Rel. 45, Created)			
DT	25-OCT-2004 (Rel. 45, Last sequence update)			
DT	25-JAN-2005 (Rel. 46, Last annotation update)			
DE	Interleukin-20 receptor alpha chain precursor (IL-20R-alpha) (IL-20R1)			
DE	(ZCYTOR7) (Cytokine receptor family 2 member 8) (CPR2-8)			
DE	(UNQ681/PRO1315)			
GN	Name=IL20RA; Synonyms=ZCYTOR7;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
OX	NCBI_TaxID=9606;			
RP	SEQUENCE FROM N.A. (ISOFORM 1).			
RA	Lok S., Kho C., Jelmberg A., Adams R., Whitmore T., Farrah T.,			
RA	O'Hara P.;			
RT	"Homo sapiens cytokine receptor homolog."			
RL	Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.			
RP	SEQUENCE FROM N.A. (ISOFORM 2).			
RX	MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;			
RA	Clark H.F., Gurney A.L., Abaya B., Baker K., Baldwin D., Brush J.,			
RA	Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,			
RA	Baton D., Foster J., Ginaldi C., Gu O., Hase P.E., Heidens S.,			
RA	Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,			
RA	Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,			
RA	Seshagiri S., Simone L., Singh J., Smith V., Stinson J., Vagts A.,			
RA	Vandlen R., Watanabe C., Wleand D., Woods K., Xie M.-H., Yansura D.,			
RA	Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,			
RA	Godowski P., Gray A.;			
RT	"The secreted protein discovery initiative (SPDI), a large-scale			
RT	effort to identify novel human secreted and transmembrane proteins: a			
RT	bioinformatics assessment."			
RL	Genome Res. 13:2265-2270(2003).			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE=22935763; PubMed=14574404; DOI=10.1038/nature02055;			
RA	Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashure J.L.,			
RA	Wilmign J., Jones M.C., Horton R., Hunt S.E., Scott C.B.,			
RA	Gilbert J.G.R., Clamp M.B., Bethel G., Milne S., Alnough R.,			
RA	Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,			
RA	Babbage A.K., Bagunley C.L., Bailey J., Banerjee R., Barker D.J.,			
RA	Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,			
RA	Blakely S.E., Bray-Allen S., Brook J., Brown A.J., Brown Y.Y.,			
RA	Burford D.C., Burrill W., Burton J., Carter C., Carter N.P.,			
RA	Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,			
RA	Collier R.E., Collins J.E., Colman L.K., Corry N.R., Coville G.J.,			
RA	Collier K.M., Dhani P., Davies J., Dunn M., Barthow M.E.,			
RA	Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,			
RA	Frankland J., French J., Garner P., Garnett J., Ghori M.J.,			
RA	Gilby L.M., Gillison C.J., Githero R.J., Grahame D.V., Grant M.,			

RA Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halle K.S.,
RA Hammond S., Hawley J.L., Hart E.A., Heath P.D., Heathcote R.,
RA Holmes S.J., Howley P.J., Howe K.L., Howell G.R., Huckle E.,
RA Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA Lawlor S., Leonardorniet D.A., Leverona M., Lloyd C.R., Lloyd D.M.,
RA Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA Maslen G.L., Matthews L., McMan O.T., McLaren S.J., McKay K.,
RA McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA Pearce A.V., Peck A.I., Phillimore B.U.C.T., Phillips S., Plumb R.W.,
RA Porter K.M., Ramsey Y., Raby S.A., Rice C.M., Rose M.T., Seale S.M.,
RA Seta H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA Durbin R., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.,
RA "The DNA sequence and analysis of human chromosome 6.",
RL Nature 425:805-811(2003).
[4]
RL SEQUENCE OF 30-44.
RP PubMed=15340161; DOI=10.1110/ps.04682504;
RX Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
RT verified cleavage sites".
RL Protein Sci. 13:2819-2824(2004).
[5]
RN SUBUNIT, LIGAND BINDING, AND TISSUE SPECIFICITY.
RP MEDLINE=21097717; PubMed=1163226; DOI=10.1016/S0092-8674(01)00187-8;
RX Blumberg H., Conklin D., Xu W.F., Grossmann A., Brenden T.,
RA Carollo S., Eagan M., Foster D., Haldeman D.A., Haugen H.,
RA Jelinek L., Kelly J.D., Madden K., Maurer M.R., Parrish-Novak J.,
RA Prunkard D., Season S., Sprecher C., Magye K., West J.,
RA Whitmore T.B., Yao L., Kuechle M.K., Dale B.A., Chandrasekhar Y.A.,
RT "Interleukin 20: discovery, receptor identification, and role in
RT epidermal function".
RL Cell 104:9-19(2001).
[6]
RN LIGAND BINDING.
RP PubMed=11564763;
RX Dumoutier L., Leemans C., Lejeune D., Kotenko S.V., Renaud J.-C.,
RT "STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor
RT complexes of two types".
RL J. Immunol. 167:3545-3549(2001).
[7]
RN SUBUNIT, AND LIGAND BINDING.
RP PubMed=12351624; DOI=10.1074/jbc.M205114200;
RX Parrish-Novak J., Xu W., Brenden T., Yao L., Jones C., West J.,
RA Brandt C., Jelinek L., Madden K., McKernan P.A., Foster D.C.,
RA Jaspers S., Chandrasekhar Y.A.;
RT "Interleukin 19, 20, and 24 signal through two distinct receptor
RT complexes. Differences in receptor-ligand interactions mediate unique
RT biological functions".
RL J. Biol. Chem. 277:47517-47523(2002).
[8]
RN SUBUNIT, AND LIGAND BINDING.
RP PubMed=14580208; DOI=10.1021/bi0354583;
RX Pietner S., Magracheva E., Kozlov S., Tobin G., Kotenko S.V.,
RA Wlodawer A., Zdanov A.;
RT "Characterization of the recombinant extracellular domains of human
RT interleukin-20 receptors and their complexes with interleukin-19 and
RT interleukin-20".
RL Biochemistry 42:12617-12624(2003).
[9]
RN SUBUNIT, LIGAND BINDING, AND TISSUE SPECIFICITY.
RP PubMed=14764663;
RX Sheith F., Baurin V.V., Lewis-Antes A., Shah N.K., Smirnov S.V.,
RA Ananba S., Dickensheets H., Dumoutier L., Renaud J.C., Zdanov A.,
RA Donnelly R.P., Kotenko S.V.;
RT "IL-26 signals through a novel receptor complex composed of IL-20
RT receptor 1 and IL-10 receptor 2.";

RL J. Immunol. 172:2006-2010(2004).
CC -1- FUNCTION: The IL20RA/IL20RB dimer is a receptor for IL19, IL20 and
CC IL24. The IL20RA/IL20RB dimer is a receptor for IL26.
CC -1- SUBUNIT: Heterodimer with IL20RB and heterodimer with IL10RB.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=G9UHF4-1; Sequence=Displayed;
CC Name=2;
CC IsoId=G9UHF4-2; Sequence=VSP_011497, VSP_011498;
CC TISSUE SPECIFICITY: Widely expressed with highest levels in skin
CC and testis and high levels in brain. Highly expressed in psoriatic
CC skin.
CC -1- SIMILARITY: Belongs to the type II cytokine family of receptors.
CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AF184971; AA091320.1; -;
CC EMBL; AY358883; AA089242.1; -;
CC EMBL; AL135902; CAC38375.1; -;
CC HSSP; P13726; 2HPT.
CC Genew; HGNC:6003; IL20RA.
CC MIM; 605620; -;
CC InterPro; IPR000282; Cytok_receptor_2.
CC InterPro; IPR008957; FN_III-like.
CC InterPro; IPR001187; Tissue_factor.
CC Pfam; PF01108; Tissue_fac; 1.
CC DR PROSITE; PS00853; FN3; FALSE_NEG.
CC Alternative splicing; Direct protein sequencing; Glycoprotein;
CC Receptor; Repeat; Signal; Transmembrane.
CC KX SIGNAL 1 29
FT CHAIN 30 553 Interleukin-20 receptor alpha chain.
FT DOMAIN 30 250 Extracellular (Potential).
FT TRANSMEM 251 271 Potential.
FT DOMAIN 272 553 Cytoplasmic (Potential).
FT DOMAIN 37 136 Fibronectin type-III 1.
FT DOMAIN 138 237 Fibronectin type-III 2.
FT DOMAIN 353 356 Poly-Glu.
FT DISULFID 87 95 By similarity.
FT CARBOHYD 215 236 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 42 42 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 83 83 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 91 91 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 162 182 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 191 191 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 200 200 N-linked (GlcNAc...) (Potential).
FT VARSPLIC 1 111 Missing (in isoform 2).
FT FTId=VSP_011497.
FT VARSPLIC 112 135 VKAIGTCKSKWAEGRFPFLFET -> MSYNGLHQRYFKE
FT LKLTLCGISSS (in isoform 2).
FT FTId=VSP_011498.
FT CONFLICT 259 259 I -> V (in Ref. 2).
FT CONFLICT 382 382 F -> L (in Ref. 2 and 3).
SQ SEQUENCE 553 AA; 62533 MW; 7C23C8543B114659 CRC64;
Query Match 100.0%; Score 1200; DB 1; Length 553;
Best Local Similarity 100.0%; Pred. No. 7.9e-100; Indels 0; Gaps 0;
Matches 221; Conservative 0; Mismatches 0;
QY 1 VPCVGGGLPKPANIFLSINMKNVLTQPTPEGLQGVKTYTVQYVIFGQKKMLNKSERN 60
DB 30 VPCVGGGLPKPANIFLSINMKNVLTQPTPEGLQGVKTYTVQYVIFGQKKMLNKSERN 89
QY 61 INRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAEGRFPFLFETQIGPPVALTTDXK 120

DB 90 INRTYCDLSAETSDYEHQYAKYKAIWGTCKSKMAESGRYPFLPTQIGPEVALTTDEK 149
QY 121 SISVVLTAPEKWRKRNEDLPVSMQOQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
DB 150 SISVVLTAPEKWRKRNEDLPVSMQOQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 209
QY 181 PNTLYCVHVESFVPGPPRRAPQSEKOCARTLKXOSSSEFPAK 221
DB 210 PNTLYCVHVESFVPGPPRRAPQSEKOCARTLKXOSSSEFPAK 250
RESULT 2
12OR_MOUSE STANDARD; PRT; 546 AA.
ID 12OR_MOUSE
AC 06P80; 06Bw64;
DT 25-OCT-2004 (Rel. 45, Created)
DT 25-OCT-2004 (Rel. 45, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Interleukin-20 receptor alpha chain precursor (IL-20R-alpha) (IL-20R1).
GN Name=120ra;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eumetazoa; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN (1)
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Oviduct;
RC MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA Nikaido I., Oseto N., Saito R., Suzuki H., Yamataka I., Kiyosawa H.,
RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gobjohri T.,
RA Balderelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA Schirral L.M., Kanpin A., Matsuda H., Batalov S., Balisei K.W.,
RA Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.B., Cousins S.,
RA Dalla E., Dragani T.A., Fletcher C.P., Forrest A., Frazer K.S.,
RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA Grindom S., Gutlich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA Kanai A., Kawai H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA Kongave A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA Maglott D.R., Maltale L., Marchionni L., McKenzie L., Miki H.,
RA Nagashima T., Numata K., Okido T., Pavan W.J., Pereira G., Pesole G.,
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA Raveil T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA Sandelin A., Schneider C., Sempke C.A., Setou M., Shimada K.,
RA Sultana R., Takeuchi Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA Verardo R., Wagner L., Wahlstedt C., Wang Y., Watanabe Y., Wells C.,
RA Wilming L.G., Wynnaw-Boris A., Yamagisawa M., Yang I., Yang L.,
RA Yuan Z., Zavalan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA Hirozane-Kishikawa T., Kono H., Nakamura M., Sakazume N., Sato K.,
RA Shiroki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA Hara A., Heshitume K., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA Birney E., Hayashizaki Y.;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=129; TISSUE=Breast tumor;
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strassberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schlier G.D.,
RA Kleene R.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins L.F., Jordan H., Moore T., Max S.I., Wang J., Heien P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stappleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,
RA Brownstein M.J., Ueda T.B., Tohiyuki S., Carninci P., Prange C.,
RA Raha S.S., Lonnellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McMan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richard S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Huiyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzyzanski M.I., Skalka U., Smallie D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -1- FUNCTION: The IL20RA/IL20RB dimer is a receptor for IL26 (By
CC IL24. The IL20RA/IL20RB dimer is a receptor for IL26 (By
CC similarity).
CC -1- SUBUNIT: Heterodimer with IL20RB and heterodimer with IL10RB (By
CC similarity).
CC -1- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC -1- SIMILARITY: Belongs to the type II cytokine family of receptors.
CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AK054215; BAC35695.1; -;
CC EMBL; BC056528; AAH56628.1; -;
CC HSSP; P13726; 2HPT.
DR InterPro: IPR000282; Cytok_receptor_2.
DR InterPro: IPR008957; FN_III-like.
DR InterPro: IPR001187; Tissue_factor.
DR Pfam; PF01108; Tissue_fac1; I.
DR PROSITE; PS05853; FN3; FALSE NEG.
KW Glycoprotein; Receptor; Repeat; Signal; Transmembrane.
KW SIGNAL.
FT CHAIN 1 32
FT DOMAIN 33 546
FT TRANSMEM 254 274
FT DOMAIN 275 546
FT DOMAIN 33 142
FT DOMAIN 143 251
FT DISULFID 90 98
FT DISULFID 218 239
FT CARBOHYD 45 45
FT CARBOHYD 86 86
FT CARBOHYD 94 94
FT CARBOHYD 185 185
FT CARBOHYD 203 203
FT CONFLICT 145 145
SQ SEQUENCE 546 AA; 61977 MW; E7EC07DA2D49A7F CRC64;
Query Match 80.4%; Score 965; DB 1; Length 546;
Best Local Similarity 79.6%; Pred. No. 1,4e-78;
Matches 176; Conservative 15; Mismatches 30; Indels 0; Gaps 0;
QY 1 VPCVSGGLPAPNATITSLNMKNVLTQMPTEGLQGVKVTYQYFYIGOKMKNSCRN 60
DB 33 VPCVSGGLPAPNATITSLNMKNVLTQMPTEGLQGVKVTYQYFYIGOKMKNASCKGS 92
QY 61 INRTYCDLSAETSDYEHQYAKYKAIWGTCKSKMAESGRYPFLPTQIGPEVALTTDEK 130
DB 93 INRTYCDLSAETSDYEHQYAKYKAIWGTCKSKMAESGRYPFLPTQIGPEVALTTGEX 152
QY 121 SISVVLTAPEKWRKRNEDLPVSMQOQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 180
DB 153 SISVVLTAPEKWRKRNEDLPVSMQOQIYSNLKYNVSVLNTKSNRTWSQCVTNHTLVLTWLE 212
QY 181 PNTLYCVHVESFVPGPPRRAPQSEKOCARTLKXOSSSEFPAK 221
DB 213 PNTLYCVHVESFVPGPPRRAPQSEKOCARTLKXOSSSEFPAK 253

```
RESULT 3
O66SH7 PRELIMINARY; PRT; 209 AA.
ID O96SH7
AC O96SH7
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DE 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE BA204P2.1.3 (Interleukin 20 receptor alpha, isoform 3).
GN Name=IL20RA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Griffiths C.;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ135902; CAC38376.1; -.
DR HSSP; P13726; 2HFT.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KM Receptor.
SQ SEQUENCE 209 AA; 23616 MW; 467AB77BE3840361 CRC64;

Query Match 74.0%; Score 888.5; DB 2; Length 209;
Best Local Similarity 90.5%; Pred. No. 3,4e-72;
Matches 171; Conservative 1; Mismatches 4; Indels 13; Gaps 3;

QY 1 VPCVSGGLPKPANITFLTSINKKVLQMTPEGLQGVKVTYTVQYFYGQKKMLKSECKN 60
DB 30 VPCVSGGLPKPANITFLTSINKKVLQMTPEGLQGVKVTYTVQYFYGQKKMLKSECKN 89
QY 61 INRTYCDLSAETSDYEHQYAKYKAIWGTCKSKMAESGRFPFLFTQIGPEVALTTDEK 120
DB 90 INRTYCDLSAETSDYEHQYAKYKAIWGTCKSKMAESGRFPFLFTQIGPEVALTTDEK 149
QY 121 STSVLTAPPKMKRNPEDLPSVMOQIYSNLKYNVSLNTKSNRTWQCVTNHTLVLTWLE 180
DB 150 STSVLTAPPKMKRNPEDLPSVMOQIYSNLKYNVSLNTKSNRTWQCVTNHTLVLTWLE 198
QY 181 PNTLYCVHV 189
DB 199 -NGAY- IHV 205

RESULT 4
O96A41 PRELIMINARY; PRT; 231 AA.
ID O96A41
AC O96A41
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Soluble cytokine class II receptor, short isoform precursor
DE (Interleukin 22-binding protein CRP2-10) (Class II cytokine receptor)
DE (IL22RA2).
GN Name=CRP2-S1; Synonyms=IL-22BP, IL22BP, IL22RA2; ORNames=UNQ5793;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Tissot-Brenier M.;
RL MEDLINE=21518574; PubMed=11607789; DOI=10.1038/sj.gene.6363786;
RA Guenaberg B.H.; Schoenemeyer A.; Weiss B.; Toschl L.; Kunz S.;
RA Wolk K.; Asadullah K.; Sabat R.;
RT "A novel, soluble homologue of the human IL-10 receptor with
RT preferential expression in placenta.";
RL Genes Immun. 2:329-334 (2001).
RN [2]
```

```
RP SEQUENCE FROM N.A.
RC TISSUE=Breast;
RA Dumoutier L.; Lejeune D.; Renaud J.C.;
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=21286453; PubMed=11390454;
RA Kotenko S.V.; Izotova L.S.; Mitrochchenko O.V.; Esterova E.;
RA Dickenheets H.; Donnelly R.P.; Pestka S.;
RT "Identification, cloning, and characterization of a novel soluble
RT receptor that binds IL-22 and neutralizes its activity.";
RL J. Immunol. 166:7096-7103 (2001).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=21396522; PubMed=11481447; DOI=10.1073/pnas.17103198;
RA Xu W.; Frennell S.R.; Parrish-Novak J.; Kindsvogel W.; Jaspers S.;
RA Chen Z.; Dillon S.R.; Gao Z.; Gilbert T.; Madden K.; Schlutemeyer S.;
RA Yao L.; Whitmore T.E.; Chandrasekhar Y.; Grant F.D.; Maurer M.;
RA Jelinek L.; Storey H.; Bender T.; Hammond A.; Topouzis S.;
RA Clegg C.H.; Foster D.C.;
RT "A soluble class II cytokine receptor, IL-22RA2, is a naturally
RT occurring IL-22 antagonist.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:9511-9516 (2001).
RN [5]
RP SEQUENCE FROM N.A.
RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F.; Gurney A.L.; Abaya E.; Baker K.; Baldwin D.; Brush J.;
RA Chen J.; Chow B.; Chui C.; Crowley C.; Currell B.; Devel B.; Dowd P.;
RA Baton D.; Foster J.; Grimaldi C.; Gu Q.; Haas F.E.; Heldens S.;
RA Huang A.; Kim H.S.; Klimowki L.; Jin Y.; Johnson S.; Lee J.;
RA Lewis L.; Liao D.; Mark M.; Robble E.; Sanchez C.; Schoenfeld J.;
RA Seshagiri S.; Simmons L.; Singh J.; Smith V.; Stinson J.; Vagts A.;
RA Vanden R.; Watanabe C.; Wiand D.; Woods K.; Xie M.H.; Yansura D.;
RA Yi S.; Yu G.; Yuan J.; Zhang M.; Zhang Z.; Goddard A.; Wood W.I.;
RA Godowski P.;
RT "The secreted protein discovery initiative (SPDI), a large-scale
RT effort to identify novel human secreted and transmembrane proteins: a
RT bioinformatics assessment.";
RL Genome Res. 13:2265-2270 (2003).
DB EMBL; AJ131161; CAC85634.1; -.
DB EMBL; AJ297262; CAC83097.1; -.
DB EMBL; AY040566; AAK85714.1; -.
DB EMBL; AY044429; AAK91775.1; -.
DB EMBL; AY358111; AAO88478.1; -.
DR HSSP; P24055; 1A21.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor; Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 22 231 soluble cytokine class II receptor, short isoform.
SQ SEQUENCE 231 AA; 26979 MW; 24A6912BFF75100F CRC64;

Query Match 38.0%; Score 336; DB 2; Length 231;
Best Local Similarity 37.2%; Pred. No. 3,5e-22;
Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;

QY 10 KPANITFLSINKKVLQMTPEGLQGVKVTYTVQYFYGQKKMLKSECKNINRTYCDLS 69
DB 30 KPANITFLSINKKVLQMTPEGLQGVKVTYTVQYFYGQKKMLKSECKNINRTYCDLS 89
QY 70 AETSDYEHQYAKYKAIWGTCKSKMAESGRFPFLFTQIGPEVALTTDEKSISVTLAP 129
DB 90 AETSDYEHQYAKYKAIWGTCKSKMAESGRFPFLFTQIGPEVALTTDEKSISVTLAP 149
QY 130 ECKKNPEDLPSVMOQIYSNLKYNVSLNTKSNRTWQCVTNHTLV-LTWLEPNTLYCVH 188
DB 150 NLPYVQKKNVSIIDY-ELLIRVFIIINSLEKQKYEGAHRAVEIALTPHSSYCV 208
QY 189 VESFVGPERRAQPSEKOC 207
```

Db 209 ARIYQPMDBRRSORSERBC 227

RESULT 5

0800F7 PRELIMINARY; PRT; 568 AA.

AC 0800F7, 01-JUN-2003 (TREMBlrel. 24, Created)
DT 01-JUN-2003 (TREMBlrel. 24, Last sequence update)
DE 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DB Helical cytokine receptor CRFB8.

GN Name=crfb8;
OS Tetradonton nigroviridis (Green puffer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetradontiformes;
OC Tetradontidae; Tetradontidae; Tetradont.
NCBI_TaxId=99883;

RN (1)
RP SEQUENCE FROM N.A.
RA Lutfalla G., Roest Crolius H., Strange-Thomann N., Jallion O.,
Mogensen K., Monneron D.;
RT "Comparative genomic analysis reveals independent expansion of a
RT lineage-specific gene family in vertebrates: The class II cytokine
RT receptors and their ligands in mammals and fish."
RL BMC Genomics 4:29-29(2003).
DR EMBL; AJ544894; CAD67782.1; -;
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor.

SEQUENCE 568 AA; 63848 MW; A8A38DC3BF78ABE2 CRC64;

Query Match 27.8%; Score 333.5; DB 2; Length 568;
Best Local Similarity 33.8%; Pred. No. 1.8e-21;
Matches 75; Conservative 41; Mismatches 87; Indels 19; Gaps 4;

QY 4 VSGGLPKPANITFLSINMKVLTQWTPPEGLQGVKVTYYQYFYGQK-----KWLNKSE 57
DB 16 VSASLPSPTSVFASVNLRLVLEWTPGNDTPS-NATFTQYALYGDSDKRRSVRMAALOR 74
QY 58 CRINNTYCDLSAETSDYEHQYAKYKAIWGTGCSKMASSGRYPFLETOIGPEVALTT 117
DB 75 CNTAOSKCDLSNQTDLEBAYYARARASRKAMSGSOTRRDPKSDITFGPPQMSVEV 134
QY 118 DEKSIISVLTAPPEKWRNPEDLPVSMQOITYSNLKYNVSVLNTKSNRTWSQCVNHTLVLT 177
DB 135 ENSNAIVTVKGPMPRYQPNQMPAVSMATYIPHAMVYLSIRNTYRNK-----TSHPISS 188
QY 178 WL-----EPNTLYCYHVESFVPGPPRAOPSEKQCARLTKD 213
DB 189 GLYKHLALRYNKEYCFSVAKFLAMPVQCOSSEWCITTPPTD 230

RESULT 6

0800G1 PRELIMINARY; PRT; 568 AA.

AC 0800G1, 01-JUN-2003 (TREMBlrel. 24, Created)
DT 01-JUN-2003 (TREMBlrel. 24, Last sequence update)
DE 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DB Helical cytokine receptor CRFB8.

GN Name=crfb8;
OS Tetradonton nigroviridis (Green puffer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetradontiformes;
OC Tetradontidae; Tetradontidae; Tetradont.
NCBI_TaxId=99883;
OK (1)

RP SEQUENCE FROM N.A.
RA Lutfalla G., Roest Crolius H., Strange-Thomann N., Jallion O.,
Mogensen K., Monneron D.;
RT "Comparative genomic analysis reveals independent expansion of a
RT lineage-specific gene family in vertebrates: The class II cytokine
RT receptors and their ligands in mammals and fish."
RL BMC Genomics 4:29-29(2003).
RN (2)

RP SEQUENCE FROM N.A.
RA Lutfalla G.;
RL Submitted (FE8-2003) to the EMBL/GenBank/DBJ databases.

DR EMBL; AJ544811; CAD67769.1; -;
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor.

SEQUENCE 568 AA; 63834 MW; FE3AA901C0C31E93 CRC64;

Query Match 27.8%; Score 333.5; DB 2; Length 568;
Best Local Similarity 33.8%; Pred. No. 1.8e-21;
Matches 75; Conservative 41; Mismatches 87; Indels 19; Gaps 4;

QY 4 VSGGLPKPANITFLSINMKVLTQWTPPEGLQGVKVTYYQYFYGQK-----KWLNKSE 57
DB 16 VSASLPSPTSVFASVNLRLVLEWTPGNDTPS-NATFTQYALYGDSDKRRSVRMAALOR 74
QY 58 CRINNTYCDLSAETSDYEHQYAKYKAIWGTGCSKMASSGRYPFLETOIGPEVALTT 117
DB 75 CNTAOSKCDLSNQTDLEBAYYARARASRKAMSGSOTRRDPKSDITFGPPQMSVEV 134
QY 118 DEKSIISVLTAPPEKWRNPEDLPVSMQOITYSNLKYNVSVLNTKSNRTWSQCVNHTLVLT 177
DB 135 ENSNAIVTVKGPMPRYQPNQMPAVSMATYIPHAMVYLSIRNTYRNK-----TSHPISS 188
QY 178 WL-----EPNTLYCYHVESFVPGPPRAOPSEKQCARLTKD 213
DB 189 GLYKHLALRYNKEYCFSVAKFLAMPVQCOSSEWCITTPPTD 230

RESULT 7

07TN14 PRELIMINARY; PRT; 229 AA.

AC 07TN14, 01-OCT-2003 (TREMBlrel. 25, Created)
DT 01-OCT-2003 (TREMBlrel. 25, Last sequence update)
DE 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DB Cytokine receptor family II soluble 1 precursor.

GN Name=crf2-61;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
NCBI_TaxId=10116;
RN (1)

RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley; TISSUE=Spleen;
RA Weiss B., Volk K., Gruenberg B.H., Volk H.D., Sterry W., Asadullah K.,
Sabat R.;
RT "Cloning of murine IL-22 receptor alpha 2 and comparison with its
RT human counterpart."

RL Genes Immun. 5:330-336(2004).
DR EMBL; AJ555485; CAD88475.1; -;
DR HSSP; P13726; IJPS.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor; Signal.

FT SIGNAL 1 20
CHAIN 21 229 cytokine receptor family II soluble 1.
SEQUENCE 229 AA; 26721 MW; 5CFPD37652A9365 CRC64;

```

Query Match      26.2%; Score 315; DB 2; Length 229;
Best Local Similarity 34.5%; Pred. No. 2.7e-20;
Matches 70; Conservative 30; Mismatches 97; Indels 6; Gaps 3;

QY 10 KPANITFLSINMKVNLQWTPPEGLQGVKVTYTYQYFIYQGKKWLKSEGNINRTYCDLS 69
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 28 KPQKVQFQSRNFHNIHQMGNSLTSNGSVFYQYTKYGGQKDKNDGCGTALFCDDL 87
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 70 AETSDYEHQYAKVKAINGTKSKMAESGRFYFLETQIGPPREVALTTBEKSLSVLTLP 129
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 88 KETLDYEPYGGVMMAMAGSYSEWTRTPFTPTWETKLDPPVYVITRVNASLRVLRBP 147
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 130 EKKRRPEDELPMVMOQIYSNLKYNVSLNT---KSNRTSQCVYNTHTLVLTWLEPNTLYC 186
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 148 ELPHRQTKNTSMENYV-NLYVRVSIINNSLEKEQKAYEG--TORAVEIQLTPTCSYC 204
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 187 VHVESFVPGPRRPAQSEKQCAR 209
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 205 VVAEMTYQPMFDRSRPSKRCVCQ 227
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

RESULT 8
Q6UWM1 PRELIMINARY; PRT; 262 AA.
ID Q6UWM1
AC Q6UWM1;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IL22RA2.
GN ORFNames=UNQ5793;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22867296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gunney A.L., Abaya B., Baker K., Baldwin D., Brueh J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.B., Heidens S.,
RA Huang A., Kim H.S., Klimewski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robble E., Sanchez C., Schoenfeld J.,
RA Seshagiri S., Simons L., Singh J., Smith V., Stinson J., Vagstad A.,
RA Vanden R., Watanabe C., Wiand D., Woods K., Xie M.H., Yansura D.,
RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P.;
RT "The secreted protein discovery initiative (SPDI), a large-scale
RT effort to identify novel human secreted and transmembrane proteins: a
RT bioinformatics assessment."
RT Genome Res. 13:2265-2270(2003).
DR EMBL; AY358737; AAQ089097.1; -.
DR HSSP; P24055; IA21.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR InterPro; IPR000282; Cytok receptor_2.
DR InterPro; IPR008957; FN_III-like.
SQ SEQUENCE 262 AA; 30418 MW; E46EFAD78ADFDA CRC64;

Query Match      25.8%; Score 310; DB 2; Length 262;
Best Local Similarity 32.0%; Pred. No. 9e-20;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

QY 10 KPANITFLSINMKVNLQWTPPEGLQGVKVTYTYQYFI----- 46
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 29 KPQKVQFQSRNFHNIHQMGNSLTSNGSVFYQYTKYGGQKDKNDGCGTALFCDDL 87
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 47 -----YQKKWLKSEGNINRTYCDLSAETSDYEHQYAKVKAINGTKSKMAES 97
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 89 FPGCRTLAKYGRQKKNKEDCMGTOLSDLTSETDIQEPYIGRRVRAASAGSYSEWMT 148
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 98 GRFPYPLETQIGPREVALTTBEKSLSVLTAPKMKRNPEDLPVSMQOIYSNLKYNVSVL 157
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

```

```

DB 149 PRFTPMWETKIDPPVNIITQVNGSLVILHAPNLPRYQKEKNYSIEDY-ELLYRVFII 207
QY 158 NTKSNRTSQCVYNTHTLV-LTWLEPNTLYCVHVSFVGPPRAPSEKQC 207
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 208 NNSLEKEQKVYEGARAVEIALTPHSSYCVAAETIYQPMLDRRSQSRERC 258
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

RESULT 9
Q969J5 PRELIMINARY; PRT; 263 AA.
ID Q969J5
AC Q969J5;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Soluble cytokine class II receptor, long isoform precursor
DE (Interleukin 22-binding protein CRF2-10L).
GN Name=CRF2-S1; Synonyms=IL22BP;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RX MEDLINE=21518574; PubMed=11607789; DOI=10.1038/sj.gene.6363786;
RA Gruenberg B.H., Schoenemeyer A., Weiss B., Toschi L., Kunz S.,
RA Wolk K., Asadollah K., Sabat R.;
RT "A novel, soluble homologue of the human IL-10 receptor with
RT preferential expression in placenta."
RT Genes Immun. 2:329-334(2001).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=21286453; PubMed=11390454;
RA Kotenko S.V., Izotova L.S., Mitrochnichenko O.V., Esterova E.,
RA Dickensheets H., Donnelly R.P., Pestka S.;
RT "Identification, cloning, and characterization of a novel soluble
RT receptor that binds IL-22 and neutralizes its activity."
RT J. Immunol. 166:7096-7103(2001).
DR EMBL; AJ31162; CAC85635.1; -.
DR EMBL; AY040567; AAK85715.1; -.
DR HSSP; P24055; IA21.
DR Genew; HGNC:14901; IL22RA2.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-claes (D200-domain. . .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor; Signal.
FT SIGNAL 1
FT CHAIN 22 263 Potential.
FT 1 soluble cytokine class II receptor, long
FT 22 isoform.
SQ SEQUENCE 263 AA; 30550 MW; C96ECBC5D78AC79B CRC64;

Query Match      25.8%; Score 310; DB 2; Length 263;
Best Local Similarity 32.0%; Pred. No. 9.1e-20;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

QY 10 KPANITFLSINMKVNLQWTPPEGLQGVKVTYTYQYFI----- 46
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 30 KPQKVQFQSRNFHNIHQMGNSLTSNGSVFYQYTKYGGQKDKNDGCGTALFCDDL 87
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 47 -----YQKKWLKSEGNINRTYCDLSAETSDYEHQYAKVKAINGTKSKMAES 97
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 90 FPGCRTLAKYGRQKKNKEDCMGTOLSDLTSETDIQEPYIGRRVRAASAGSYSEWMT 149
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 98 GRFPYPLETQIGPREVALTTBEKSLSVLTAPKMKRNPEDLPVSMQOIYSNLKYNVSVL 157
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 150 PRFTPMWETKIDPPVNIITQVNGSLVILHAPNLPRYQKEKNYSIEDY-ELLYRVFII 208
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

QY 158 NTKSNRTSQCVYNTHTLV-LTWLEPNTLYCVHVSFVGPPRAPSEKQC 207
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :
DB 209 NNSLEKEQKVYEGARAVEIALTPHSSYCVAAETIYQPMLDRRSQSRERC 259
   ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| : ||| :

```



```
DR PRINTS; PR00346; TISSUEFACTOR.
DR SMART; SMO0060; FN3; 2.
DR PROSITE; PS00853; FN3; 1.
KW Receptor.
SQ SEQUENCE 341 AA; 39062 MW; 18027239BFA9C87 CRC64;

Query Match
Best Local Similarity 32.4%; Score 264.5; DB 2; Length 341;
Matches 70; Conservative 43; Mismatches 80; Indels 23; Gaps 9;

QY 3 CYSGLPKRANITFLISINKNVLQTPPEGLQGVKTYVQ-YFLYGQKMLINKSECRNI 61
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 16 CYSGLVPPKRNARISSVNFRSVLMDPP-GVRRKNSISYVQAKSIFPKQNFNNVT--TTL 72
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 62 NRTYCDLSAETSDYEHQYAKVKAIVGTGCSKMASSGRVPLETOIGPPEVALTTDEKS 121
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 73 NVTEDCVSS-LSVY-GAYLVRAVTEWEDSHDAVY-RKRPADYITIGPSSVNVSESGT 129
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 122 ISVVLTPA-----EKMKNPEDLPVSMQOISNLKYNVSVLNTKSNRTWSQCVTNH-TL 174
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 130 LHVDFTPGPADEHDKM-----SLKQYGSWYRLLYWKKGSKNKVHIDTQHNSE 180
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 175 VITLSEPNITLYCVHVESFVPGPPRAQPSKOCART 210
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 181 ILSQLEPWTICIQVGVIPENWKTGERSQELCEQT 216
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

RESULT 13
ID Q6ZVU9 PRELIMINARY; PRT; 327 AA.
AC Q6ZVU9;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein FLJ42063.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OC NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Synovial membrane tissue;
RA Suzuki O., Sasaki N., Aotsuka S., Shoji T., Ichihara T., Shiohata N.,
RA Matsumoto K., Hirano M., Sano S., Nomura R., Yoshikawa Y.,
RA Matsumura Y., Moriya S., Chiba B., Momiyama H., Onogawa S.,
RA Kaeriyama S., Satoh N., Matsumawa H., Takahashi E., Katoaka R.,
RA Kuga N., Kuroda A., Satoh I., Kamata K., Takami S., Terashima Y.,
RA Watanabe M., Sugiyama T., Isono Y., Otsuki T., Sato H., Wakamatsu A.,
RA Ishii S., Yamamoto J., Ito R., Kawai-Hito Y., Saito K., Nishikawa T.,
RA Kimura K., Yamashita H., Matsuo K., Nakamura Y., Sekine M.,
RA Kikuchi H., Kanda K., Wagatsuma M., Murakawa K., Kanehori K.,
RA Takahashi-Fujii A., Ohnima A., Sugiyama A., Kawakami B., Suzuki Y.,
RA Sugano S., Nagahara K., Masuno Y., Nagai K., Isogai T.;
RA Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK124057; BAC85761.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0004896; F:hematopoietin;interferon-class (D200-domain. .; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR008957; FN_III-like.
KW Receptor.
SQ SEQUENCE 327 AA; 37430 MW; DACH38F7312B0EF6 CRC64;

Query Match
Best Local Similarity 29.2%; Score 233.5; DB 2; Length 327;
Matches 63; Conservative 36; Mismatches 94; Indels 23; Gaps 6;

QY 6 GGLPKRANITFLISINKNVLQTPPEGLQGVKTYVQYFYGQKMLINKSECRNIRTY 65
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 21 GWPPEPBNVMSVNFKNIIQMSPAFAG-NITFTAQYLSYR---IFPDKCNITLITE 75
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 66 CDLSAETSDYEHQYAKVKAIVGTGCSKMASSGRVPLETOIGPPEVALTTDEKSISV 125
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
```

```
DB 76 CDFSSLSKYGCHT--LRYRAEPADSHSDPVNI-TFCPVDDITIGPPGMQVEVLADSLMR 132
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 126 LTAP-----EKMKNPEDLPVSMQOISNLKYNVSVLNTKSNRTWSQCVTNHTLVTWL 179
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 133 FLAPKLEMEYETW-----TMKNVNSWMTYVQYKNGKNGDEKFGQITPQDFEVLRL 183
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 180 EPNITLYCVHVESFVPGPPRAQPSKOCARTLKDS 215
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
DB 184 EFWITTCVQVRGFLPDRNKAGWSEPVCEQTHDET 219
   |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

RESULT 14
ID I10S HUMAN STANDARD; PRT; 325 AA.
AC 008334;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 25-JAN-2005 (Rel. 46, Last annotation update)
DE Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)
DE (Cytokine receptor family 2 member 4) (Cytokine receptor class-II
DE CRF2-4).
DE Name=I10RB; Synonyms=CRFB4;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OC NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Fetal brain;
RX MEDLINE=93500510; PubMed=8314576;
RA Lutfalla G., Gardiner K., Uze G.;
RT "A new member of the cytokine receptor gene family maps on chromosome
RT 21 at less than 35 kb from IFNAR.";
RL Genomics 16:356-373(1993).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=96054036; PubMed=7563119;
RA Lutfalla G., McInnis M.G., Antonarakis S.E., Uze G.;
RT "Structure of the human CRFB4 gene: comparison with its IFNAR
RT neighbor.";
RL J. Mol. Evol. 41:338-344(1995).
RN [3]
RP SEQUENCE OF 20-34.
RX PubMed=15340161; DOI=10.1110/pe.04682504;
RA Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
RT verified cleavage sites.";
RL Protein Sci. 13:2819-2824(2004).
RN [4]
RP CHARACTERIZATION.
RX MEDLINE=97459974; PubMed=9312047; DOI=10.1093/emboj/16.19.5894;
RA Kosenko S.V., Krause C.D., Izotova L.S., Pollack B.P., Wu W.,
RA Pestka S.;
RT "Identification and functional characterization of a second chain of
RT the interleukin-10 receptor complex.";
RL EMBO J. 16:5894-5903(1997).
RN [5]
RP CHARACTERIZATION.
RX MEDLINE=20469498; PubMed=10875937; DOI=10.1074/jbc.M005304200;
RA Xie W.-H., Aggarwal S., Ho W.-H., Foster J., Zhang Z., Stinson J.,
RA Wood W.I., Goddard A.D., Gurney A.L.;
RT "Interleukin (IL)-22, a novel human cytokine that signals through the
RT interferon receptor-related proteins CRF2-4 and IL-22R.";
RL J. Biol. Chem. 275:31335-31339(2000).
RN [6]
RP FUNCTION: Receptor for IL10 and IL22. Serves as an accessory chain
RP essential for the active IL10 receptor complex and to initiate
RP IL10-induced signal transduction events.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- SIMILARITY: Belongs to the type II cytokine family of receptors.
CC -1- SIMILARITY: Contains 2 fibronectin type III domains.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
```


CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.emb-ebi.ch/announce/>
CC or send an email to license@emb-ebi.ch).

CC -----
DR EMBL; Z17227; CA78933.1; -;
DR EMBL; U08988; AAA86872.1; -;
DR PIR; A47003; A47003.
DR HSSP; P13726; 1TFH.
DR Genew; HGNC:5965; IL10RB.
DR H-INVD; Hix0016074; -;
DR MIM; 123889; -;
DR GO; GO:0016021; C:Integral to membrane; TAS.
DR GO; GO:0005586; C:Plasma membrane; TAS.
DR GO; GO:0004920; F:Interleukin-10 receptor activity; TAS.
DR GO; GO:0004872; F:Receptor activity; TAS.
DR GO; GO:0006955; P:Immune response; TAS.
DR GO; GO:0006954; P:Inflammatory response; TAS.
DR GO; GO:0007165; P:Signal transduction; TAS.
DR InterPro; IPR000282; Cytok receptor_2.
DR InterPro; IPR008957; FN_III-like.
DR InterPro; IPR001187; Tissue factor.
DR Pfam; PF01108; Tissue_fac1.
DR Direct protein sequencing; Glycoprotein; Receptor; Signal;
KW Transmembrane.
FT SIGNAL 1 19
FT CHAIN 20 325 Interleukin-10 receptor beta chain.
FT DOMAIN 20 220 Extracellular (Potential).
FT TRANSMEM 221 242 Potential.
FT DOMAIN 243 325 Cytoplasmic (Potential).
FT DOMAIN 113 205 Fibrinectin type-III.
FT DISULFID 66 74 By similarity.
FT CARBOHYD 188 209 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 49 49 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 68 68 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 102 102 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 161 161 N-linked (GlcNAc...) (Potential).
FT FT 124 124 A -> D (in Ref. 2).
FT CONFLICT 269 273 FLAGHP -> VGRME (in Ref. 2).
FT CONFLICT 274 325 Missing (in Ref. 2).
SQ SEQUENCE 325 AA; 37011 MW; 66706C79F8514B3 CRC64;

Query Match 19.4%; Score 232.5; DB 1; Length 325;
Best Local Similarity 29.2%; Pred. No. 1.2e-12;
Matches 63; Conservative 36; Mismatches 94; Indels 23; Gaps 6;

QY 6 GGLPKRANITFLSINKNVLQWTPPEGLQGVKVTYVQYFIYQOKMLNKSERNINRY 65
DB 19 GWPPEPNVAMNSVNFKNILQWESPAKAG-NLFTAQYLSYR----IPDKCMNTLTLE 73
QY 66 CDLSAETSDYEHQYAKVAKIMGTCKSKMAESGRFPFLPETOIGPREVALTTDEKSI 125
DB 74 CDFSSLSKYGDHT--LRVRAEPADSHSDWNI-TFCPVDDTIIGPDMQVEVLADSLHMR 130
QY 126 LTRAP-----EKMKRPEDLPVSMQOIYSNLTKNVSLANTKSNRTMSQCVTNHTLVLTWL 179
DB 131 FLAPKLENEYETM-----TMKVVYNSWNTYNVQVWKNGTKBEKPGITQYDPEVLARNL 181
QY 180 EPNITLYCVHVESFVPGPPRAQSEKQACATLKDQS 215
DB 182 EPNITLYCVHVESFVPGPPRAQSEKQACATLKDQS 217

RESULT 15
Q9BU04 PRELIMINARY; PRT; 325 AA.
Q9BU04
AC Q9BU04 (TREMblrel. 17, Created)
DT 01-JUN-2001 (TREMblrel. 17, Last sequence update)
DT 25-OCT-2004 (TREMblrel. 28, Last annotation update)
DE Interleukin 10 receptor, beta.
GN Name=IL10RB;

OS Homo sapiens (Human).
OC Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Krausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marushia K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Tohiyuki S., Carninci P., Prange C.,
RA Raba S.S., Loggellano N.A., Peters G.J., Abramson R.D., Mulhally S.J.,
RA Boak S.A., McKernan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.R., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smalios D.E., Schmeich A., Schein J.B.,
RA Jones S.J., Matra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RA Krausberg R.;
RN Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
RP [3]
RP SEQUENCE FROM N.A.
RA Rieder M.J., Carrington D.P., da Ponte S.H., Haetings N.C.,
RA Ahearn M.O., Kuldaneck S.A., Rajkumar N., Toth E.J., Yi Q.,
RA Nickerson D.A.;
RN Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
RP [4]
RP SEQUENCE FROM N.A.
RA Kainline N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA Koudinya M., Raphael J., Moreira D., Kelley T., Labaer J., Lin Y.,
RA Phelan M., Farmer A.;
RN Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC001903; AA001903.1; -;
DR EMBL; A1323826; AAP72016.1; -;
DR EMBL; BT009777; AAP88779.1; -;
DR HSSP; P13726; 1TFH.
DR GO; GO:0016021; C:Integral to membrane; IEA.
DR GO; GO:0004896; F:hematopoietin/interferon-class (D200-domain...); IEA.
DR GO; GO:0004872; F:Receptor activity; IEA.
DR GO; GO:0007596; P:Blood coagulation; IEA.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR000282; Cytok receptor_2.
DR InterPro; IPR008957; FN_III-like.
DR InterPro; IPR001187; Tissue factor.
DR Pfam; PF01108; Tissue_fac1.
DR SMART; SM00060; FN3; Z.
KW Receptor.
SQ SEQUENCE 325 AA; 36995 MW; E470726619AF54C2 CRC64;

Query Match 19.4%; Score 232.5; DB 2; Length 325;
Best Local Similarity 29.2%; Pred. No. 1.2e-12;
Matches 63; Conservative 36; Mismatches 94; Indels 23; Gaps 6;

QY 6 GGLPKRANITFLSINKNVLQWTPPEGLQGVKVTYVQYFIYQOKMLNKSERNINRY 65
DB 19 GWPPEPNVAMNSVNFKNILQWESPAKAG-NLFTAQYLSYR----IPDKCMNTLTLE 73
QY 66 CDLSAETSDYEHQYAKVAKIMGTCKSKMAESGRFPFLPETOIGPREVALTTDEKSI 125
DB 74 CDFSSLSKYGDHT--LRVRAEPADSHSDWNI-TFCPVDDTIIGPDMQVEVLADSLHMR 130

QY 126 L7AP-----EKWRNPEDLPVSMOOIYSNLKYNVSJLNTKSNRTWSQCVTNHTLYLTWL 179
Db 131 FLAPKIENEYETW-----TMKNVYNSWTYNVOYWKNGTDEKFOITPQYDFEVLKRL 181
QY 180 EPNTLYCVHVESFVPGPPRRAPSEKQCARLTKDQS 215
Db 182 EPWTYYCVQVRGFLPDRNKAGWSEPVCEQTHDET 217

Search completed: February 25, 2005, 02:43:34
Job time : 120.276 secs